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SUMMARY
Summary
The o ra lly -a c t ive , a n t i-a l le rg ic ,  chromone drug, proxicromi!, 
(6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-l-naphtho[2,3-b] 
pyran-2-carboxylate), produced an unexpectedly high incidence and 
severity of gastro-intestinal disorders in humans. These side-effects  
had not been predicted following a complete safety evaluation 
programme in animals. The purpose of the work described in the 
following chapters was to elucidate the mechanism by which 
proxicromi! caused gastro-intestinal disorders in man, to determine 
whether the effect in humans could have been predicted from animal 
studies and, i f  so, to develop a simple but e ffective  to x ic ity  study 
that could be used with future drugs to predict the ir  potential to 
induce this type of si de-effect in humans.
The gastrointestinal effects of proxicromi! were found to be 
associated with delayed gastric emptying, and a method was developed 
in rats for demonstrating the potential of a candidate compound to 
cause an inhibition of gastric emptying. The method was shown to be 
reproducible and to detect the effect of ‘ standard1 drugs such as 
codeine phosphate (decreases in gastric emptying) and metoclopramide 
(increases). A secondary screen used to evaluate drugs shown to be 
active in the primary test and to screen out false-positives was 
developed in marmosets. X-ray photography a fter  a barium meal also 
demonstrated inhibition of gastric emptying. Proxicromi! was shown to 
be a potent inh ib itor of gastric emptying in both the rat primary 
screen and the marmoset secondary screen.
Inhib ition of gastric emptying was associated with a much lower and 
f la t t e r  plasma drug concentration v time course than was the case
where inhib ition did not occur. This effect has consequences on the 
relevance of to x ic ity  studies in d iffe ren t species.
From measurements of stomach pressure changes in spontaneously 
contracting rat stomachs and spontaneous contractions of rat fundic 
strip  preparations, i t  was concluded that proxicromi! had no direct 
effect on the musculature of the stomach. The drug was also shown to  
have no direct a c t iv ity  on the pyloric sphincter.
An in situ preparation, developed to enable recordings of spontaneous 
contractions of the stomach to be made whilst retaining both nervous 
and blood supplies, showed that proxicromi! had no e ffec t when 
administered d irec tly  into the stomach. However when administered to 
the duodenum the drug induced a dramatic and immediate cessation of 
stomach contractions. I t  was demonstrated that the drug exerted its  
inhibitory a c t iv ity  on gastric emptying by a reflex mechanism 
in it ia te d  in the f i r s t  20 to 30 cm of the rat duodenum, that the 
effect occurred immediately when the compound reached the duodenum 
and that the duration of a c t iv ity  was related to the concentration of 
drug in the duodenum.
The re la tive  inhibitory a c t iv it ie s  of proxicromi1 on gastric emptying 
after oral and intravenous administration indicated that absorption 
was not necessary for a c t iv ity .  The time of onset of the a c t iv i ty ,  
the lack of a c t iv ity  in rats with a common blood circulation to 
proxicromi1 treated animals, and the inhibitory effect of a local 
anaesthetic in the duodenum, a l l  demonstrated that the drug exerted 
i ts  inhibitory a c t iv ity  via a nervous rather than a hormonal pathway. 
I t  was demonstrated that the reflex was probably centrally-mediated 
via a non-cholinergic component of the vagus nerve.
S tructure-activ ity  studies with a range of chromones and other drugs, 
from the completely inactive sodium cromoglycate to the very potent 
proxicromil, indicated that certain groupings on the chromone nucleus 
could be expected to increase or-decrease the potential of a new 
chemical en tity  to induce similar gastro-intestinal disorders in 
humans. A positive correlation between inhibition of gastric emptying 
and sensory irr itancy  in the lung was demonstrated, indicating that 
the a c t iv ity  of proxicromil in the duodenum may be associated with 
i ts  i r r i t a n t  properties. Thus the drug may in i t ia te  a reflex in the 
duodenum that has a physiological role in protecting the intestine  
from i r r i t a n t  or otherwise noxious substances. An a lternative  
explanation to this arose as a result of the finding that b ile  salts  
were potent inhibitors of gastric emptying and that many of the 
active chromones, particu larly  proxicromil, have high surface tension 
properties. These results lead to the suggestion that proxicromil may 
exert i ts  a c t iv ity  by stimulating a reflex that has a physiological 
role in responding to b ile  salts to regulate the rate at which fats 
enter the duodenum. -
In conclusion, this research has shown that the gastro-intestinal  
side-effects that occurred in humans with this drug could have been 
predicted from special animal studies. Animal to x ic ity  tests were 
developed that could potentia lly  predict the effect in man of future  
drugs of this class. Structure-activ ity  studies indicated certain  
groupings on the chromone nucleus that are l ik e ly  to increase the 
potential to produce gastro-intestinal side-effects in man. A 
combination of the knowledge gained from the s truc tu re -ac tiv ity  
studies and the use of the animal tests developed as screens for this  
type of a c t iv i ty ,  should prevent drugs with this type of s ide-effect  
from being developed to an advanced stage.
CHAPTER 1
INTRODUCTION
Animal to x ic ity  studies and prediction to man
Occasionally, in c lin ic a l practice, marketed drugs induce to x ic ity  
that had not been predicted from animal studies. Unpredicted 
side-effects can vary from minor problems that are acceptable within 
a r isk /benefit  context, such as the diarrhoea or constipation 
following chlorpromazine treatment, to the unacceptable effects of 
thalidomide.
H is to r ic a lly , the science of toxicology has always lagged behind the 
development of efficacious drugs. In 1949 for example, 
chloramphenicol was introduced as an anti-microbial substance 
produced i n i t i a l l y  from the growth of Streptomyces venezuelae. As 
well as inducing some minor and re la t iv e ly  infrequent s ide-effects , 
(although blindness due to damage of the optic nerve has also been 
attributed to the drug), (Meyler, 1966; Meyler & Herxheimer, 1968), 
chloramphenicol induced serious blood dyscrasias in several hundreds 
of patients, particu larly  children, of which the majority of cases 
were fa ta l (Dillon e t a ] . ,  1964; B r it .  Med. J . ,  1967; Garrod, 1964). 
Toxicity studies in animals in 1949 were rare, the emphasis being on 
efficacy.
Chloramphenicol was probably the f i r s t  major medical disaster in 
modern medicine. The occurrence was excused on the grounds that 
no-one expected such an effect and that i t  could therefore not have 
been forseen. The medical profession however was awakened to the 
possib ility  of serious adverse effects induced by otherwise useful 
and efficacious drugs.
The second major disaster however came with as much surprise as had 
the f i r s t .  Thalidomide, introduced in 1955 as an extremely safe 
sedative was withdrawn from marketing in 1961 a fte r  i ts  now 
well-known teratogenic effects had become apparent. Teratogenicity, 
or even placental transfer, of drugs were concepts that had not at , 
that time been considered to have relevance to apparently safe drugs. 
That neither the tota l dose nor  the duration of administration were 
of much influence on the incidence of congenital malformations were 
also novel concepts; the c r i t ic a l  factor being that the drug, even 
possibly a single ta b le t ,  had been taken during the f i r s t  trim ester,  
particu larly  between the 27th and 40th days of pregnancy (Mellin & 
Katzenstein, 1962). Chloramphenicol may have stirred the surface o f  
toxicology; thalidomide r e s u l t e d  in action.
There have been few major disasters to compare with thalidomide or 
chloramphenicol since the 1960s (practolol perhaps being the most 
notorious exception), due to both the much more vigorous testing by 
the pharmaceutical companies and the close scrutiny and approval 
required by Regulatory Authorities commencing in the UK with the 
formation of the Dunlop Committee. I t  is unlikely that another potent 
teratogen or a potent bone-marrow depressant w ill  ever be marketed. 
However, i t  is unacceptable to be reasonably confident of this for 
each physiological function, only a fte r  a serious medical c r is is  has 
occurred. Toxicologists are occasionally reminded of the po ss ib ility  
of serious problems in man; the most recent being the withdrawal in 
1983 of benoxaprofen (Opren), the pharmacokinetics of which had not 
been adequately studied in ageing animals. The to x ic ity  of this drug 
in old patients verged on being a major disaster, and was saved from 
being so only by post-marketing observations and surveillance, not
by to x ic ity  studies in animals as should have been the case. Once 
again this particular door should now be closed.
The lessons are therefore there to be learned, not only that major 
disasters may occur but also that less dramatic side-effects are not 
infrequent. The occurrence of minor side-effects necessitates taking 
into account the r isk /benefit  ra tio  to meet an acceptable risk to the 
patient for the disease or condition being treated (Pochin, 1981). A 
number of side-effects however have led d irectly  to the use of drugs 
for conditions other than those for which they were o r ig ina lly  
introduced (Breckenridge, 1981). (See Table 1 .1 ) .
Table 1.1 Major disease en tit ies  treated by drugs 
not introduced for that purpose
Drug Condition treated
Propranolol
Sulphinpyrazone
Diazepam
Phenobarbitone
Chlorpromazine
Oestrogens/Progestogens
Imipramine
Probenecid
Lignocaine
Hypertension
Ischaemic heart disease
Status epilepticus
Epilepsy
Schizophrenia
Contraception
Depression
Gout
Arrhythmias
(From Breckenridge, 1981)
However, although side-effects per se may not necessarily be 
detrimental, i t  should be the aim of the toxicologist at least to 
predict them.
Although the introduction of regulatory requirements has undoubtedly 
been largely responsible for preventing many unsafe medicines from 
being sold (Grahame-Smith, 1981), regulations have not been without 
some detrimental e ffects . As a resu lt, primarily of the thalidomide 
disaster, the number of to x ic ity  studies, the duration of those 
studies, and the ir  cost, have risen substantially. The design of some 
of these studies were, in retrospect, ill-conceived (see for example 
Zbinden, 1982; T a tte rs a ll ,  1982, 1983) but have nevertheless become 
established as normal requirements.
Although v ir tu a l ly  a l l  regulatory statements are claimed to be only 
guidelines, the pharmaceutical companies are faced with the dilemma 
of risking a delay of perhaps 12 months or more in marketing a new 
drug. This can occur i f  the product license application is rejected 
because the company has not carried out a study which they believed, 
r igh tly  or wrongly, was s c ie n t if ic a l ly  un justified . A twelve month 
delay can result in a financial loss of four to six m illion pounds 
(Christensen, 1981). The tendency therefore is to do a l l  recommended 
studies. This is expensive and time-consuming and reduces the 
opportunity to explore new, perhaps more relevant studies. A solution 
to these contradictory aims ought gradually to evolve as 
international regulations become more consistent, a freer  
communication between the pharmaceutical companies and the 
authorities develops, and toxicology i t s e l f  concentrates more on 
individual organ funtions in more predictive studies.
Furthermore, i t  is d i f f i c u l t  to predict that a drug w i l l  be free from 
side-effects just because an analogue is known to be free from 
to x ic ity .  In ta l (sodium cromoglycate) despite 15 years of extensive 
c lin ica l use world-wide, has not been reported to induce any
consistent s ide-effects , but i t  would be unjustified to assume that 
because of th is ,  a l l  chromone compounds can be considered to be safe. 
As a class of chemicals they certa in ly  appear to induce less toxic 
reactions in animals than many others, but each individual chromone 
has the potential to induce a toxic response. Proxicromil is one such 
compound.
Proxicromi1, (6 ,7 ,8 ,9-tetrahydro-5-hydroxy-4-oxo-10-propy1-4H-1- 
naphtho[2,3-b]pyran-2-carboxylate) a chromone carboxylic acid 
derivative that has a n t i-a l le rg ic  properties, was found to induce 
such a high incidence of gastro-intestinal side-effects in humans 
that withdrawal of the drug was considered. These side-effects had 
not been predicted from animal studies.
The purpose of the work described in the following chapters was to 
elucidate the mechanism by which proxicromil caused gastro­
in testinal disorders, to determine whether the effect in humans could 
have been predicted from animal studies and, i f  so, to develop a 
simple but effective to x ic ity  study that could be used with future  
drugs to predict th e ir  potential to induce this type of si de-effect  
in humans. The in i t ia l  hypothesis on which this work was based was 
that the gastro-intestinal side-effects which occurred in humans were 
due to an inhibition of gastric emptying. This hypothesis arose from 
a consideration of the symptoms, particu larly  nausea, (see page 50),  
and th e ir  time course a fte r  administration of the drug and the ir  
s im ila r ity  to symptoms which occur shortly before and during the 
nausea and vomiting accompanying gastric in fection. In such 
circumstances vomitus invariably contains food consumed many hours 
previously, indicating a marked inhibition of gastric emptying that 
must have occurred prior to the nausea, and possibly in it ia te d  i t .
Physiology of the stomach -  secretory function
The principal functions of the gastro-intestinal trac t are secretory, 
absorptive and propulsive. The gastro-intestinal trac t is also an 
organ of excretion. No other organ, or group of organs, comes into 
contact with the large variety of externally applied insults as does 
the gastro-intestinal t ra c t .  Whatever the content of the food or 
liquid consumed, however concentrated or noxious i t  may be, the 
gastro-intestinal trac t  is structured so that by the time the 
ingested material has proceeded only a short distance along the 
duodenum i t  has been altered so that i ts  pH, fa t  content, protein 
content, energy content, noxious or i r r i t a n t  content etc. have a ll  
been adjusted to within quite narrow, acceptable ranges. The stomach, 
although generally considered as a receiving and storage organ, is 
much more important as a major homeostatic organ. The duodenum 
provides information concerning its  food content and the stomach 
responds by retaining or allowing food through to the in testine.
The alimentary trac t produces both exocrine and endocrine secretions. 
Exocrine secretions begin with the saliva. The salivary glands appear 
to be unique within the gastro-intestinal trac t by being under the 
exclusive control of nervous mechanisms, with parasympathetic 
stimulation causing both secretion and vasodilation. Sympathetic 
neurones releasing noradrenaline also innervate the salivary glands 
causing secretion of a more viscous saliva and vasoconstriction 
although Emmelin (1968) contested such a conclusion.
In the stomach, the digestive enzyme pepsin, is secreted along with 
the gastric ju ice which is produced from the mucus, oxyntic and Chief 
c e lls .  As secretion increases, the sodium ion concentration fa l ls  and
the hydrogen ion concentration rises. The surface of the epithelium 
is lined by mucus glands which also line the rugae and gastric p its ,  
See figure 1 .1 , and produce mucus that contains a variety of 
mucopolysaccharides and mucoproteins and the in tr ins ic  factor 
necessary for the absorption of vitamin B12.
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Figure 1.1 Schematic representation of the gastric wall showing 
the muscle layers and nerve complexes (From Hally & Lloyd, 1968).
The oxyntic, or p a r ie ta l,  cel Is .secrete hydrochloric acid and the 
Chief, or zymogen, cells  secrete pepsinogen. Both these ce ll types 
occur in the fundic region of the stomach (Oi et a l . ,  1959). The 
production of hydrochloric acid by the parietal cells  works against a 
concentration gradient of up to 10 , the energy being derived from 
adenosine triphosphate. One theory for the generation of hydrochloric 
acid involves the formation of carbonic acid by the hydration of 
carbon dioxide through the action of carbonic anhydrase (see figure  
1 .2 ) . The bicarbonate ion so formed is removed in the venous blood. 
The carbonic acid acts as a hydrogen donor, neutralising the hydroxyl
ion that results from the hydrolysis of water. The remaining hydrogen 
ion from the water is secreted in the gastric ju ice  coupled with 
chloride transported by an active process. The ambient HCOg" plays an 
important role in the protective mechanisms of gastric mucosa against 
autodigestion (Cummins et a l . ,  1948; Kivilaakso, 1981), by secretion 
into the gastric mucus b arr ie r , and by acting as an in tra c e llu la r  
buffer (Kivilaakso, 1981, 1983).
Plasma Parietal Cell Stomach
Lumen
■>C0
Carbonic 
i Anhydrase
Bicarbonate 
barriers in 
gastric mucus
HCO
Cl’ active transport
passive transport
Figure 1.2 Production of hydrogen ions in parietal cells  from 
carbon dioxide and water.
When food is eaten, gastrin production is in it ia te d  from 
enterochromaffin type of cells  (G ce lls ) located in the pyloric  
antrum (McGuigan, 1968), by a number of mechanisms, See Figure 1.3. 
These are princ ipa lly , centrally  mediated vagal stimulation, gastric
distension and chemical stimulation by amino acids, peptides etc. in 
the food.
Mechanical stimuli 
(eg. distension - food
Acid
Vagal stimulation + Gastrin /  -  Atropine
releasing 
cel Is
Chemical stimuli 
(eg. amino acids)'
Gang!ion 
blocking 
drugs
Figure 1.3 Factors causing stimulation (+) and inhib ition  (-)  of 
gastrin from G cells  (From El win & Uvnas, 1966).
Lichtenberger and his collegues (1982) have shown that the a b i l i ty  of 
amino acids to release gastrin is correlated with th e ir  l ip id  
so lu b il ity  in v itro  and that amino acid decarboxylation may be a 
necessary step in gastrin release. Gastrin release induced by vagal 
stimulation and gastric distension are enhanced by atropine (Feldman 
et a l . ,  1979; Dockray & Tracy, 1980), indicating that a non- 
cholinergic vagal stimulation is involved and also that a cholinergic 
vagal stimulation inhibits the release of gastrin. Bombesin may be 
this non-cholinergic transmitter. In contrast to th is ,  gastrin 
stimulation by amino acids is inhibited by atropine.
Gastrin is also released when food enters the in testine , even when 
the stomach is denervated. Cholecystokinin is a hormone released from 
the intestine that may be responsible for this subsequent release of 
gastrin. Although atropine and related anti-cholinergics have been 
used for many years to reduce gastric secretions, Ito  (1981) has 
shown that there is l i t t l e  evidence that post-ganglionic,
parasympathetic cholinergic fibres actually innervate parietal ce ll  
d ire c t ly .  A simplified diagram of the nerve supply to the stomach 
wall is shown in figure 1.4.
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Figure 1.4 Simplified diagram showing the major nerve supplies 
to the stomach wall (From Hally & Lloyd, 1968)
Pirenzipine, a muscarinic receptor antagonist, also decreases gastri 
secretions and accelerates the healing of peptic ulcers (Jaup et a l .  
1980; Londong, 1982). Pirenzipine however has se lec tiv ity  in its  
action; showing inhib ition in the stomach but not, for example, the 
heart, bladder or eye (Jaup et a l . ,1 9 8 0 ) .  Hammer & collegues have 
suggested that this se lec tiv ity  is due to two types of muscarinic 
receptor, designated Ml and M2 (Hammer & Giachetti, 1982). Those in 
the stomach are of the Ml type.
The rise in gastrin secretion that occurs a fte r  vagotomy (Alumets et 
a l . ,  1980) due to the lack of acid feedback inhibition of gastrin 
release, demonstrates the effect of one of the many feedback 
mechanisms under which the gastro-intestinal tra c t  functions.
Gastrin i t s e l f  does not appear to be the actual stimulator of the 
oxyntic c e lls . This fina l stimulation appears to be due to 
histamine - synthesised in the gastric mucosa (Soil et a l . ,  1979) -  
acting on receptor sites (Black et a l . ,  1972), particu larly  
following vagal stimulation (Macintosh, 1938).
When the stomach contents enter the duodenum, reflexes in it ia te d  in 
the la t te r  organ, not only control the rate of gastric emptying
(discussed la ter) but also control the rate of acid secretion in the
stomach. Thus an acid ified duodenum reduces both the rate of gastric  
emptying and the rate of acid secretion. This e ffect is generally 
referred to as the in testinal phase of the control of acid secretion.
The major motor component of the stomach consists of a series of 
p e r is ta lt ic  waves occurring in rhythmic sequence. In man the rhythm 
is approximately three per minute (Hightower & Code, 1950); in dogs 
i t  is four to five per minute (Bass et a l . ,  1961; Carlson et a l . ,  
1966) and in rats i t  is three to f ive  per minute, (This report, 
Chapter 2 ) .  As the contraction moves into the terminal antrum, the 
pyloric canal also contracts. This results in most of the contents 
propelled by the contraction being forced back into the stomach, thus
mixing and breaking up the stomach contents. Therefore only a limited
quantity of food is expelled into the duodenum following each 
contraction.
Gastro-intestinal hormones
The word hormone was introduced in 1905 by Starling to describe a 
chemical system that allowed stimuli received at one part of the body 
to a lte r  a c t iv ity  at a remote s ite .  Numerous hormones have since been 
discovered but the f i r s t ,  discovered in 1902 by Bayliss and Starling ,  
was secretin. Despite this early s tart and the plethora of 
publications ever since, the a c t iv ity  of gastro-intestinal hormones, 
including that of secretin, s t i l l  has not been fu l ly  elucidated.
The problems associated with determining precisely the role of each 
identified  hormone are partly explained by factors that most 
investigators are aware of but do not always fu l ly  appreciate. One 
such factor is species variation , and a second, rarely considered, is 
the possible presence of vestig ia l hormones or receptors.
Most authors are aware of species differences but few comment on its  
implications. When species differences are referred to , i t  is 
frequently cursory. For example in a paper devoted to whether or not 
motilin levels are increased or decreased by a lka lin isation of the 
in testine, Mitznegg and co-workers (1976a) mention that although 
the ir  results show that in man motilin is decreased under these 
circumstances, other workers (Dryburgh & Brown, 1975) had shown 
precisely the opposite in dogs. Such a difference c learly  may have 
been of importance in the interpretation of the results , but th is was 
not discussed. I t  is important that theories regarding the mechanism 
of the gut hormones should take such species differences into 
account.
I t  would be surprising i f ,  amongst the many dozens of hormones that 
have been implicated in gastro-intestinal functions, some of them, or 
the receptors and tissues on which they act, are not ve s tig ia l.  
Because a hormone is present in re la t iv e ly  large concentrations i t  
does not mean that i t  is either functional or essential. One only has 
to compare the size of the human appendix with that of the human 
adrenal or p itu ita ry  to appreciate that quantity is not proof of 
u t i l i t y .  Insulin receptors for example are found on lymphocytes that 
do not respond to insulin (Gavin, 1974). The reason could be that a 
vestigial condition is present. Species differences may also, in some 
cases, be explained by variations in the vestigial nature of the 
various hormonal components.
Thus when an action of a hormone is determined in an animal and the 
same hormone is found to be present in man, to conclude, by 
implication or otherwise, that the hormone has that same action in 
man may be incorrect. In gastro-intestinal research the frequency of 
assumptions ignoring the possib ility  of vestig ia l components and 
species variation, is very high. For example the opening sentance of 
the paper by Debas et a l .  (1977) concerned with human 
gastro-intestinal hormones, states: "Motilin is the only peptide 
extracted from the upper small intestine that stimulates motor 
a c t iv ity  of the gastric fundus. (Brown et a l . ,  1971)." No mention 
is made of the fact that Brown only referred to dogs. S im ilarly  the 
opening sentance to the paper by Christofoides et a l.,(1979b) states: 
"Motilin has been shown to stimulate gastro-duodenal motor a c t iv ity  
(Jennewein et a l . ,  1975) and to accelerate in testinal tran s it  time 
(Ruppin et a l . ,  1976) in humans." In fact the paper by Jennewein only 
refers to dogs. These examples i l lu s t ra te  how essential i t  is to 
consider species variation, and within tha t, to be aware of the high
probability that some of the gastro-intestinal hormones are l ike ly  to 
be v e s tig ia l.
Gastrin:
Very few of the actions of the gastro-intestinal hormones (gastrin , 
secretin, vaso-active polypeptide, cytocystokinin, m otil in ,  
enkephalins, Substance P) on gastric m o til ity  have been shown 
conclusively to be physiological. One exception to this is the action 
of gastrin on the antral or d ista l stomach to induce contractions. 
Gastrin is released from 1G1 ce lls  located in the pylorus (Solcia et 
a l . ,  1969). I t  is released by a number of factors, but primarily  
a fte r  the ingestion of food due to the prescence of amino acids or 
th e ir  polypeptides (Davenport, 1977). Meal-stimulated gastrin release 
is atropine-sensitive (Schiller et a 1 .,  1981; Artnak et a l . ,  1981), 
but so also is vagal stimulation which inhibits gastrin release.
The dominant neuronal pathway resulting in gastrin release appears to 
be a high threshold, non-cholinergic neurone (Schubert et a l . ,  1981; 
Track et a l . ,  1981). This hypothesis is supported by the findings of 
Harty et a l . ,  (1981), that although both nor adrenaline and carbachol 
increase gastrin release, noradrenaline is more potent, inducing a 
greater maximum release and an e a r l ie r  peak response. Thus the 
sympathetic neurones may have a major part to play in gastrin release 
and do not appear to involve jS-receptors (Sank et a l . ,  1981).
Released gastrin enters both the antrum of the stomach and the 
general circulation but these two types of release are independent of 
one another, i . e .  the release of gastrin into the lumen can be 
abolished without decreasing the release into the c irculation (Palmer 
et a l . ,  1981), where a c tiv ity  depends on intact vagal innervation 
(Okike & Kelly, 1977).
Gastrin does not a ffect the gastric emptying of solids and liquids  
equally. The hormone causes ( i )  relaxation of the proximal stomach 
(Wilbur & Kelly , 1974) thus slowing gastric emptying of liquids,
( i i )  increases the c o n tra c t i l i ty  of the antral or d ista l stomach 
(Kelly, 1970; Cooke et a l . ,  1972; Gregory & Tracy, 1964; Sanders & 
Schimmel, 1970) thus increasing gastric emptying and tr i tu ra t io n  of 
solids; and ( i i i )  inhib its  constriction of the pylorus (Thomas et a l , 
1979b) thus enhancing gastric emptying of both liquids and solids.
The reciprocal relationship that exists between gastrin and 
somastatin (Saffouri et a l . ,  1980), each having opposing actions on 
acid secretion (Bloom et a l . ,  1974), w il l  also result in indirect  
opposing actions on m o til ity  as a result of the changes in the pH of 
the gastric contents. The mechanisms controlling the secretions of 
these two hormones are quite d iffe ren t and separate (Martindale 
et a l . ,  1982).
Moti1 in :
Motilin is also released, and appears in the circulation a fte r  the 
ingestion of a mixed meal (Christofides et a l . ,  1979a), a fte r  fa t  
(Christofides et a l . ,  1979a), or a fte r  water (Christofides et a l . ,  
1979d). Exogenous motilin increases gastric emptying of solids 
(Christofides et a l . ,  1979b), and liquids (Christofides et a l . ,
1979c), but at low, physiological concentrations stimulation of 
gastric emptying of fats does not occur (Christofides et a l . ,  1981), 
thus supporting the hypothesis that physiological motilin has its  
major e ffect on the proximal stomach.
Motilin has been shown to stimulate the canine proximal stomach 
(Pinnington & Wingate, 1981; Debas et a l . ,  1977) and thus to enhance 
the gastric emptying of liquids. The canine distal stomach also
contracts to motilin (Green et a l . ,  1976), but this has not been 
shown to be a physiological response. Vagal tone is essential for 
optimal a c t iv ity  of motilin (Debas et a l . ,  1977) and both motilin  
release and motilin a c t iv ity  are atropine sensitive (Lee et a l . ,  
1981).
The peculiarity  concerning m otilin is that despite being exitatory i t  
frequently causes a decreased rate of stomach emptying in humans, 
(Ruppin et a l . ,  1975). The probable explanation for this is that
motilin is also excitatory to the duodenum, much more so in fact than
i t  is to the antrum. Thus an unreceptive duodenum and a weakly 
contracting antrum may result in delayed gastric emptying because of 
a disturbance in the co-ordination between antrum, pylorus and 
duodenum (Green et a l . ,  1976).
The rise in motilin levels that occurs in man on ac id ification  of the 
small intestine has been proposed as an explanation for the gastric  
a c tiv ity  that occurs (via the release of secretin and bicarbonate 
ions) on ac id ification  and for the inhibition of motilin release by
the output of bicarbonate ions (Mitznegg et a l . ,  1976a). This would,
however, have the effect of inhib iting the release of motilin when i t  
was most needed, i . e .  when the output of bicarbonate ions was high 
because of a low duodenal pH. I t  is much more l ik e ly  that the release 
of motilin is stimulated by a lower pH per se, i . e .  until the 
bicarbonate ions have the pH under control motilin release is high, 
thus inhibiting gastric emptying and hence decreasing the 
introduction of more acid into the small in testine.
Secretin:
As its  name implies, secretin has a gastric secretory function as its  
primary action, although this function is inhibitory rather than 
excitatory. Its  action on gastric m o til ity  is also fundamentally 
inh ib itory , causing relaxation of the proximal and antral stomachs 
and constriction of the pylorus in dogs, (Valenzuela, 1976; Kelly et 
a l . ,  1969; Fisher et a l . ,  1973), thus tending to decrease gastric  
emptying. Contrary to these reports that secretin constricts the 
pylorus in man which would tend to decrease b ile  reflux into the 
stomach, Ivey et a l . ,  (1981) report an increased b ile  reflux a fte r  
secretin administration to man; this suggests a relaxation of the 
pylorus.
In d irec tly , the anti-secretory a c t iv ity  of secretin, on gastrin- and 
food-stimulated acid secretion (Johansson et a l . ,  1972; Tumpson & 
Johnson, 1969), effects m o til ity  as a result of the decreased acid ity  
•of the gastric contents.
Vasoactive polypeptide
Vasoactive polypeptide (VIP) appears to be a neurotransmitter rather 
than a local hormone (Angel at a l . ,  1981). I t  inhib its  proximal 
contractions (Valenzuela, 1976), and relaxes gastric muscle, (Cooke,
1975), antagonises gastrin-induced contractions of the distal stomach 
(Morgan et a l . ,  1978a) and relaxes pyloric muscle (Edin, 1980). VIP 
uncouples elecro-mechanical coupling during spontaneous and 
acetylcholine-induced ac tiv ity  and antagonises pentagastrin-induced 
increases in a c t iv ity  by a d iffe ren t mechanism. Both the force and 
amplitude of pentagastrin-induced contractions are decreased whereas 
only the force of acetylcholine-induced and spontaneous contractions 
are reduced (Morgan et a l . ,  1978a).
Cytocystokinin:
Although cytocystokinin (CCK) is found in the brain, i t  does not 
appear to play a role in appetite control (Hansky et a l . ,  1981). I t  
is released a fte r  food in man, the greatest response being a fte r  
protein, possibly due to duodenal ac id ification  following a protein 
meal (Bernard et a l . ,  1981). CCK relaxes the proximal stomach 
(Valenzuela, 1976) hence slowing the rate of gastric emptying of 
liquids (Yamagishi & Debas, 1978). The inhibition of gastric emptying 
by CCK is one of the exceptions mentioned e a r l ie r  that have been 
shown to have a physiological ro le , at least in dogs (Debas et a l . ,  
1975; Strunz & Grossman, 1978). Under the influence of CCK antral 
peris ta ls is  is enhanced by an increase in the frequency of the 
pacesetter potential and the number of action potentials in the 
dista l stomach (Morgan et a l . ,  1978b). CCK is a potent stimulator of 
pyloric contractions (Fisher et a l . ,  1973; Isenberg & Csendes, 1972; 
Yamagishi & Debas, 1978), enhancing the slowing of gastric emptying 
induced by relaxation of the proximal stomach. Contraction of the 
pylorus and enhanced antral perista ls is  lead to increased 
t r i tu ra t io n .  CCK therefore is probably important in the regulation of 
the size of particles passing through to the duodenum and, in the 
regulation of the pH of the food passed into the duodenum.
Endogenous opiate derivatives:
Although the endogenous opiate derivatives are found in neurones 
(Edin, 1980) and reduce gastric emptying, th e ir  physiological 
function remains unknown. Physiological stimuli causing th e ir  release 
also remain undefined although Shea-Donohue et a l . ,  (1981), have 
demonstrated that the enkephalins are unlikely to be released due to
distension of the stomach. Opiate receptors have been demonstrated in 
gastric muscle cells (B itar and Makhlouf, 1981) but such a finding 
does not automatically proove a physiological ro le . The enkephalins 
induce pyloric contraction and gastric relaxation, both of which are 
abolished by the morphine antagonist naloxone (Edin, 1980). Both 
diamorphine and pethidine have been demonstrated to cause a marked 
delay in gastric emptying in humans (Nimmo et a l . ,  1975).
The complete role of any of the gastro-intestinal hormones remains 
unresolved. They a ll  appear to play e ither a d irect role in m o til ity  
or an indirect role by v irtue of th e ir  actions on acid secretion. 
Undoubtedly there are mechanisms that have as yet received l i t t l e  
attention. One of the most l ik e ly  of these that w ill  probably have a 
major influence on the understanding of the a c tiv ity  of 
gastro-intestinal musculature and hence on m o til ity  and gastric  
emptying is the role that calcium plays and the effect that calcium 
antagonists w il l  have on these organs. I t  is known for example that 
oral calcium leads to gastric hypersecretion without an increase in 
serum gastrin (Holtermuller, 1974). This e ffect is more pronounced in 
patients with duodenal ulcer (Barclay et a l . ,  1983) leading to the 
conclusion that milk may be detrimental for ulcer patients, contrary 
to popular b e lie f .
The role of prostaglandins in the gastro-intestinal trac t
Prostaglandins were orig ina lly  discovered in the 1930s (Kurzrok &
Lieb, 1930; Von Euler, 1934) and shown to be present in seminal f lu id  
by Von Euler (1966) as a result of the ir  a b i l i ty  to affect the state 
of contraction of smooth muscle, although at that time they were not
known as prostaglandins. Seminal f lu id  appears to be the only s ite  
within the body in which prostaglandins are stored rather than being 
produced as they are required, McGiff (1981). In other organs and 
tissues the prostaglandins are stored as precursors, the most 
ubiquitous one being arachidonic acid. Prostaglandin F whose 
structure was elucidated by Bergstrom & Sjovall (1960), was one of 
the f i r s t  of the prostaglandins to be the subject of intense 
investigation.
The formation of prostaglandins from arachidonic acid and other 
20-carbon poly-unsaturated fa tty  acids begins with the release of 
these precursors, chiefly  by the action of phospholipases, (Kunze & 
Vogt, 1971) which release arachidonic acid from membrane 
phospholipids which contain large quantities of this acid. The second 
step is common to a l l  cells  and tissues -  the formation of 
endoperoxides, a reaction catalysed by cyclo-oxygenase (Hamberg 
et a l . ,  1974), followed by tissue-specific  reactions to form active 
products. For example d iffe ren t enzymes result in prostacyclin I^ 
(PGI2 ) being formed in the vasculature, prostaglandin E£,  (PGE2 ) in 
the gastro-intestinal t ra c t ,  thromboxanes in p la te le ts , etc. A few 
synthetic pathways are shown in Figure 1.5.
The synthesis of the prostaglandins also involves the cyclic  
nucleotides and as shown by Kuehl et a l .  (1973), the synthesis of the 
F series is related to activation of cyclic guanosine mono-phosphate 
(cGMP) and that of the E series to cyclic adenosine mono-phosphate 
(cAMP). There also exist mechanisms for producing one from the other. 
For example, Wong and co-workers, (1977) have shown that 
prostaglandin F^^ can be produced from PGE2  by reduction of the 
9-keto group of PGE2 J a reaction catalysed by PGE-9-keto-reductase.
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Figure 1.5 The metabolism of arachidonic acid to form 
prostaglandins, prostacyclins and thromboxanes. Eicosatrienoic and 
eicosapentaenoic acids, bracketed at the top of the figure, give rise  
to other products that have one and three double bonds, respectively. 
(From McGiff, 1981)
Wong and his collegues have also demonstrated that this particular  
reaction is stimulated by bradykinin. Thus, although the formation of 
a particular prostaglandin may be triggered by a stimulus, this  
production can subsequently be modified to produce a d if fe re n t  
prostaglandin with a d iffe ren t a c t iv i ty .  This a b i l i ty  to a lte r  the 
type of a c t iv ity  desired is probably very important in the regulatory 
role played by this series of natural substances.
The formation of prostacyclins in the vasculature is particu larly  
interesting as MacIntyre et a l .  (1978) have shown tha t, due to the 
presence of what has become known as a plasma factor, vascular PG^ 
synthesis can be stimulated by human plasma. PG^ was shown by 
Vane and colleagues in 1976 to be a short lived metabolite of the 
prostaglandin endoperoxides PGG2  and PGH2  which inhib its  p la te le t  
aggregation. However the short lived nature of PG^ can be overcome 
by its  conversion to an active m etabolite ,. 6-keto-PGE^, which has 
prolonged a c t iv ity .
Concentrations of most prostaglandins in the blood, particu larly  in 
a rte r ia l  blood, are generally low (less than 20 pg/ml), as many, e .g .  
PGE2  and PGE^are rapidly degraded as they pass through the lungs 
(Ferreira & Vane, 1967). Notable exceptions to this are 
prostaglandin (PGA2 ) (McGiff et a l . ,  1969), and PG^ (Moncada & 
Vane, 1977) which are not destroyed in the lungs. These la t te r  two 
prostaglandins can therefore act as circulating hormones, rather than 
as local tissue hormones. As local hormones, most of the actions of 
the prostaglandins are a consequence of the ir  local effects achieved 
at very low concentrations.
Prostaglandins and the related prostacyclins and thromboxanes 
probably a l l  have a common purpose that is related to maintaining
homeostasis. They appear to be released in order to re-establish  
normal function, often through the regulation of blood flow and 
metabolism. For example, hypoxia triggers prostaglandin release in 
skeletal muscle (Messina et a l . ,  1977). Within this context, they 
can be considered as agents of defence.
Prostaglandins appear to have three major roles in the stomach. These 
are effects on m o t i l i ty ,  cyto-protection and anti-secretory  
properties. The la t te r  two are not necessarily related (Muller et 
a l . ,  1981). Prostaglandins may be involved in the maintenance of 
tone. The c r i te r ia  required to establish that prostaglandins are 
physiological mediators in the stomach are almost, but not 
unquestionably, met. Prostaglandins are found in high concentrations 
in the rat stomach (Bennett et a l . ,  1967) and the human stomach can 
metabolise prostaglandins (Peskar & Peskar, 1976; Spenney, 1979). The 
stomach mucosa can also synthesise prostaglandins (Peskar et a l . ,  
1980; Konturek et a l . ,  1979; Peskar, 1977) in both the fundal and 
antral mucosa (LeDuc & Needleman, 1980), although metabolism occurs 
more rap id lly  in the antrum (Spenney, 1979).
Prostaglandins are released from the rat stomach following distension 
(Bennett et a l . ,  1967) and by hyperosmolarity (Knapp et a l . ,  1978). 
However, they do not appear to be regulators of gastric secretions 
since inhibition of prostaglandin synthesis by indomethacin does not 
a lte r  acid output (Tepperman et a l . ,  1981), and pentagastrin 
stimulation only induces a small change in PGE^  output (Bennett,
1976). Exogenous PGE^  and PGI2 do, however, reduce acid secretion 
in dogs and rats (Gerkens et a l . ,  1978; Whittle et a l . ,  1978).
Exogenous PGE2 causes increased gastric emptying in man (Nylandeer & 
Mattsson, 1975) and in monkeys (Nompleggi et a l . ,  1980). However
gastric emptying and gastric secretion a fte r  a water load were 
unaffected by indomethacin in monkeys at a dose that completely 
inh ib its  the conversion of arachidonic acid to prostaglandins 
(Nompleggi et a l . ,  1979). This suggests that prostaglandins are not 
involved in the physiological control of gastric emptying. PGE2 
causes an increase in intraluminal pressure in vivo and contraction 
of the rat fundus preparation (Main & Whittle, 1975). Both PGE2 and 
PGF^ contract human stomach longitudinal muscle; PGF2ot also 
contracts c ircular muscle; PGE2 , however, relaxes c ircular muscle 
(Bennett & Posner, 1971). As contraction of longitudinal muscle and 
relaxation of c ircular muscle are conditions required for 
p eris ta ls is , PGE2 is most probably involved in per is ta ls is .
As stated e a r l ie r ,  the primary role of the prostaglandins and related 
substances is probably one of regulatory control to maintain the 
gastro-intestinal tract in a functional state rather than as 
mediators of gastric function per se.
The control of gastric emptying
Gastric emptying is controlled by a l l  three regions of the stomach. 
The proximal or fundic region acts as a reservoir and exibits  slow, 
sustained contractions; emptying of liquids from the stomach is 
mainly under the influence of the proximal stomach (Wilbur and Kelly ,
1973). The antrum is concerned with mixing, breaking up the food into 
smaller particles ( tr itu ra t io n )  and expulsion of solids; the food is 
forced against a closed or partly closed pylorus by the antral 
contractions, most of the food is forced back into the antrum and
a small quantity leaves the stomach usually only when the particles  
are less than 2mm in diameter, (dog) (Meyer et a l . ,  1979), or less 
than 0.5mm in diameter, (human) (Mazzotta & Malagelada, 1981). That 
the la t te r  is a generalization is demonstrated by the finding of a 
set of dentures in the jejunum of a human who died (from other 
causes) 13 minutes a fter  swallowing them, (Morgan, 1945). The pylorus 
is the fina l control of gastric emptying as far as the stomach i t s e l f  
is concerned but, as discussed la te r ,  this organ only plays a minor 
role in the control of gastric emptying, i ts  main function being to 
prevent duodenal re flux , (Fisher & Cohen, 1973).
Gastric m o til i ty  is controlled and influenced by many factors 
mediated via nervous or hormonal mechanisms or by a combination of 
the two. Emotional states also influence gastric m o t i l i ty .  Pain, 
anxiety, sadness and h o s t i l i ty  have expression in changes in gastric  
m o til ity  (Davenport, 1977). The predominant nervous control of the 
stomach is vagal. However, this vagal innervation is very complex and 
can be excitatory or inhibitory on the same part of the Stomach under 
diffe rent conditions, or be excitatory in one part of the stomach and 
inhibitory in another at the same time. Vagal innervation is also 
influenced by sympathetic tone, stomach and duodenal contents via 
vago-vagal and other reflexes and by hormonal influences.
Stimulation of the vagal nerve results in contractions, in particu lar  
an increase in the force and number of antral contractions (Lombardi 
et a l . ,  1981), which are atropine-sensitive (Downing & Morris, 1979). 
In the presence of muscarinic blockade, stimulation of the vagus 
results in relaxation which is sensitive to ganglionic blockade 
(Beani et a l . ,  1971). In the absence of muscarinic blockade but in 
the presence of ganglionic blockade, stimulation of the vagus also
results in relaxation which is sensitive to hyoscine (Downing & 
Morris, 1979). (see Figure 1 .6 ) .  Therefore there appear to be 
atropine-sensitive excitatory fibres that involve ganglia, and 
inhibitory fib res , also atropine-sensitive, which e ither do not 
involve ganglia or contain muscarinic receptors on the ganglion 
c e lls .  The relaxation induced in the presence of atropine is mediated 
via non-cholinergic, non-adrenergic nerves (Beani et a l . ,  1971). 
Differing degrees of vagal stimulation result in d iffe r in g  responses. 
Low threshold cholinergic fibres enhance gastric m o t i l i ty ,  whereas 
high threshold fibres decrease gastric m o til ity  via non-cholinergic, 
non-adrenergic fibres (Martinson, 1965).
The types of neurones involved in the non-cholinergic, non-adrenergic 
pathways remain unknown although a number have been proposed, for 
example peptidergic neurones (Angel et a l . ,  1981). Purinergic 
neurones have also been suggested (Burnstock et a l . ,  1970), and 
in v itro  work with dipyridamole; a pyrimidopyrimidine derivative  
which protects nucleotides from enzymic destruction (Bunag et a l . ,  
1964), and hence potentiates the effects of nucleotides (Stafford, 
1966); showed that the action of both adenosine triphosphate (ATP) 
and stimulation of non-adrenergic inhibitory nerves in the stomach 
were potentiated by dipyridamole. However, in vivo stimulation of 
vagal inhibitory nerves to the cat stomach were not enhanced by 
pyridylisatogen tosylate, a specific antagonist of ATP (Heazell,
1975). The hypothesis that the non-cholinergic, non-adrenergic nerves 
are purinergic was therefore not supported.
Substance P, enkephalin and vasoactive polypeptide (VIP) are a l l  
present in the vagal nerves (Edin, 1980). VIP in fact meets many of 
the c r i te r ia  to be considered as a neuro-transmitter substance. I t
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Figure 1.6 I l lus tra ted  are three components of the vagal nerve that  
influence gastric contractions. Stimulation of component 1 results in 
increased force and frequency of contractions that are inhibited by 
atropine. Stimulation of component 2 in the presence of muscarinic 
blockade causes a relaxation that is inhibited by ganglion blockers. 
Stimulation of component 3 in the presence of ganglionic blockade 
results in a relaxation that is inhibited by atropine acting e ither  
at postganglionic receptors or at muscarinic receptors at the 
ganglia.
mimics the effect of non-adrenergic, non-cholinergic vagal 
stimulation in the dog resulting in abolition of spontaneous action 
potentials and decreasing tone; i t  is present in the muscularis 
mucosa and i t  is released on nerve stimulation (Angel et a l . ,  1981). 
Not a l l  vagal excitatory fibres however are cholinergic. The vagus 
nerves supplying the pylorus in the cat contain both excitatory and 
inhibitory fib res , neither of which are either cholinergic or 
adrenergic (Edin, 1980). This is in contrast to the cholinergically  
innervated gastric contractions in the cat.
Afferent vagal nerves are as equally complex and even less understood 
than efferent nerves. Afferent vagal activation causes pyloric 
contraction and gastric relaxation via a vago-vagal reflex (Edin, 
1980). Reflex mechanisms may also involve the sympathetic nerves, . 
in tr in s ic  plexuses and hormones (Davenport, 1977). Afferent impulses 
are in it ia te d  from the stomach probably as a result of both chemical 
and mechanical receptors (Iggo, 1957; Harper et a l . ,  1959; Painta l,  
1954), and probably serve as a feedback mechanism reflecting the 
content and distention of the stomach.
The sympathetic nervous system can induce excitation or inhib ition of 
gastric contractions. Excitatory responses mediated via adreno- 
receptors have been demonstrated in a number of species including man 
guinea-pig and ra t ,  (Haffner et a l . ,  1969; Guimaraes, 1969; Innes & 
Kohli, 1969), which have been shown by Bailey (1971), to be 
^-mediated in the guinea-pig. Inhibitory responses appear to be 
mediated by both«*and p-receptors (Bailey, 1971; Daniel, 1966).
Dopaminergic neurones may also be involved in the contracti1ity  of 
the stomach. Stimulation of these neurones causes a decrease in 
gastric emptying. Some drugs which increase the rate of gastric
emptying are thought to act by antagonising endogenous dopamine 
(Pinder et a l . ,  1976). Metoclopramide for example stimulates gastric 
emptying only when the la t te r  is abnormally long or when other 
abnormal conditions prevail. This drug appears to act by increasing 
the co-ordination between stomach and duodenum (Pinder et a l . ,  1976), 
in contrast to the loss of co-ordination induced by m otil in . Whether 
dopamine acts on specific dopaminergic receptors or on adrenergic 
receptors has not been conclusively demonstrated (Thompson & 
de Carle, 1981).
Many chemicals have been proposed as having a role in the 
control of gastric m o ti l i ty .  Some of these, such as VIP may be 
neuro-transmitters, others may not be released from neurones but 
released as a result of nerve impulses, pH changes, stomach 
distension, liquids and other food constituents and by other 
hormones. For example, VIP inhib its  gastrin release in vivo but not 
in v itro  and secretin inhib its gastrin release in v itro  (Saffouri et 
e l . ,  1981). Among those proposed as being involved in the control of 
gastric m o t i l i ty ,  the most important are gastrin, m otil in , VIP, 
secretin, the enkephalins, prostaglandins, prostacyclins and 
cholecystokinin (CCK). Many of these hormones occur in more than one 
form (e .g . gastrin) and some probably describe an action that may 
involve a number of d iffe ren t substances but which are conveniently 
classified under one name (eg. CCK).
The role of the duodenum in controlling gastric emptying
Evidence that the duodenum influences the rate of gastric emptying, 
particu larly  to in h ib it  i t ,  was demonstrated many years ago, See for 
example, Best & Cohnheim (1910), Cohnheim & Dreyfus (1908) and Tobler 
(1905). I t  was found that in dogs with duodenal f is tu la s , the chyme 
lost through a f is tu la  had to be re-inserted into the intestine in 
order to reduce the rate of gastric emptying. I t  has also been known 
since the beginning of the century that no n-irr ita t ing  liquids leave 
the stomach rapidly compared to the time taken for i r r i t a t in g  liquids  
to leave. D ig e s t ib i l i ty  of food has usually been judged by the 
duration of i ts  stay in the stomach.
Isotonicity  is an important determinant of the rate of gastric  
emptying; isotonic solutions leaving the stomach faster than e ither  
hypertonic or hypotonic solutions, (Cooke, 1975; Carnot & Chassevant, 
1905). Both duodenal ac id if ica t io n , (Cohnheim & Best, 1910), and 
concentrated alkaline solutions, (Spencer et a l . ,  1916), delay 
gastric emptying. As with to n ic ity ,  therefore, the duodenum controls 
gastric emptying in order to prevent an unacceptable concentration of 
noxious material within its  lumen.
The presence of fa t  in food markedly delays gastric emptying and this  
fact has lead to several theories concerning the method by which this  
inhib ition of gastric emptying is achieved.
The f i r s t  theory was that of a reflex closure of the pylorus. When 
the duodenum received material in such a concentration that the pH, 
osmolarity, fa t content, or other constituent was too high, then a 
reflex closure of the pylorus was triggered. There appeared to be
some evidence for this theory, for example Marbaix (1898) and Tobler 
(1905), but what they were studying was inhibition of gastric  
emptying per se, and not the mechanism. In other words they assumed 
a closure of the pylorus as being the cause of the inhib ition of 
gastric emptying which they were undoubtedly recording. However, Von 
Mering (1893) had suggested that the delay in gastric emptying could 
be due to a decreased gastric muscular a c t iv ity  rather than to a 
closure of the pylorus. In 1897 he had shown that despite a resected 
pylorus, which could not close, the expulsion of various stomach 
contents occurred at the same rates, either fast or slow, as occurred 
in the presence of a normal pylorus. Thus the reflex triggered from 
the duodenum was shown to reduce the a c tiv ity  of the gastric muscle, 
although constriction of the pyloric sphincter does appear to occur 
in response to appropriate duodenal stimulation under some 
conditions.
The second theory was simply that fa t ,  e .g. o live o i l ,  slowed gastric  
emptying by v irtue of i ts  v iscosity, Moritz (1901). That high 
viscosity does reduce gastric emptying is beyond dispute (Prescott,
1974), but Edelmann (1906) did dispute the viscosity theory to 
explain the long emptying time of fats as Vaseline did not cause a 
similar long delay.
The f i r s t  theory, concerning a reflex closure of the pylorus, had 
been superseded by the viscosity theory but re-emerged in the 1930s. 
Thomas et a l .  (1934) showed that the reflex acting on the gastric  
musculature occurred in vagotomised animals, therefore indicating  
mediation via the myenteric plexus. I t  is of particular interest to 
the results presented in the following chapters of this thesis that 
whilst acid could trigger the reflex when administered to the upper, 
and as far down as the middle o f, the small in testine , fa t  could only
tr igger the reflex from the upper small in testine, Best (1911). Fat 
however has no influence on gastric m otil ity  whilst i t  is present in 
the stomach but is only e ffective  when placed in the upper part of 
the small in testine. This inhib itory effect of fa t was abolished by 
novocaine (Best & Cohnheim, 1910).
A further theory arose from the work of Ivy & Farrell (1926) who 
showed that fa t in the intestine inhibited the a c t iv ity  of a 
transplanted, and therefore denervated, gastric pouch. The 
explanation for this effect was that a hormonal mechanism was 
involved. Lim and his co-workers (Kosaka & Lim, 1930; Lim, 1933) 
have since shown that fats inhibited gastric emptying by the release 
of a hormone, enterogasterone. However, the hormone theory was also 
not the fina l explanation as Harris et a l .  (1947) showed that 
intravenous enterogasterone inhibited the vagally-in tact stomach but 
not the vagally-denervated stomach. Furthermore Waddell & Wang,
(1953) reported that vagotomy greatly increased the emptying of 
high-fat meals in patients with gastroenterostomy, thus indicating  
that the duodenal gastric reflex may be important in the control of 
gastric emptying of fa ts . Thus both a nervous and a hormonal 
component appear to be responsible for the control of gastric  
emptying of fats and these effects can either work independently or 
together.
Much of the work referred to above was done in dogs and although i t  
is unlikely that fats act on the stomach by to ta l ly  d iffe rent  
mechanisms in d ifferent species, the re la tive  importance of nervous 
v hormonal components of the reflex could d i f fe r  s ign ificantly  
between species. Thus i t  may be wrong to assume that a l l  the above 
results apply equally to a l l  species. I t  is also possible that i t  
is not the fa t per se that triggers the re flex , but the b ile  acids
released by the fa t .  There may also be a contribution from the energy 
content of fa ts . In mixed meals of fa t ,  carbohydrate and protein,
Hunt & Stubbs (1975) showed that slowing of gastric emptying allowed 
the same energy content to pass into the small intestine in unit 
time. I f  more calories were present in the stomach then smaller 
volumes were passed into the duodenum. I t  was possible to predict 
mean half-times of gastric emptying from the energy content of meals.
Although the isotonicity  of solutions is important as a control of 
the rate of gastric emptying, whether the solution is of s a lt ,  
glucose or some other solute, in the case of glucose there appears to 
be an additional, more specific , control depending on i ts  
concentration. Again evidence is contradictory; some suggesting that 
this is a vagally-mediated enterogastric re flex , others suggesting a 
hormonal control or, as seems most l ik e ly ,  a combination of the two 
(Quigley & Phelps, 1934). The use of dextrans, which cause inhib ition  
of gastric emptying but do not introduce the isotonicity  factor, have 
proved useful in helping to determine the mechanism o f action and 
indicate, in i t i a l l y  at least, that a nervous reflex is involved.
Thomas and Crider (1936, 1939) have also shown that the inhib ition  of 
gastric emptying induced by the products of protein digestion was 
probably a nervous reflex that did not involve a hormonal mechanism 
at al 1.
The term enterogastric reflex was coined to describe the control of 
gastric m o til ity  by acid in the in testine. This reflex is greatly  
modified by vagotomy although a myenteric reflex also appears to be 
involved (Thomas et a l . ,  1934). Other i r r i ta n ts ,  specifica lly  5% 
aqueous sodium chloride and 10% aqueous ethyl alcohol, were also 
found to have very similar effects to hydrochloric acid in causing an 
inhib ition of gastric peristalsis when placed in the in testine.
Two physiological functions control gastric emptying. One is the 
opening and closing of the pylorus by the pyloric sphincter and the 
other is the a lteration in the tone and a c t iv ity  of the stomach 
muscles. The former (effects on the pylorus) were i n i t i a l l y  looked 
upon, erroneously, as the most probable mechanism for the control of 
gastric emptying. I t  was assumed that a sphincter at the 'end* of the 
stomach must be there to control gastric emptying. This led to the 
pyloric reflex theory discussed above. Also, as acid is such an 
important component of normal stomach contents, i t  was also assumed 
that acid control of gastric emptying via the pylorus was the major 
regulatory mechanism. However, i t  is now well known that the acid in 
the stomach does not open the pyloric sphincter (eg. Carlson & L i t t ,  
1924; McCann, 1929; McSwiney & Pyrah, 1932), nor does acid in the 
in testine have more than a minor e ffect on the pyloric sphincter, 
(Quigley et a l . ,  1942). The pylorus has a minimal part to play in the 
control of gastric emptying, its  main role being to control gastric 
reflux . Other factors that in h ib it  gastric emptying include exercise 
(Hellebrandt & Tepper, 1934), changes in oxygen tension (Stickney & 
Van Liere, 1942; Van Liere et a l . ,  1933, 1936), environmental 
temperature (Sleeth & Van Liere, 1937) and emotional disturbances. 
(Bennett & Venables, 1920; Cannon, 1898; Quigley et a l . ,  1943), 
particu larly  stress.
Nervous control of the gastrointestinal trac t can be summarized as a 
pattern that moves from voluntary control at each end, (swallowing 
and defaecation), largely through centrally-controlled mechanisms, 
(oesophageal perista ls is  and rectal p e r is ta ls is ) ,  to mechanisms 
independent of the central nervous system (gastric emptying and 
in testinal propulsion). The stomach, small in testine, and most of the 
large intestine can therefore function in the absence of cen tra lly -
mediated nervous control. Although a l l  these parts of the 
gastrointestinal trac t may be influenced by autonomic nerves, th e ir  
basic control is under in tr in s ic  autonomous myenteric control systems 
such as the myenteric plexus. A generalisation can be made that  
v ir tu a lly  a l l  substances entering the duodenum, that have an e ffect  
on the rate of gastric emptying, tend to decrease the rate rather 
than to increase i t .
The history of chromones
The origin of the chromone series of drugs lies in the natural 
product khellin (see Figure 1 .7 ) ,  that occurs in the seeds of Ammi 
visnaga (Umbel!iferae), a plant from the Midddle East. Khellin was 
known to have vasodilatory (Bagouri, 1949) and bronchodilatory 
a c t iv i ty .  The aim of the research programme begun in 1954 by Fisons 
was to develop the bronchodilator a c t iv ity  of khellin for use in the 
treatment of asthma and at the same time to reduce the cardiovascular 
side-effects. To increase s o lu b il i ty ,  the research was directed 
towards the 2-carboxychromones which were more soluble than the 
2-methylchromones of khellin and its  direct derivatives.
Figure 1.7 Khellin
Research was severely handicapped by the lack of an animal model of 
human asthma. Guinea-pig anaphylaxis, and other pharmacological 
studies, demonstrated that none of the synthesised chromones had any 
greater a c tiv ity  as bronchodilators than had khellin i t s e l f .  
Additionally anti-spasmogenic a c t iv ity  was negligible (Cox et a l . ,  
1970). The whole chromone research programme may then have floundered 
had i t  not been for the appointment of Dr. R.E.C. Altounyan as a
c lin ic a l pharmacologist. Dr. Altounyan is an a lle rg ic  asthmatic and 
because of the very low to x ic ity  of the chromone-2-carboxylic acids, 
was w illing  to test them on himself.
Despite th e ir  poor bronchodilator and anti-spasmogenic a c t iv ity  i t  
was found that these chemicals were able to prevent or reverse 
a lle rg ic  bronchospasm induced by a standard antigen challenge. 
Activ ity  however was of short duration until in 1963 a series of 
bis-chromones, (two carboxychromone molecules linked by an alkylene 
dioxy chain) were synthesised (Fitzmaurice & Lee, 1969). In 1965 one 
of these, designated FPL 670 (sodium cromoglycate, see Figure 1 .8 ) ,  
was found to have a n t i-a l le rg ic  a c t iv ity  in man that lasted for 
several hours (Altounyan, 1967; Pepys, et a l . ,  1968). After further  
studies an extensive research programme was begun to develop FPL 670 
for c lin ic a l use in asthma.
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Figure 1.8 Sodium cromoglycate
FPL 670, the disodium salt of 1 ,3-bis (2-carboxychromon-5-epoxy)-2- 
hydroxypropane, disodium cromoglycate, sodium cromoglycate, was 
introduced into Britain in 1968 as In tal and has since been marketed 
world-wide as an effective and safe treatment for asthma and other 
a llerg ic  conditions.
Sodium cromoglycate is not an anti-inflammatory agent, a 
bronchodilator nor a pharmacological antagonist of mediators, nor h 
i t  any corticostero id-like  effects (Pepys, 1973). The a c t iv ity  of 
the drug is due to its  a b i l i ty  to in h ib it  IgE antibody/antigen 
reactions by a s tab iliz ing  effect on mast c e lls . By this mechanism, 
degranulation with the consequential release of pharmacologically 
active mediators is inhibited (Spataro & Bosmann, 1976). How this  
a c tiv ity  occurs is not fu l ly  understood but sodium cromoglycate may 
stab ilize  the mast cell membranes by ind irectly  blocking the 
entrance of calcium ions which are essential for mediator release 
(Orr, 1973; Spataro & Bosmann, 1976). See Figure 1.9.
Figure 1.9 I l lu s tra ted  is one of the possible mechanisms for the 
a c t iv ity  of sodium cromoglycate in asthma. The drug may ind irec tly  
block the entrance of calcium into the mast cell where i t  is 
essential for mediator release.
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Although sodium cromoglycate shows marked a n t i-a l le rg ic  a c t iv ity  
against the 'ea rly ' antigen-induced response, i t  also has a long-term 
prophylactic a c t iv ity  that reduces the hyper-reactivity that normally 
occurs on repeated exposure to antigen. (Altounyan, 1970; Dickson, 
1970). This reduction in hyper-reactivity probably occurs as a result 
of the drug's a b i l i ty  to in h ib it  the ' late ' anaphylactic response 
that appears to sensitize the bronchi to anaphylactic mediators 
(Cockcroft et a l . ,  1977). A second mode of action of sodium 
cromoglycate has also been proposed to explain its  a c t iv ity  in both 
exercise-induced (Davies, 1968), and sulphur dioxide-induced (DeVries 
et a l . ,  1976) bronchospasm, neither of which conditions appear to 
result in mediator release (Altounyan, 1979). An inhib itory effect of 
the drug on a reduced sympathetic tone, that is induced by exercise 
or sulphur dioxide, may explain the a c t iv ity  in these conditions.
This hypothesis however, although being studied, has not been proven.
Because of the low so lu b il ity  of In ta l ,  conventional aerosol 
administration was found to be unsuitable as a delivery system. A 
novel turbo-inhaler, the Spinhaler, was therefore developed. Despite 
the simplicity of using the Spinhaler, patient compliance, 
particu larly  amongst children, has always been less than perfect -  as 
i t  is with a l l  other aerosol administered drugs (Eney & Goldstein,
1976). Analysis of sodium cromoglycate in urine specimens of 186 
children taking In tal demonstrated that 13 % were non-compliant ( i . e .  
were either not taking the drug at a l l  or were not using the 
Spinhaler properly) and a further 16 % were e ither only p a r t ia l ly  
compliant or whose use of the Spinhaler was poor (Morrison-Smith & 
Pizarro, 1972). Although these results were not considered to be 
unacceptable, they were less than optimal. An ora lly  active drug with
the same or improved a c t iv ity  over In tal had for a long time been a 
desirable a lternative . Therefore in 1972 the search began for a 
chromone or related chemical with the efficacy of In tal but with oral 
a c t iv i ty .  Once again the lack of a specific animal model for human 
asthma hindered the early development although the percutaneous 
anaphylactic (PCA) response in rats proved to be an acceptable screen 
that gave a reasonable correlation with anti-human asthmatic a c t iv ity  
and was used extensively during the 1970s.
In 1974 proxicromil was synthesised and found to have good anti­
a lle rg ic  a c t iv ity  in animals, particu larly  in the rat PCA screen, 
a fte r  oral administration. Extensive pharmacological and safety 
evaluation testing then followed with the drug being introduced into 
c lin ica l t r ia ls  in 1976.
The to x ic ity  of proxicromil
Proxicromil is a chromone carboxylic acid derivative (6 ,7 ,8 ,9 -  
tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-l-naphtho[2,3-b]pyran-2- 
carboxylic acid) (see Figure 1 .10 ), that has a n t i-a l le rg ic  properties 
and is absorbed and active a fte r  oral administration.
The to x ic ity  p ro fi le  of the drug was evaluated in almost a hundred 
animal to x ic ity  experiments ( l is ted  in the Appendix, Table 1 ) .  Single 
doses of the drug administered ora lly  to a number of species 
including mice, ra ts , rabbits, cats, guinea-pigs and squirrel monkeys 
showed the drug to have a low order of acute to x ic ity .  Where LD5Qs 
were determined (rodents) they were approximately 2000 mg/kg ora lly  
and 100 mg/kg intravenously. Pharmacodynamic studies showed the 
compound to have no specific or potent effects on behaviour, on the 
central and autonomic nervous systems, or on the cardiovascular and 
respiratory systems. In a l l  of these systems the maximum no-effect 
dose was greater than 50 mg/kg ora lly  and 3 mg/kg intravenously.
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Figure 1.10 * Proxicromil (FPL 57787)
A range of repeated-dose studies was carried out in rats and in four 
non-rodent species. In these studies animals were dosed daily  for up 
to six-months. Apart from dogs, in which hepatotoxicity was seen at 
doses of 60 mg/kg/day and above, the main finding in these studies 
was some evidence of a dose-related i r r i t a n t  e ffect upon the gastro­
in testinal trac t at high doses. However 80 mg/kg/day was without 
serious effect in the majority of cynomolgus monkeys (the most 
susceptible species) over 180 consecutive days of treatment at this  
dose level. Similarly 80 mg/kg/day was very well tolerated by baboons 
for 180 days. Squirrel monkeys tolerated 100 mg/kg/day with few 
adverse e ffects . Generally rodents were insensitive to these actions 
of proxicromi1.
A mild anti-coagulant effect of proxicromi! was detected in vitamin 
K-deficient male rats . Careful evaluation of this finding led to the 
conclusions that i t  was a very mild e ffect in contrast to warfarin 
which was 5,000 to 10,0000 times more potent and that the effect had 
only been due to a vitamin K-deficient diet that was unknowingly 
being fed to the animals. There were some renal lesions (b i la te ra l  
tubular ectasia) in three cynomolgus monkeys that became moribund as 
a result of treatment with 80 mg/kg/day of proxicromi1. However i t  
was considered that these lesions may have been secondary to the 
severe dehydration that occurred in these animals and the consequent 
effects of high concentrations of urinary constituents (including the 
drug and its  metabolites) passing through the kidneys. No other 
studies showed evidence of renal to x ic ity .
Evaluation of the drug for i ts  potential effects on reproduction and 
i ts  potential as a teratogen was carried out in rabbits and rats . The 
results indicated that proxicromi! had no detectable effects on
f e r t i l i t y ,  nor on development of the foetus in utero, nor on 
peri/post-natal development. Furthermore the drug did not adversely 
affect the general development of young rats in a study on endocrine 
function.
A range of mutagenicity tests was completed in which the drug showed 
no mutagenic potential even at re la t iv e ly  high dose levels and 
concentrations. A series of studies also provided evidence for the 
lack of e ffect of proxicromi1 on host defense mechanisms. S im ilarly ,  
interaction studies with a number of drugs l ik e ly  to be administered 
concurrently with proxicromi1 were negative.
Life-time carcinogenicity studies were carried out in hamsters and 
rats. Although there was no indication of any carcinogenic potential 
in the hamster study, an incidence of renal tumours occurred in the 
rat study that led to the conclusion that proxicromi1 could have been 
the cause. Subsequent studies showed that the a c t iv ity  of proxicromi! 
in this respect was l ik e ly  to be as a tumour promoter and not as a 
tumour inducer. The effect only occurred at very high doses that 
probably saturated metabolic processes and thus would not be 
applicable in c lin ica l use. Nevertheless, the drug was withdrawn from 
c lin ica l t r ia ls ,  (a decision influenced by the high incidence of 
gastro-intestinal side-effects in man), and plans for the imminent 
marketing of the drug were abandoned.
Drug kinetic studies showed that proxicromi! was well absorbed a fte r  
oral administration. The drug was rapidly cleared from the blood and 
from tissues and was excreted in the urine and faeces as unchanged 
compound or as metabolites. Proxicromil was extensively metabolised 
by hydroxylation of the a lic y c lic  ring in man, ra t ,  rabbit,  
cynomolgus monkey, baboon, and hamster. Dogs however did not readily
metabolise the drug. Experiments indicated that the rate of 
metabolism was a major factor in determining plasma clearance. Dogs 
therefore had a much lower plasma clearance than the other species 
listed above, which were capable of substantial metabolism, and led 
to the severe to x ic ity  of the l iv e r  that was unique to the dog.
From a l l  of these studies i t  was concluded that proxicromil showed a 
moderately low order of to x ic ity  in acute and in repeated-dose 
studies and was without adverse effects upon the majority of 
physiological systems and functions even at high dose levels. The 
most l ik e ly  side-effect anticipated with high doses was a degree of 
i r r i ta t io n  to the gastro-intestinal t ra c t .  This was however 
considered unlikely to occur at c l in ic a l ly  useful doses. I t  was 
therefore surprising to discover the high incidence of gastro­
intestinal side effects that occurred when i t  was introduced into 
c lin ica l t r i a ls .
In humans i t  was found that proxicromil caused gastro-intestinal 
side-effects in 10-15 % of volunteers or patients. In a typical t r i a l  
in volunteers, 1 mg/kg of proxicromil administered ora lly  to six 
volunteers known to be intolerant to the drug, caused a to ta l of 20 
side-effects that were of a gastro-intestinal nature (Thomas, 1979a). 
The majority of these side-effects occurred 0.5 to 1.5 h a fter  the 
administration of proxicromil.
The results of this t r ia l  are summarized in Table 1 .2 .
Table 1.2 Incidence of gastro-intestinal side-effects
reported by six volunteers a fte r  taking 
proxicromil at 1 mg/kg ora lly
Half of these gastro-intestinal side-effects were of moderate or 
severe severity.
Data from Thomas, (1979a).
Symptom No. of volunteers reporting 
the symptom (out of 6)
Nausea (5 Subjects)
Diarrhoea (4 Subjects)
Epigastric-pain/Heartburn (4 Subjects)
Co 1 i c (4 Subjects)
Flatulence (2 Subjects)
Vomiting (1 Subject)
Such a range, severity and incidence of side-effects should have been 
predicted and led to the work reported in the following chapters.
CHAPTER 2
METHODS FOR STUDYING GASTRIC EMPTYING 
AND THE EFFECT OF SOME CHROMONES
IN RATS AND MARMOSETS
2.1 INTRODUCTION
The chromone (6 ,7 ,8 ,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-l- 
-naphtho[2,3-b]pyran-2-carboxylate, FPL 57787, proxicromil) has been 
reported to have gastro-intestinal side-effects (nausea, vomiting, 
abdominal pain) in some patients a fte r  oral administration of doses 
as low as 1 mg/kg bodyweight (Thomas 1979a, 1979b). Gastro­
in testinal side-effects at these dose levels had not been predicted 
from animal studies. I t  was therefore considered that the gastro­
intestinal side-effects seen in humans might be due to a functional 
rather than a pathological change. The time course of these effects  
(0.5 to 2h a fte r  dosing) supported a functional change. Gastro­
in testinal m o til i ty  had been studied in rats and mice as part of the 
conventional safety evaluation programme (see Appendix, Table 1 ) ,  and 
oral doses of proxicromil up to 50 mg/kg had shown no e f fe c t .  I t  was 
therefore considered that previous methods ( i . e  charcoal meal tran s it  
in rats, and faecal bolus production in mice) were in su ff ic ien tly  
sensitive.
The f i r s t  studies were therefore designed to study gastric emptying 
as a method of detecting functional changes induced by proxicromil in 
rodents. Later studies were designed to improve and simplify the 
techniques and to increase the p red ic tab ility  of the animal studies 
to man. A second Fisons oral chromone (FPL 52806) which had been 
shown to have minimal gastro-intestinal side-effects in humans was 
also studied. The marmoset, a species anatomically and probably 
functionally closer to man than rodents, was also used. From these 
experiments i t  became apparent that functional changes in the gastro­
in testinal trac t of animals in to x ic ity  studies might a ffect the rate 
of absorption of the drug and thus the plasma concentrations, hence 
this aspect of oral dosing in to x ic ity  studies was included.
2.2 METHODS
2.2.1 Transit of glass beads
The method consisted of administering small glass beads o ra lly  to 
rats and measuring the rate of tra n s it  from the stomach. The in i t ia l  
idea of using beads for this purpose arose from a paper by Christian 
and Johnson (1979) who used polystyrene beads to measure 
gastro-intestinal function in term embryos to assess the teratogenic 
potential of drugs administered to the mother. Actual techniques used 
in the present studies were developed from this original method.
Sprague Dawley (S/D) male rats weighing from 200 to 500g were used. 
Ferrets were found to be unsuitable because of both th e ir  tendancy to 
vomit and the nature of th e ir  stomach contents. Five rats per group 
were necessary to show s ta t is t ic a l significance with a l l  but the most 
active doses. The administration of drug under te s t ,  or vehicle 
control was made six minutes before the administration of the glass 
beads.
Ten beads with diameters between 5.5 and 5.8 thousands of an inch 
were administered to each animal. The animals were k il le d  at various 
times a fte r  administration of the glass beads by an intraperitoneal 
injection of sodium pentobarbitone, and were opened along the ventral 
surface, the oesophagus clamped immediately above the stomach and the 
stomach and small intestines dissected free. The contents of the 
intestines (divided into five equal parts) and the stomach were 
washed through a 50 thousands of an inch metal f i l t e r .  Although 
recovery usually approached 100%, recovery from the stomach and each 
section of the intestines was expressed as the percentage of to ta l  
recovery to account for any losses.
Studies with positive controls
Metoe1 opramide: As a positive control to increase the rate of gastri 
emptying, metoclopramide monohydrochloride [N(diethylaminoethyl)-2- 
methoxy-4-amino-5-chlorobenzamide monohydrochloride] (Maxolon, 
Beecham Research Laboratories) at 5 mg/kg (po) was used. The animals 
were k il led  60 minutes a fte r  administration of the beads.
Codeine and atropine: The f i r s t  of three experiments using codeine 
phosphate at 1 mg/kg ora lly  and atropine sulphate at 50 ^ig/kg ora lly  
(to seperate groups) did not demonstrate any a c t iv ity .  These doses 
were therefore increased by f iv e - fo ld .  The animals were k il le d  90 
minutes a fte r  administration of the beads.
Studies with proxicromil
A preliminary experiment indicated that proxicromil decreased the 
rate of gastric emptying. Proxicromil administered ora lly  at 10 or 
50 mg/kg in 0.5% methyl cellulose (M450) was then tested in male S/D 
rats. The animals were k il le d  90 minutes a fter  the administration of 
beads. A further experiment was also done with proxicromil 
administered intravenously. ■
As an exception to the author carrying out the studies reported in 
Chapters 2 to 5, two experiments with proxicromil were done by a 
junior technician. The purpose of this exercise was to determine 
whether the method would be practical in routine use and how long a 
person, new to the method, would take to both learn and perform the 
experiment.
2.2.2  Development of a weight-method that estimates the volume of
intragastric  contents remaining at a specific time.
Proxicromil has been shown to be active in the studies reported in 
Sections 2.2.1 and 2.3.1 in inhibiting the rate of gastric emptying 
in rats. The following studies were in it ia ted  with the intention of 
using the method described in Section 2.2.1 to evaluate further the 
a c t iv ity  of the drug, to study some standard drugs and to attempt to 
establish a s tructu re-activ ity  relationship of a series of chromone 
compounds with the ir  a c t iv ity  as inhibitors of gastric emptying. (The 
structure-activ ity  studies are reported in Chapter 5 ) .
During the autopsy of the rats treated with glass beads i t  was 
observed, subjectively, that the volume of the stomach contents 
appeared to be proportional to the number of glass beads remaining 
there, leading to the conclusion that when inhibition of gastric  
emptying occurred, not only were the glass beads retained, but so 
also were the 10 ml/kg of solution or suspension administered as the 
dose. Since gastric-emptying involves the removal of material from 
the stomach, a simple method is to measure the decline with time of 
the volume of the in tragastric  contents. This can be assessed by 
weighing the stomach and contents at specific times a fte r  the 
administration of a test meal (or water load). Therefore, with the 
exceptions noted in the methods, a l l  experiments in this series of 
studies were carried out by measuring the stomach weights, rather 
than by counting beads.
The drug being tested was administered ora lly  at a dose volume of 
10 ml/kg via a rubber catheter (FG 10). All drugs were administered 
in 0.5% methyl cellulose (M450). Dosing of the animals was done in a 
random order between dose groups. Six minutes a fte r  dosing with the
drug, 20 ml/kg of tap water was administered o ra lly . The purpose of 
this water was to increase the volume of the stomach in order to 
accentuate any inhibition or stimulation of gastric emptying.
All rats were k il le d  by an intraperitoneal injection of sodium 
pentobarbitone (Sagatal 60 mg/kg, 3 ml/kg) 90 minutes a fte r  the water 
was administered. This interval was particu larly  suitable for 
demonstrating a decreased gastric emptying rate , as control stomachs 
(10 ml/kg of methyl cellulose followed six minutes la ter  by 20 ml/kg 
of water) were v ir tu a l ly  empty by this time. To demonstrate an 
increased emptying rate shorter time intervals were employed.
The stomach and contents were immediately weighed and the weights 
expressed as percentages of to ta l bodyweights to take into account 
the variations in size of the animals and hence the weights of the 
stomach tissue per se and the variable volumes actually administered 
which were also based on bodyweights.
As well as studying the effect of proxicromi1, a number of 
experiments were done to study the effect of commercially available  
drugs either as positive controls (metoclopramide, codeine phosphate 
and atropine sulphate); because they are known to have gastric  
side-effects (aspirin , sodium aspirin , ibuprofen and indomethacin); 
or because they have other gastric a c t iv ity  (cim etidine).
During the toxicological 'evaluation of proxicromil i t  had been 
noticed that gastro-intestinal damage in rats tended to occur more 
markedly during the f i r s t  few days of oral treatment. By one month 
gastro-intestinal damage tended to be less. Although inhib ition  of 
gastric emptying may not be related to pathological damage, a number 
of studies were included to demonstrate whether inhib ition of gastric  
emptying also decreased a fte r  multiple daily dosing.
2.2 .3  Studies on gastro-intestinal function
by X-ray photography
Both rats and marmosets were used in these experiments. The rats 
(male) were surplus to the Toxicology Teratology Breeding Unit and 
weighed approximately 350 g at the time of use. The marmosets (male) 
were surplus to the requirements of a six-month to x ic ity  study. The 
animals were c l in ic a l ly  healthy.
Oral administration of test drug was achieved either by mixing a 
solution (or a suspension) of the dose with a barium sulphate 
suspension and administering the two together, or by administering 
them separately by gavage. Whole-body X-ray photographs were then 
taken at various times a fter dosing (between 5 and 120 minutes) 
whilst the animals were b r ie f ly  anaesthetised. Rats were 
anaesthetised with carbon dioxide and marmosets with halothane. The 
treatment of individual animals is shown in Table 2 .1 .
Table 2.1 Treatment schedule o f  animals and times
of X-ray photography a fte r  dosing
X indicates the times a fte r  dosing at which X-ray photographs 
were taken. M/C = 0.5% methyl cellulose as vehicle control.
Species Drug Dose 
(mg/kg)
Time of X-ray 
(mins) a fte r  dose
5 10 15 20 30 120
Rat M/C - X
Rat M/C - X
Rat Proxicromi1 50 X
Rat M/C - X X X
Rat Proxicromil 50 X X X
Rat FPL 52791 50 X X X
Marmoset M/C - X X X
Marmoset FPL 52806 50 X X X
Marmoset Proxicromi1 50 X X X
2.2 .4  Plasma concentrations of FPL 52806 a fter
oral administration to marmosets
FPL 52791 is absorbed re la t iv e ly  slowly in rats a fte r  oral 
administration (Fisons internal document). Both FPL 52791 and its  
sodium s a lt ,  FPL 52806, (see Table 5.4 for structures) have also been 
shown to in h ib it  gastric emptying in rats (see this and Chapter 5 ) ,  
although the la t te r  did not in h ib it  gastric emptying in marmosets.
The slow absorption seen in rats may be due to this inhib ition of 
gastric emptying which reduces the rate at which the drug enters the 
small intestine from where absorption can occur. I f  this hypothesis 
is correct then the lack of inhib ition of gastric emptying in 
marmosets should lead to a more rapid rise in plasma concentration in 
th is species compared to the ra t .  This study was designed to 
determine plasma concentrations of FPL 52806 at various times a fte r  
an oral dose of the drug.
Two male marmosets (C a lith r ix  jacchus) were used. Cannulae were 
inserted into a caudal vein o f each animal and a blood sample 
(approximately 0.3 ml) was taken from each animal prior to dosing.
4.4 mg of ^C-FPL 52806 of specific a c t iv ity  9.0 jjCi/mg was mixed 
with non-radiolabel led FPL 52806 to give a total concentration of 
FPL 52806 of 2.5 mg/ml.
The animals were ora lly  dosed by gavage with this mixture at a dose 
volume of 20 ml/kg to give a dose of 50 mg/kg. Serial blood samples 
(each of 0.3 ml) were taken from each animal at various times a fte r  
dosing (see Results). Plasma was prepared by centrifugation in a 
Gelman Hawkley haematocrit centrifuge. The radioactiv ity  in 10 pi 
aliquots of each plasma sample was determined by liquid s c in t i l la t io n  
spectrometry in 5 ml of Fisofluor "mpc" s c in t i l la to r ,  and the results  
expressed in equivalents of parent drug.
2.3 RESULTS
2.3.1 Transit of glass beads
Studies with positive controls 
Metoclopramide
Metaclopramide at 5 mg/kg ora lly  (approximately five times c l in ic a l ly  
effective doses) increased the rate of gastric emptying, see 
Table 2 .2 . The lack of v a r ia b i l i ty  was good. The drug also increased 
in testinal tran s it  for up to the third f i f t h  of the small in testine.
Codeine and atropine
Both codeine and atropine induced s ta t is t ic a l ly  s ignificant decreases 
in the rate of gastric emptying, see Table 2 .3 .
The method was therefore shown to have demonstrated s ign ificant  
responses to drug induced increases and decreases in the rate of 
gastric emptying.
Studies with proxicromil
The f i r s t  two of these experiments were carried out to determine 
whether the method was suitable for routine use as a toxicology 
screen by an otherwise untrained technician. A satisfactory 98% 
recovery of beads on the second attempt by an otherwise untrained 
person demonstrated the p rac ticab ili ty  of the method and the minimal 
training required to use the method routinely.
Proxicromil showed a dose-related decrease in the rate of gastric  
emptying, see Table 2 .4 . This decrease was very s ignificant  
(p < 0.01) at 50 mg/kg.
Table 2.2 Mean percent recover ies  o f  glass beads from the
stomach and from each 20% length of the small 
intestine 60 minutes a fte r  5 mg/kg of metoclopramide
Means of 5 animals per group
Significant reductions * * * ,  or increases ###, in glass beads at 
the stated sites a fter  metoclopramide compared to control 
values (p < 0.001).
Five equal lengths of the small intestine shown as percentages 
of the tota l length with zero commencing at the gastric end.
Treatment Stomach
(%) Small intestine
0-20 21-40 41-60 61-80 81-100
Percentage recovery of glass beads at each s ite
Control 58.4 6.0 31.0 4.4 0 0
Metoclopramide Q * * * 0 g * * * 100 ### 0 0
Table 2.3 Mean percent recover ies  o f  g lass beads from the stomach
and from each 20% of the small intestine 90 minutes 
a fte r  5 mg/kg of codeine or 250 pg/kg of atropine
These doses were approximately 2 to 10 times c lin ic a l doses.
Means of 3 animals per group
* Significant increases in glass beads a fte r  codeine and atropine 
compared to control values (p < 0 .05 ).
Five equal lengths of the small intestine shown as percentages 
of the tota l length with zero commencing at the gastric end.
Treatment Stomach
(%) Small intestine
0-20 21-40 41-60 61-80 81-100
Percentage recovery of glass beads at each s ite
Control 13.3 6.7 10.0 50.0 20.0 0
Codeine 86,7* 0 10.0 0 3.3 0
Atropine 63.3* 3.3 23.3 3.3 6.7 0
Table 2.4 Mean percent recove r ies  o f  g lass beads from the
stomach and from each 20% length of the small 
in testine a fte r  oral doses (po) of proxicromil at 
10 or 50 mg/kg and intravenously ( iv )  at 20 mg/kg
Means of 3 animals per group
Significant increase in glass beads a fter  proxicromil compared 
to control values * *  (p < 0.01)
Significant decrease in glass beads a fte r  proxicromil compared 
to control values * * *  (p < 0.001).
Five equal lengths of the small intestine shown as percentages 
of the to ta l length with zero commencing at the gastric end.
Treatment Stomach
(%) Small intestine
0-20 21-40 41-60 61-80 81-100
Percentage recovery of glass beads at each s ite
Control (po) 28.3 11.0 35.3 17.3 7.3 0
Proxicromi1 
(10 mg/kg)(po)
80.0 3.3 13.3 3.3 0 0
Proxicromi1 
(50 mg/kg)(po)
100.0** 0 Q * * * 0 0 0
Control ( iv ) 33.3 0 6.7 56.7 3.3 0
Proxicromi1 
(20 mg/kg) ( iv )
100.0** 0 0 0 0 0
2.3.2 Development of a weight-method that estimates the volume of
intragastric  contents remaining at a specific time.
Studies with proxicromil 
Dose/Response studies with proxicromil
A linear response to proxicromil was obtained when the increase in 
stomach weights of proxicromi1-treated animals compared to control 
animals was plotted against log concentration of proxicromil. The 
results are tabulated in Table 2.5 and shown graphically in 
Figure 2.1.
The effect of pre-treatment with proxicromil on subsequent 
inh ib ition of gastric emptying induced by the drug
I t  was shown that proxicromil could induce tachyphylaxis in most 
animals a fte r  only one day of pre-treatment with the drug. However 
some animals did not ex ib it  this phenomenom with the result that 
s ta t is t ic a l ly  s ignificant tachyphylaxis did not always occur. After a 
minimum pre-treatment period of 21 consecutive days however there was 
a well established tachyphylaxis. The v a r ia b il i ty  of response a fte r  
less than 21 days pre-treatment was too great for this e ffect to be 
useful in aiding studies on the mode of action of proxicromil.
A second chromone, FPL 52806, was found to be at least as active as 
proxicromil in inhibiting gastric emptying in rats. Table 2.6 shows 
the comparative ac tiv ity  of these two drugs.
Table 2.5 Group mean stomach weights as percent of bodyweights
a fte r  proxicromal administered ora lly
Means of 5 animals per group (10 control animals) with standard 
errors indicated.
* * *  S ignificant increases in stomach weights compared tq control 
values a fte r  proxicromil (p < 0.001).
N/A = Not applicable
Proxicromi1 
(mg/kg)
Stomach Weights 
as % Bodyweights
% increase 
v control
0 1.16 i  0.09 N/A
2 1.41 i  0.21 22
10 2.20 -  0.26 gQ * * *
50 2.98 i  0.22 157 * * *
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Figure 2.1 Dose response relationship of proxicromil on the 
rate o f gastric emptying in rats
Means o f  f iv e  animals per group with standard errors indicated  
Proxicromil administered o ra lly  90 minutes before the animals were 
k il le d  and the stomachs weighed.
Data from Table 2.5
Table 2.6 Comparative a c t i v i t y  o f  p ro x ic ro m il  and FPL 52806
in the ir  a b i l i ty  to in h ib it  gastric emptying
Group mean stomach weights with standard errors indicated.
* * *  Significant reductions in gastric emptying compared with 
control values (p < 0 .001), 90 minutes a fte r  dosing.
Treatment 
(50 mg/kg)
Stomach Weights 
as % Bodyweights
Control 2.06 -  0.36
Proxicromi1 4.35 ± 0.41
FPL 52806 4.77 -  0.39
Expressed as a percentage of the a c t iv ity  of proxicromil, FPL 52806 
had an inhib itory a c t iv ity  on gastric emptying of 111%.
Because of this very marked a c t iv ity  of FPL 52806, studies were done
to test the hypothesis that the two drugs would cause cross-
\
tachyphylaxis, as proxicromil had been shown to in h ib it  i ts  own 
a c t iv ity  a f te r  21 days of dosing.
FPL 52806 i t s e l f ,  l ike  proxicromil, was tachyphylactic 
(44% reduction in a c t iv ity  a fte r  pre-treatment with FPL52806 . 
p < 0 .0 1 ) . However, although pre-treatment with proxicromil did 
not cause cross-inhibition of FPL 52806 to a s ignificant extent 
(p > 0 .0 5 ) ,  pre-treatment with FPL 52806 did cause a s ignificant  
reduction in the ac tiv ity  of proxicromil (34% p < 0 .05 ).
As confirmation of the study mentioned e a r l ie r  FPL 52806 was shown to 
be at least as active as proxicromil (106% of the a c t iv ity  of 
proxicromil). Proxicromil i t s e l f  induced a large inhib ition of 
gastric emptying. I t  was also demonstrated that pre-treatment with 
proxicromil for 32 days did not influence the control response to 
methyl cellulose thus demonstrating that no permanent change to the 
control of gastric emptying had been induced by the drug.
Studies with positive controls
Atropine sulphate
An experiment designed to demonstrate whether recovery of glass beads 
and measurement of stomach weights resulted in the same conclusion 
was done using atropine sulphate as the gastric in h ib ito r , see 
Table 2 .7 .
Assessing the results by measurement of stomach weights revealed a 
30% increase over control values and by bead retention a 45% increase 
over controls. Thus both methods demonstrated similar levels of 
a c t iv ity  with the bead retention method being s lig h tly  more 
sensitive.
Dose/response studies with codeine phosphate
A linear response to codeine was obtained when the increase in 
stomach weights of codeine-treated animals compared to control 
animals was plotted against log concentration of codeine. The results 
are tabulated in Table 2.8 and shown graphically in Figure 2 .2 .  
Codeine phosphate was shown to have approximately the same degree of 
a c t iv ity  as proxicromil.
Table 2.7 Group mean stomach weights as percent of bodyweights
and percent recovery of glass beads a fte r  atropine 
sulphate administered ora lly  at 500 pg/kg
Means of 5 animals per group with standard errors indicated. 
Animals k i l le d ,  glass beads counted and stomachs weighed 
90 minutes a fte r  administration of atropine sulphate
a) Absolute values
Atropine
Sulphate
(jig/kg)
% of recovered 
beads present 
in Stomach
Stomach Weights 
as Percent of 
Bodyweights
0 62 2.22 -  0.32
500 90 2.88 -  0.34
b) Percentage increases over control values
Atropine 
Sulphate 
(>jg/ kg)
recovery as 
% of control 
values
Stomach Weights 
as % of control 
values
500 45 30
p value < 0.05 < 0.05
Table 2.8 Group mean stomach weights as percent of bodyweights 
a fte r  codeine phosphate administered ora lly
Means of 5 animals per group (10 control animals) with standard 
errors indicated.
Stomachs weighed 90 minutes a fte r  administration of codeine 
phosphate.
Significant increases in stomach weights compared to control 
values a fte r  codeine phosphate *  (p < 0 .05 ) , * * *  (p < 0 .001).  
N/A = Not applicable
Codeine P0 
(mg/kg)
Stomach Weights 
as % Bodyweights
% increase 
v control
0 2.09 -  0.17 N/A
1 1.98 i  0.13 0
5 2.88 -  0.33 38 *
25 4.10 -  0.19 gg * * *
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Figure 2 .2 Dose response re lationship o f codeine phosphate on 
the ra te  of gastric  emptying in rats
Means of f iv e  animals per group with standard errors indicated
Stomach weighed 90 minutes a fte r  the oral administration of codeine 
phosphate
Data from Table 2.8
Metoclopramide
The effect of metoclopramide on the gastric  
inhibitory a c t iv ity  of proxicromil
The purpose of this experiment was to determine whether
metoclopramide inhibited the decrease in gastric emptying induced by 
proxicromil. Proxicromil alone induced a 148% increase in stomach 
weights compared to controls (p <0.001). Although proxicromil with 
metoclopramide s t i l l  induced a s ignificant increase in weight over 
control values (84% p <0.001) this e ffect was s ign ificantly  less than
with proxicromil alone (p < 0 .05 ). The 50 mg/kg dose of proxicromil
used was probably a maximally effective  dose (as very l i t t l e  f lu id  
had le f t  the stomachs of animals receiving this dose).
The control values from this study were also used to assess whether 
the stomach weight data was parametric, in order to determine the 
most applicable method of s ta t is t ic a l ly  analysing the data from both 
this and other experiments involving rat stomach weights. A test for 
non-normality showed clearly  that the data was not non-parametric 
(p > 0 .05 ). Therefore stomach weights are analysed by parametric 
methods. At 25 mg/kg metoclopramide s ign ificantly  inhibited the 
gastric e ffect of proxicromil. The re la t iv e ly  poor a c t iv ity  of 
metoclopramide in this series of experiments, see Table 2 .9 , was 
probably due to the ninety minute period between the administration 
of the drug and weighing of the stomachs. I t  was necessary to use., 
this long period in order to demonstrate the inhibitory a c t iv ity  of 
proxicromi1.
Table 2.9 The effect of metoclopramide on gastric  
emptying at various times a fte r  dosing
Group mean stomach weights (5 animals per group) with 
standard errors indicated.
Time intervals between dosing with metoclopramide ora lly  
and weighing the stomachs are shown in the table .
*  No s ign ificant e ffect due to metoclopramide (p > 0 .0 5 ) .  
* *  Significant increase in the rate of gastric emptying 
induced by metoclopramide (p < 0 .0 5 ) .
Maximum a c t iv ity  of metoclopramide in increasing the 
rate of gastric emptying was shown to be 60 minutes a fte r  
administration.
*(v  Gp 1)
*(v  Gp 3)
* * (v  Gp 5)
*(v  Gp 7)
Dose
Group
Time
Interval
(min)
Metoclopramide
(mg/kg)
Stomach Weights 
as % Bodyweights
1 15 0 1.28 i  0.14
2 . 15 10 1.56 ± 0.10
3 30 0 1.34 i  0.25
4 30 10 1.06 -  0.05
5 60 0 1.64 i  0.13
6 60 10 1.10 -  0.15
7 90 0 1.02 ± 0.08
8 90 10 1.22 -  0.07
Drugs w i th  known e f fe c ts  on the  g a s t r o in t e s t i n a l  t r a c t
Proxicromil as a positive control induced a 95% inhib ition of gastric  
emptying compared to control values. As shown in Table 2.10, neither 
aspirin , sodium aspirin , indomethacin, ibuprofen nor cimetidine had 
any e ffec t on the rate of gastric emptying.
Table 2.10 The effects of aspirin , sodium aspirin , indomethacin, 
ibuprofen and cimetidine on the rate of gastric  
emptying compared to the a c t iv ity  of proxicromil
Group mean stomach weights (5 animals per group) with standard 
errors indicated.
# No significant a c t iv ity  compared to control values (p > 0 .0 5 ) .
* * *  Significant inhibition of gastric emptying (p < 0 .0 0 1 ) .
N/A = Not applicable
*
Treatment
(50mg/kg)
Stomach Weights 
as % Bodyweights
% Change from 
Control values
(Control) 2.77 -  0.32 N/A
Proxicromi1 5.39 i  0.55 gtj * * *
Aspirin 2.76 -  0.08 o *
Na Aspirin 2.56 i  0.31 0 *
Indomethacin 2.59 -  0.63 0 *
Ibuprofen 2.21 t  0.41 0 *
Cimetidine 2.44 i  0.24 0 *
2 .3 .3  Studies on g a s t r o - in t e s t in a l  fu n c t io n  by X -ray photography
Within 5 minutes of the oral administration of a barium sulphate 
suspension to rats , the contrast medium had progressed 20 to 30 cm 
along the small intestine (See Figures 2.3 & 2 .5 ) .  When proxicromil 
or FPL 52791 (the sodium sa lt of FPL 52806) were administered at the 
same time as the barium sulphate, the contrast medium had again 
progressed 20 to 30 cm along the intestine (See Figures 2.4 & 2 .6 ) .  
However, i t  was noticeable in these animals, part icu larly  the 
proxicromil treated animals (See Figure 2 .4 ) ,  that the contrast 
medium did not extend back as far as the stomach, ie . there was a 
break in contrast medium of approximately 5 to 10 cm, between the 
stomach and the f i r s t  section of the in testine. Thus gastric emptying 
had i n i t i a l l y  taken place but had then ceased although in testinal  
propulsion had continued. By two hours v ir tu a l ly  a l l  of the contrast 
medium had le f t  the stomach and upper intestines of control animals 
(See Figure 2.7) whereas the stomachs of animals treated with e ither  
proxicromil or FPL 52791 s t i l l  contained appreciable quantities of 
contrast medium (See Figure 2 .8 ) .
In marmosets the contrast medium had progressed 30 cm or more along 
the intestine by 30 mins (See Figure 2 .9 ) .  By two hours the stomach 
was almost empty of contrast medium which at that time was found 
predominantly in the colon. Ten minutes a fte r  an oral dose of 
FPL 52806 the contrast medium had progressed approximately 20 to 
30 cm along the intestine with further progression a fte r  30 minutes. 
(See Figure 2 .10). By two hours very l i t t l e  remained in the stomach, 
the majority appearing in the colon, as in the controls. Ten minutes 
a fte r  dosing with proxicromil however, no appreciable quantity of 
contrast medium had le f t  the stomach and this picture remained the 
same for 30 minutes. (See Figure 2 .11 ).
Figure 2.3 X-Ray photograph taken 5 min a f te r  
methyl ce l lu lose  and barium sulphate admin is t ra t ion  
to a r a t .
Figure 2.4 X-Ray photograph taken 5 min a f te r  
50 mg/kg of proxicromil  and barium sulphate 
admin is t ra t ion  to a r a t .
Figures 2.3 and 2.4 Note the distance the contrast medium has moved 
w i th in  5 minutes and the absence of contrast medium in the proximal 
duodenum (between the arrows) in the prox icromil  t reated animal.
Figure 2.5 X-Ray photograph taken 5 min a f t e r  
methyl ce l lu lose  and barium sulphate admin is t ra t ion  
to a ra t .
Figure 2.6 X-Ray photograph taken 5 min a f te r  
50 mg/kg of FPL 52791 and barium sulphate 
admin is tra t ion to a ra t .
Figures 2.5 and 2.6 Note the large amount o f contrast medium tha t  
has l e f t  the contro l  stomach and the re la t i v e  absence o f  medium in 
the in te s t in e  of the FPL 52791 treated animal.
Figure 2.7 X-Ray photograph taken 2 hours a f te r  
methyl ce l lu lose  and barium sulphate admin is t ra t ion  
to a ra t .
Figure 2.8 X-Ray photograph taken 2 hours a f te r  
50 mg/kg of FPL 52791 and barium sulphate 
admin is tra t ion  to a ra t .
Figures 2.7 and 2.8 Note the complete absence of con tras t  medium 
in the contro l  stomach and the large amount s t i l l  remaining in the 
FPL 52791 treated stomach.
Figure 2.9 X-Ray photograph taken 30 mins 
a f te r  methyl ce l lu lose  and barium sulphate 
admio is t ra t ion  to a marmoset.
Figure 2.10 X-Ray photograph Figure 2.11 X-Ray photograph
taken 30 mins a f te r  50 mg/kg of taken 30 mins a f te r  50 mg/kg of
FPL 52806 and barium sulphate proxicromil  and barium sulphate
admin is tra t ion to a marmoset. admin is tra t ion to a marmoset.
Figures 2.9, 2.10 and 2.11 Note the progression of the contrast 
medium along the in tes t ines  o f  the contro l  and FPL 52806 treated 
animals but the absence of any gas t r ic  emptying in the prox icromil  
t reated animal.
2 .3 .4  Plasma concentrations of FPL 52806 a fte r
oral administration to marmosets
Specific A ctiv ity  of . = 0.66 pCi per mg
FPL 52806
Dose Concentration = 2.5 mg per ml of FPL 52806
10 pi dose solution = 20152 dpm = 25 pg FPL 52806
Therefore 1 pg of FPL 52806 = 806 dpm
Plasma concentrations of FPL 52806 are shown in Table 2.11 and 
graphically in Figure 2.12 along with previously obtained plasma 
data from rats.
Table 2.11 , Plasma concentrations of FPL 52806 in marmosets
The data below i l lu s tra te  the rapid absorption of FPL 52806 in 
marmosets and a re la tive ly  fast decline in plasma concentrations.
p l/1
*  Pre-dose sample * *  dpm  (since 1 pg =806 dpm)
806
Animal
No
Sample
Time
(h:min)
* *
FPL 52806 
(pg/mi)
0* 0
0:10 10.6
0:20 17.0
0:30 12.3
1 1:00 24.5
1:30 13.2
2:00 6.0
3:00 2.1
4:00 1.3
5:00 0.2
0* 0
0:10 13.7
0:20 24.8
0:30 30.8
2 1:00 28.2
1:30 32.6
2:00 20.7
3:00 11.1
4:00 No Sample
5:00 2.3
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Figure 2.12 Plasma concentrations of rad ioactiv ity  a f te r  oral 
administration of 14  ^ FPL 52806 to rats and
marmosets
G ------ Q  Marmoset No. 1 a f te r  50 mg/Kg
X-------- x Marmoset No. 2 a fte r  50 mg/Kg
O ----- O  *Mean of three rats a fte r  100 mg/Kg
*  Rat data from Fisons internal report (Department of Metabolic Studies)
2.4 DISCUSSION
A method for demonstrating inhib ition of gastric emptying in vivo was 
developed. The method of measuring gastric emptying using glass beads 
was superceded by an easier and quicker method that involved only 
weighing the stomach and i ts  contents; with three animals per group 
and five  at low doses, s ta t is t ic a l  significance was achieved.
Proxicromil had a marked e ffect on the rate of gastric emptying, at 
doses as low as 10 mg/kg o ra lly ,  or 20 mg/kg intravenously. The 
degree of inhibition a fte r  intravenous dosing was low, which 
indicates that oral doses probably do not depend on absorption to 
exert the ir  e ffe c t .  The dose of 10 mg/kg ora lly  is approximately ten 
times the c lin ica l dose that induced nausea and other gastro­
intestinal si de-effects in man. Proxicromil also induced a linear  
log-dose response on the rate of gastric emptying. The 
reproducibility of the method was demonstrated with proxicromil which 
was used as a positive control in some experiments.
The rat in vivo method also detected changes in gastric emptying 
induced by known drugs, e .g. codeine (decrease) and metoclopramide 
(increase). The period between administration of the drug and autopsy 
was varied depending on the a c t iv i ty ,  e.g. for a drug decreasing 
gastric emptying, 90 minutes allowed gastric emptying to occur in 
control animals thus demonstrating a decreased rate , whereas for a 
drug increasing the rate of gastric emptying, 30 to 4 5 .minutes would 
be more appropriate as control stomachs would then s t i l l  contain most 
of the ir  contents and an increased rate could be readily seen. For a 
drug of unknown a c t iv i ty ,  60 minutes is probably the optimal time.
A degree of tolerance was demonstrated with proxicromil which 
confirms results obtained in humans that on repeated dosing the 
gastric side-effects (mainly nausea) tend to decrease in incidence. 
Similarly another chromone, FPL 52806, which was shown to be at least 
as active as proxicromil in decreasing the rate of gastric emptying 
in ra ts , also showed some tolerance. Both drugs also induced some 
cross-tolerance. The development of tolerance however was too 
inconsistent to be of value in determining the mode of action of 
either drug but did indicate the possib ility  of the two drugs having 
a common mode of action in rats.
In an attempt to visualise gastric contractions and the e ffec t of 
proxicromil on them, rats were dosed ora lly  with barium sulphate and 
then X-ray photographs taken. Gastric emptying and its  inh ib ition  
were well demonstrated. The method confirmed e a r l ie r  results that 
proxicromil inhibited gastric emptying in rats.
These X-ray studies indicated that the contrast medium, and with i t  
proxicromil, appeared to have le f t  the stomach in a small quantity 
before inhibition of gastric emptying had taken place. Propulsion of 
in testinal contents had continued, leaving a 'gap' in contrast medium 
in the proximal duodenum. This finding supported the b e lie f  (from 
studies reported in Chapter 3) that the drug acted via the duodenum.
Both proxicromil and FPL 52791 (the acid of FPL 52806) have been 
administered ora lly  to humans and both are very active as inhibitors  
of gastric emptying in rats. However proxicromil has been reported as 
causing significant gastro-intestinal discomfort in humans whilst 
FPL 52791 has not. This is therefore at variance with the results  
seen in rats. In the marmoset X-ray studies i t  was notable that 
although proxicromil caused in h ib it ion , FPL 52806 did not. (The loss
of proxicromil between 0.5 hours and 32 hours a fter  dosing due to 
vomiting is to be expected when gastric emptying is almost to ta l ly  
abolished.) Thus the marmoset appeared to respond to these two drugs 
in a manner similar to man.
The rat model therefore appears to be less specific and less 
predictable for man than does the marmoset. However, continued use of 
the rat is ju s t i f ie d  as a primary screen because although i t  may 
demonstrate false positive results i t  is unlikely to give false  
negatives -  an important requirement of any safety evaluation study. 
Any candidate drug showing a positive result in rats can then be 
examined in more detail in marmosets.
Plasma concentrations a fter  ora lly  administered FPL 52791 were 
already available from previous work carried out by Fisons Metabolic 
Studies Department. Because of the marked difference in effects on 
gastric emptying between marmosets and rats with this drug, the 
plasma concentrations were studied a fte r  oral dosing in marmosets.
The slow absorption of FPL 52791 in rats resulting in low plasma 
concentrations (shown in Figure 2.12) could have been due to the 
inhibition of gastric emptying.
The present study suggests that this was the case since plasma 
concentrations a fte r  oral administration to marmosets reached a peak 
within one hour of dosing with near-maximum concentrations at the 
f i r s t  sample time of ten minutes. Thus the lack of an inhib itory  
a c t iv ity  on gastric emptying in the marmoset allowed the drug to 
leave the stomach rapidly and hence be absorbed from the duodenum 
rapidly. The relevance of to x ic ity  studies with this drug in rodents 
for prediction to man where inhib ition of gastric emptying does not 
appear to occur may therefore be reduced. This point is discussed 
further in Chapter 6.
In conclusion, these studies have demonstrated the development of 
simple practical primary and secondary screens for evaluating the 
potential of a new drug to cause some gastro-intestinal symptoms in 
man as a result of inhib ition of gastric emptying.
Some other facets arising from an inhib ition of gastric emptying have 
been seen during these studies and are explored and discussed further 
in the following chapters.
Proxicromil has been shown to be a potent inh ib itor of gastric  
emptying in both rodents and primates. Considering the nature of the 
side-effects induced by this drug in humans, the inhibition of 
gastric emptying is almost certa in ly  the cause of the high incidence 
of gastro-intestinal discomfort that occurred in c lin ic a l t r i a ls .
CHAPTER 3
THE MECHANISM OF ACTION 
OF PROXICROMIL-INDUCED
INHIBITION OF GASTRIC EMPTYING
3.1 INTRODUCTION
Experiments described in Chapter 2 have shown that proxicromil 
reduced the rate of gastric emptying in rats in vivo. To evaluate 
this e ffect of the drug i t  was desirable to demonstrate decreased 
gastric a c t iv ity  following the addition of the drug to an in v itro  
stomach preparation.
The nature of the mechanism of the gastro-intestinal e ffect of 
proxicromil was completely unknown when these experiments were 
in it ia te d . The f i r s t  p r io r ity  was therefore to tes t the hypothesis 
that the drug had a direct e ffect somewhere on the musculature of the 
stomach, e ither by causing a long-lasting relaxation of the gastric  
muscle, a sustained contraction, or possibly an e ffect on the pyloric  
sphincter causing i t  to remain closed for long periods.
The f i r s t  three of the experiments described in this chapter were 
therefore designed to demonstrate any such a c t iv ity  of the drug. As 
these studies fa iled  to demonstrate a direct a c t iv ity  of the drug on 
the stomach, an in situ preparation was subsequently developed which 
was intermediate between the conscious in vivo screen described in 
Chapter 2 and the in v itro  screen described in the early sections of 
this chapter.
Following the successful demonstration of an inhibitory a c t iv ity  of 
proxicromil in this in situ preparation, further studies were done to 
characterize the mode, s ite  of action and nature of the a c t iv ity  of 
the drug.
3.2 METHODS
3.2.1 An organ bath in v itro  method and the effect  
of proxicromil on stomach contractions
The medium used throughout these experiments was McEwen's solution 
(McEwen, 1956) gassed continuously with 95% 02/5% CO2  and maintained 
at 35 - 1° C. Organ bath washing was by overflow. Animals were 
k illed  by cervical dislocation. The conditions pertaining to the 
in vivo stomach were reproduced as far as possible in v i t r o . To this  
end, two conditions were met; the stomach i t s e l f  was not damaged by 
inserting cannulae through the w a ll , and the drugs tested were used 
in the same concentrations as had been used in vivo. Additionally, to 
ensure that only the co n tra c t i l i ty  of the stomach was recorded, the 
a c t iv ity  of the pyloric sphincter was not involved in the 
preparation.
In i t i a l  experiments were used to determine the optimal conditions, 
procedures, and the design of the apparatus. The rats were k il le d  and 
the abdomen opened so that the gastro-intestinal trac t was exposed. 
Catheter Y was inserted through the oesophogeal junction until i t  lay 
1 cm inside the stomach (see Figure 3 .1 ) .  Catheter X was passed 
through the pyloric sphincter until i t  lay 1 cm inside the stomach. 
Contractions of the stomach were recorded using a P23BB pressure 
transducer recording on a Devices MX2 multi-channel recorder. The 
stomach was then distended via Catheter Y with 20 ml/kg of tap-water. 
After approximately 10 to 20 minutes when regular contractions had 
been obtained the stomach was washed and r e - f i l le d  with 0.5% methyl 
cellulose at 20 ml/kg. The stomach was allowed to re-establish  
regular contractions before being washed and r e - f i l le d  with either  
proxicromil, atropine sulphate, or with methyl cellulose solutions,
each at 20 ml/kg. Proxicromil was used at a concentration to give the 
equivalent of an in vivo dose of 50 mg/kg and atropine sulphate to 
give the equivalent of an in vivo dose of 1 mg/kg. Both of these 
doses of drugs had caused marked inhib ition of gastric emptying 
in vivo.
3.2.2 The effect of proxicromil on isolated 
fundic s trip  preparations
Since proxicromil was shown in the previous experiments (see Results 
Section 3 .2 .1 ) to have no effect on the contractions of the rat whole 
stomach preparation in v i t r o , this study was designed to determine 
whether or not the drug had any inhibitory effect on the rat fundic 
s tr ip .  As proxicromil had fa iled  to in h ib it  the contractions of the 
whole isolated stomach i t  was considered unlikely to have an e ffect  
on isolated muscle s trips . However, this was an assumption and needed 
to be examined in order to eliminate i t  as a possible mode of action 
of the drug.
The fundic s tr ip  preparation was as described by Vane (1957). This 
consisted of dissecting the fundic portion of the stomach from a 
freshly k il led  ra t .  The fundus was cut open to form a f l a t  sheet and 
then cut so as to produce a long s tr ip  of muscle. The muscle was 
suspended in an organ bath containing Kreb's solution warmed to 37° C 
and gassed with 95% oxygen/ 5% carbon dioxide. The preparations were 
washed by overflow and attached to an isometric strain-gauge 
transducer under a base-line tension of 1 g. Solutions or suspensions 
were added to the Kreb's solution bathing the tissue, and responses 
recorded via the transducer on an MX2 Devices recorder.
a2/s%c\i2
Reservoir
Heating Coil 35 + 1 C
li/aste Overflow 
Catheter X (Duodenum)
Catheter Y (Oesophagus)
Water Oacket (35 +  1°C)
Syringe for Dosing 
Inflow Bath Wash
Figure 3.1 Isolated stomach preparation - apparatus
Changes in intraluminal stomach pressures were recorded 
continuously a fte r  in i t ia l  distension with 0.5% methyl 
cellu lose. Test drugs were added to the lumen of the 
stomach at 20 ml/kg of pre-death bodyweight. Recordings 
of stomach contractions were made via a P23BB pressure 
transducer and a Devices MX2 multi-channel pen recorder,
3 .2 .3  An in  v i t r o  p repa ra t ion  to  demonstrate
pyloric sphincter function
The previous studies had shown that proxicromil had no direct  
inhibitory a c t iv ity  on the isolated rat stomach despite a marked 
a c t iv ity  in vivo. The possib ility  that the drug exerted i ts  a c t iv ity  
by causing constriction of the pyloric sphincter was examined in the 
studies reported in this section. The method was similar to that 
described in Section 3.2.1 except that the stomach was le f t  open at 
the pylorus with 2 to 3 cm of duodenum le f t  attached. The stomach was 
bathed in McEWen's solution. The organ bath was maintained at 
35 - 1° C and was washed by overflow. The rats were k il led  and the 
stomachs prepared as described in Section 3 .2 .1 .  A dual catheter was 
inserted through the oesophogeal junction until i t  lay 1 cm inside 
the stomach. One of the catheters was connected to a Statham P23BB 
pressure transducer recording on a Devices MX2 Recorder and the 
second catheter to a p e r is ta lt ic  pump.
Methyl cellulose (0.5% aqueous) as control, or a suspension or 
solution of the drug under test was pumped at various speeds (between 
1 and 3 ml/min) into the stomach. This resulted in a build-up of 
pressure inside the stomach as long as the pyloric sphincter remained 
closed. When the sphincter opened as a result of the increased 
pressure, the f lu id  was forced out with a consequential loss of 
pressure. The pressure changes were monitored and the maximum 
pressure reached inside the stomach before the pyloric sphincter 
opened were recorded.
3 .2 .4 .  An in  s i t u  stomach p repa ra t io n  to  demonstrate
fuctional parameters and the e ffect of proxicromil 
administered into the stomach or duodenum
This study was designed to test the hypothesis that proxicromil acted 
ind irectly  on the stomach by a mechanism that was not present 
in v i t r o . The rats were anaesthetised with sodium pentobarbitone 
administered intravenously through an in-dwelling catheter in the 
t a i l  vein. More anaesthetic was administered to maintain the level of 
anaesthesia during the experiments. The anaesthetised rats were 
opened along the midline and the stomach and the f i r s t  few 
centimetres of the duodenum were l i f te d  to the surface. For 
intraduodenal administration one short cannula was placed through an 
incision cut in the duodenum approximately 1 cm from the stomach. A 
dual cannula was inserted through the same incision in the duodenum 
but passed in the opposite d irection , ie .  into the stomach. The 
oesophagus was then ligated immediately distal to the stomach to 
prevent regurgitation with a consequential loss in stomach pressure.
To in i t ia te  stomach contractions, 0.5% aqueous methyl cellulose was 
administered to the stomach at 10 ml/kg. For administration of drug 
or vehicle into the stomach or into the duodenum a dose volume of 
1.25 ml/kg was used. As described .below, most animals were dosed with 
either proxicromil or with control methyl cellulose solution. Some 
animals however received proxicromil a fte r  methyl cellu lose, thus 
serving as the ir  own controls.
3.2.5 Dose-response relationship of proxicromi1 and
the inhibition of gastric emptying in situ
Proxicromil was administered intraduodenally to rats prepared with 
stomach and duodenal cannulae as described previously in Section 
3 .2 .4 . Pressure changes occurring in the stomach were recorded. The 
anaesthetised rats were allowed to develop spontaneous stomach 
pressure changes a fte r  the administration of 0.5% methyl cellulose  
into the stomach. Proxicromil was then administered at 1 ml/kg into  
the duodenum at doses of 1 to 16 mg/kg. After each inhib iting dose, 
the stomachs were allowed to re-establish contractions before a 
further dose was administered.
3 .2 .6  In v e s t ig a t io n  o f  the s i t e  o f  a c t io n  o f
proxicromil in the gastro-intestinal trac t
The previous studies described in Section 3.2.4 (with results in 
Section 3 .3 .4 ) demonstrated that proxicromil exerted i ts  inhib itory  
action on gastric emptying by an e ffect on the small intestine and 
not by an e ffect on the stomach i t s e l f .  This inhibition of gastro­
in testinal a c t iv ity  was demonstrated by administering the drug into 
the f i r s t  2 to 3 cm of the proximal duodenum. This study was designed 
to determine how far down the intestine this a c t iv ity  of the drug 
occurred.
The rats were prepared as described in Section 3 .2 .4 . In those 
e a r l ie r  studies the duodenal cannula was inserted as close to the 
stomach as was practical. During the present study i t  was found that  
when proxicromil was administered 80 or more centimetres from the 
stomach the drug was inactive. Therefore animals in this study had 
the duodenal cannula inserted at d iffe ren t points between 1 and 80 cm 
from the stomach in order to find where the inhibitory a c t iv ity  of 
the drug ceased.
In order to keep any disturbance of the intestines to a minimum, the 
position of the duodenal cannnula was estimated upon in i t ia l  
insertion. After each animal had been treated with proxicromil and 
the response recorded, the animal was k il le d  with an over-dose of 
sodium pentobarbitone (intravenously). The intestines were separated 
from the mesenteries and the actual distance of the cannula from the 
stomach measured. This procedure necessarily resulted in non-standard 
distances between the stomach and cannula insertion being used, as 
shown in the results.
3-2 .7  E f fe c t  o f  FPL 57787KA on stomach pressure changes in  s i t u
Proxicromil (FPL 57787), the re la t ive ly  insoluble acid, was used in 
a l l  the previously described experiments to in h ib it  gastric emptying 
the drug was administered as a solid suspended in 0.5% methyl 
cellulose. The possib ility  that i ts  action depended upon the 
insoluble particulate drug was investigated in this study by using 
the soluble sodium s a lt ,  FPL 57787KA.
The rats were prepared as described in Section 3 .2 .4 .  The abdomen of 
each of the anaesthetised rats were opened and a dual cannula 
inserted into the stomach. A second cannula was inserted into the 
duodenum. FPL 57787KA, the soluble sodium salt of proxicromil, was 
dissolved in saline at 20 mg/ml (pH 7.0) and administered into the 
duodenum at 20 mg/kg. Stomach pressure changes were recorded 
throughout the experiment.
3.3 RESULTS
3.3.1 An organ bath in v itro  method and the effect
of proxicromil on stomach contractions
Spontaneous pressure increases of 5 to 10 mm of water pressure 
usually occurred, although increases above 20 mm of water were 
occasionally seen. A number of patterns (or type of response) were 
apparent. The most consistent spontaneous pressure increase (referred  
to here as a contraction) had a frequency of approximately four per 
minute. This regular contraction occurred in a l l  preparations and is 
i l lu s tra ted  in Figure 3.2. The second most frequent, regular response 
was a periodic increase and decrease in amplitude of the. 
contractions. This occurred in most preparations and is also shown in 
Figure 3 .2 . The frequency of these amplitude changes was generally 
between 3 and 5 minutes.
S ta t is t ic a l analysis of the amplitude and frequency of the 
contractions, and of changes in base pressure recordings before and 
after treatment, and subjective assessment of the pattern and type of 
contractions, demonstrated that neither proxicromil at 50 mg/kg nor 
atropine sulphate at 1 mg/kg (doses based on pre-death bodyweights) 
had affected the pressures developed within the stomachs.
flinutes
Figure 3.2 An example of spontaneous stomach pressure 
changes in isolated rat stomachs
Contractions were in it ia te d  with 20 ml/kg (based on pre-death 
bodyweights) of 0.5% methyl cellulose. Two regular patterns of 
response are apparent; one with a frequency of approximately 
four contractions per minute and a second with a frequency of 
three to five minutes per contraction involving a regular 
increase and decrease in the amplitude of the contractions.
3.3.2 The effect of proxicromil on isolated
fundic s tr ip  preparations
Responses of fundic strip  preparations to histamine and proxicromil 
were recorded and analysed. Spontaneous contractions of the strips  
were obtained but these tended to fade over the duration of the 
experiments. Histamine at 400 jjg/ml of organ bath f lu id ,  (as the acid 
phosphate) induced contractions in two of the preparations and a 
relaxation in the th ird . The contractions were not inhibited by the 
presence of 2 jjg/ml of mepyramine maleate. Proxicromil at 500 )jg/ml 
and above, caused contractions in one preparation that had also 
contracted to histamine but had no e ffect in the second preparation 
that had contracted to histamine. A relaxation occurred a fter  
proxicromil in the preparation that had also relaxed in the presence 
of histamine. Proxicromil caused a relaxation a fter  mepyramine 
maleate (at 2 pg/m1) in the preparation in which the drug had e a r l ie r  
had no e ffec t.  Neither histamine nor proxicromil abolished the 
spontaneous contractions of the tissues.
Thus i t  was demonstrated, in both this experiment and in that 
described in Section 3 .3 .1 ,  that proxicromil had no direct inhib itory  
a c t iv ity  on the co n tra c t i l i ty  of rat stomachs.
3 .3 .3  An in  v i t r o  p repa ra t ion  to  demonstrate
pyloric sphincter function
Figure 3.3 i l lu s tra te s  the rise in intra-luminal stomach pressure 
that occurred when a liquid was pumped slowly (2 ml/min) into the 
stomach. The pressure increased gradually until the pyloric sphincter 
opened and allowed the liquid to escape. Opening of the sphincter 
could also be seen visually by the escape of food debris from the 
open end of the duodenum. The rate o f  infusion had l i t t l e  e ffect upon 
the responses at rates between 1 and 3 ml/minute but at higher rates 
than this the pyloric sphincter remained open permanently and no 
pressure build-up could be achieved.
Table 3.1 shows the effect of infusions of proxicromil at 5 mg/ml 
compared to infusions with methyl cellu lose. There were no marked 
differences between the peak pressure responses in the presence of 
proxicromil compared to those in the presence of methyl cellu lose.
T im e  ( m i n e )  o f  I n f u s i o n
Opening of Pyloric Sphincter
Figure 3.3 Intraluminal stomach pressures prior to
and a f te r  opening of the pyloric sphincter 
in iso lated ra t  stomachs
The trace i l lu s t ra te s  the maximum pressure developed w ith in  
an isolated ra t  stomach before the pyloric sphincter opened. 
In this example proxicromil was infused at 1 ml/min and at  
5 mg/kg (based on pre-death bodyweight).
Table 3.1 Peak pressures achieved whilst infusing proxicromil
at 5 mg/kg compared to 0.5% methyl cellulose
Maximum pressures (mm of water) developed within isolated rat  
stomachs before the pyloric sphincters opened.
Mean pressures with standard errors shown.
Measurements made during infusions of either methyl cellulose or 
of proxicromil at a dose equivalent to an in vivo dose of 
5 mg/kg, each at three d iffe ren t rates of infusion.
Infusion
Rate
(ml/min)
Rat
No
Peak 
Response 
(mm water)
0.5%
Methyl
Cellulose
1 15 10
2 14
18
25
10
3 24
25
25
12
Mean 16.4 i  3.2
1 16 35
17 0
2 12 0
Proxicromi1 13 30
5 mg/kg 19 15
22 20
3 23 15
26 25
Mean 17.5± 4.5
3 .3 .4  An in  s i t u  p repa ra t ion  to  demonstrate
fuctional parameters and the effect of proxicromil 
administered into the stomach or duodenum
When administered into the stomach, proxicromil had no e ffect on the 
spontaneous stomach contractions (See Figure 3 .4 ) .  However, the drug 
caused an immediate and complete cessation of stomach contractions 
when i t  was administered into the duodenum (See Figure 3 .5 ) .
Table 3.2 shows group mean responses expressed as a change above or 
below the pre-test reading and i l lu s tra te s  the reproducibility  of the 
responses to proxicromil administration.
3.3.5 Dose response relationship of proxicromil and 
the inhib ition of gastric emptying in situ
Doses of proxicromil administered intraduodenally between 1 and 
8 mg/kg induced inhibition of stomach contractions. However, the 
responses to proxicromil did not result in d iffe ren t degrees of 
inh ib ition . The drug, at whatever dose was used, caused e ither 100% 
inhib ition or zero inh ib ition . The difference in responses with 
diffe ren t doses was in the time taken to recovery.
Detailed results are shown in Table 3.3 and expressed graphically in 
Figure 3 .6 . A sample of a recording made from one rat is shown in 
Figure 3 .7 .
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Figure 3.4 The effect of proxicromil on spontaneous 
stomach contractions a fte r  administration 
to a rat stomach in situ
The recording shows intraluminal stomach pressure changes. 
(Minutes marked at the top of the trace.)
Neither 0.5% aqueous methyl cellulose as control nor proxicromil 
(FPL 57787) at 50 mg/kg had any marked effect on the spontaneous 
contractions of the rat stomach.
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Figure 3.5 The effect of proxicromil on spontaneous 
stomach contractions a fte r  administration 
to a rat duodenum in situ
The recording shows intraluminal stomach pressure changes 
before and a fte r  proxicromil (FPL57787) administration to  
the duodenum at 50 mg/kg. The immediate (less than 5 seconds) 
and complete cessation of spontaneous stomach pressure 
contractions occurred in a l l  animals treated with this dose 
of proxicromil, (see Table 3 .2 ) .
Recovery usually occurred within 30 minutes.
marked)
Table 3.2 The e f fe c t  o f  p ro x ic ro m il  on spontaneous
stomach contractions in situ
The results are shown as pressures (mm H 0) at the stated times
2
a fte r  treatment, expressed as percentage changes from pressures 
recorded before treatment.
Each result is the mean of f ive  consecutive contractions.
M/C = 0.5% methyl cellulose as vehicle and control
Site of 
Treatment
% Change in pressures from pre-treatment 
levels at the stated times a fte r  treatment
Treatment Time a fte r  Treatment (min)
5 10 30 60
Stomach
M/C -19.5 -23.6 4.7 -30.8
Proxicromil 20.1 39.3 73.5 42.1
Duodenum
M/C -3.5 9.0 3.0 -9 .0
Proxicromi1 -100.0 -100.0 -100.0 -100.0
Table 3.3 I n h ib i t io n  o f  stomach pressure changes to  va r ious
doses of proxicromil administered into the duodenum
Results are expressed as the duration of inhibition (min) 
following the stated dose of proxicromil.
Means with standard errors (SE) indicated.
*  The single dose of 16 mg/kg is not included in Figure 3 .6 .
N/A = Not administered
Duration of inhibition (minutes)
\  Dose 
Rat\(mg/kg) 
N o . \
1 2 4 8 16*
3 1 N/A 7 35 70
4 0 4 8 16 N/A
5 1 5 8 15 N/A
6 4 6 8 N/A N/A
7 2 1 0 6 N/A
8 2 2 14 25 N/A
Mean - SE 1.7 t  0.2 3.6 - 0.4 8.6 i  0.8 19.4 t  2.2 (70)
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Figure 3.6 Dose-response relationship of proxicromil 
on inhibition of gastric emptying in rats
Mean responses with standard errors indicated.
The graph shows the linear relationship between the dose 
of proxicromil and the duration of inhibition of gastric  
emptying (as measured by inhib ition of stomach contractions) 
after  administration of proxicromil to the duodenum.
Data from Table 3.3
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Figure 3.7 The e ffe c t  of increasing doses of proxicromil 
administered to the duodenum on spontaneous 
stomach contractions in s itu
The trace shows the inh ib ition  of stomach contractions following  
the administration of proxicromil to the duodenum of an 
anaesthetised ra t .  The 'A ll or None' (the la t t e r  at 1 mg/kg) 
nature of the response to proxicromil is i l lu s tra te d  in this  
recording which also demonstrates the increasing duration of 
in h ib it io n  a f te r  increasing doses of proxicromil.
3 .3 .6  In v e s t ig a t io n  o f  the s i t e  o f  ac t ion  o f
proxicromil in the gasto-intestinal tract
Some minor, part ia l inhibition of gastric contractions occurred a fte r  
the administration of proxicromil wherever the in testinal cannula was 
inserted. However, to ta l inhib ition as seen in previous studies, was 
taken as the measurable response to the administration of the 
compound. The distances along the intestine at which this occurred 
are shown in Table 3 .4 . Complete inhib ition of stomach contractions 
occurred when proxicromil was administered into the f i r s t  25 cm 
(approximately 25% of the in testinal length) of the small in testine.  
Inhibition of stomach contractions did not occur when the drug was 
administered beyond 30 cm from the stomach.
3.3.7 Effect of FPL 57787KA on stomach pressure changes in situ
The experiment was repeated in three rats . All animals showed 
cessation of stomach responses immediately a fte r  the administration 
of FPL 57787KA.
The soluble sodium s a lt ,  FPL 57787KA, showed the same a c t iv ity  on the 
stomach a fte r  administration to the duodenum as has been demonstrated 
previously with the insoluble acid, proxicromil (FPL 57787). Thus i t  
can be concluded that the a c t iv ity  of proxicromil is not dependant on 
solid particulate compound resulting in a physical i r r i ta t io n  in the 
duodenum.
Table 3.4 Duration o f  in h ib i t i o n  o f  stomach c o n t ra c t io n s  a f te r
the administration of 8 mg/kg of proxicromil into the 
small intestine at various distances from the stomach
The table i l lu s tra te s  the lack of inhibitory effect o f  
proxicromil on stomach contractions when the drug was 
administered into the duodenum more than 25 cm from the stomach.
*  No inhib ition of stomach contractions occurred.
Rat
No.
Cannula 
Insertion  
(cm from 
stomach)
Duration of 
inhib ition of 
contractions 
(min)
4 10 3
5 10 6
10 12 3
13 14 1.5
9 18 2
12 18 1
8 20 2
7 27 1
6 28 < 1
11 30 0*
1 43 0*
2 46 0*
3 80 0*
3.4 DISCUSSION
As proxicromil had such a marked inhibitory a c t iv ity  on gastric  
emptying in vivo i t  was anticipated that i f  an in v itro  stomach 
preparation could be developed that showed spontaneous pressure 
changes then the drug would in h ib it  these contractions. A suitable  
in v itro  preparation was developed that demonstrated very regular and 
reproducible contractions. The addition of proxicromil to this  
preparation however showed a notable lack of inhibitory a c t iv i ty .
Thus i t  was concluded that the drug probably did not exert i ts  
a c t iv ity  by a d irect effect on the stomach. As confirmation of this  
conclusion, the drug was also shown to have no inhibitory a c t iv ity  on 
the more conventional rat stomach strip  in v itro  preparation.
Because the drug did not d irec tly  in h ib it  stomach contractions the 
possib ility  that i t  caused a sustained contraction of the pyloric  
sphincter was investigated. Although the pyloric sphincter 
preparation would not make an ideal routine screening method due to 
the v a r ia b i l i ty  of response, i t  was clear that by considering a l l  of 
the responses in the presence of methyl cellulose and proxicromil, 
and at a l l  the infusion rates used, that there was no difference  
between these two treatments. The peak response in a ll  the methyl 
cellulose-treated stomachs was 16.4 mm of water whilst that in the 
proxicromil treated stomachs was 17.5 mm of water (p >0.05).
Thus i t  was concluded that proxicromil did not exert i ts  inh ib itory  
a c t iv ity  on gastric emptying by a direct effect on the pyloric  
sphincter. This result, together with the previous finding that the 
drug did not have a direct e ffect on the stomach i t s e l f ,  suggested 
that the a c t iv ity  of the drug must be due to an indirect action that 
would not be demonstrated in v itro .
Studies to examine the effect of the drug on an in situ stomach 
preparation were therefore instigated. The administration of 
proxicromil to the stomach of each of these animals had no marked 
effect although there was a s light suggestion that i t  may have 
increased the contract!* 1 i ty  of the stomach. As this would have been 
in opposition to the known effect of the drug in vivo ( ie .  inhib ition  
of gastric emptying) the possib ility  of this being a real e ffec t was 
unlikely . Comparison of Figures 3.4 and 3.5 and the data in Table 3.2 
shows very c learly  the complete and immediate effect on the stomach 
of proxicromil administered into the duodenum. The drug completely 
inhibited the gastric contractions.
These results confirm previous suggestions, for example a fte r  X-ray 
photography (Chapter 2) that the drug does not in h ib it  gastric 
emptying whilst in the stomach, but does so only when present in the 
duodenum. There are a number of possible mechanisms by which this  
could occur. The drug could be absorbed from the duodenum and exert 
an effect d irec tly  on the stomach via the c ircu lation . This 
possib ility  appears unlikely as the rapidity of the in situ  
inhib ition was so marked.
Nevertheless the possib ility  has been examined and is described in 
Chapter 4. A lternatively the drug could have been triggering a re flex  
in the duodenum that fed back to the stomach to in h ib it  that organ. 
This is most l ik e ly  the mechanism of action of the drug, but whether 
such a reflex is nervous or hormonal was not c la r if ie d  in the studies 
described here. Chapter 4 examines these poss ib ilit ies  in more 
deta i1.
Part of the classical confirmation of a pharmocological action of a 
drug is the demonstration of a dose-response relationship. However 
with this drug and in this in situ preparation a conventional 
dose-magnitude of response relationship could not be established. The 
effect of proxicromil on the stomach pressure changes a fte r  
administration to the duodenum appeared to be an 'a l l  or none' 
response. However there was a dose-duration of response relationship  
that is shown graphically in Figure 3 .6 . This e ffect was probably 
related to the time taken for the drug to be removed from the 
sensitive portion of the duodenum, or to be so distributed that the 
concentration became ineffective .
To test this hypothesis, proxicromil was administered into the 
duodenum at various distances from the stomach. The rate of recovery 
a fte r  small doses of proxicromil had e a r l ie r  indicated that the 
sensitive portion of the duodenum was not extensive. This was 
confirmed by the finding that the gastric inhibitory a c t iv ity  of 
proxicromil was restricted to the f i r s t  20 to 30 cm of the duodenum.
The possib ility  existed that the inhibitory a c t iv ity  of proxicromil 
was not due to a pharmacological a c t iv ity  but was a result of the 
physical presence of the insoluble acid. By inhib iting stomach 
contractions a fte r  the administration into the duodenum of the 
soluble sodium salt of proxicromil ( i . e .  FPL 57787KA) i t  was shown 
that the inhibition of gastric emptying was not due to particulate  
m ateria l.
In conclusion, this series of experiments has demonstrated that  
proxicromil exerts its  inhibitory a c t iv ity  on gastric emptying by an 
unknown mechanism (but probably by a reflex) in it ia te d  in the f i r s t  
20 to 30 cm of the rat duodenum, that the effect occurs immediately 
that the drug reaches the duodenum and that the duration o f a c t iv ity  
is related to the presence or concentration of the drug in the 
duodenum. Proxicromil had no direct e ffect on the gastric musculature 
nor on the pyloric sphincter.
CHAPTER 4
FURTHER STUDIES ON THE 
MECHANISM OF ACTION
OF PROXICROMIL
4.1 INTRODUCTION
Previous studies described in Chapters 2 and 3 have shown that 
proxicromil caused inhibition of gastric emptying by an effect  
in it ia te d  in the duodenum. Although these results were consistent 
with a nervous re flex , i t  has not been conclusively shown that the 
drug does not exert its  action by either the release of local 
hormones into the blood vasculature or as a result of absorption of 
the drug from the duodenum into the blood.
The f i r s t  series of experiments described below examines the e ffect  
of intravenous administration of proxicromil. As other studies have 
shown that o ra lly  administered proxicromil in rats results in very 
low plasma concentrations but very marked inhibition of gastric  
emptying, intravenously administered drug should have a much 
greater e ffect on gastric emptying i f  absorption from the 
gastro-intestinal trac t was necessary for a c t iv i ty .  Also, to test the 
hypothesis that the drug exerted its  action by releasing hormones 
into the blood vasculature, pairs of rats have been prepared with 
mixed blood circulations. To study the nervous reflexes involved, 
rats have been vagotomised, atropinised or had the central nervous 
system (CNS) p a r t ia l ly  or wholly destroyed.
4.2 METHODS
4.2.1 In situ inhibition of gastric emptying a fter
intravenous administration of proxicromil
Previous studies have shown that proxicromil was only active in 
inhib iting gastric emptying when i t  was administered into the 
duodenum and that i t  had no ac tiv ity  when administered into the 
stomach and prevented from entering the duodenum. The po ss ib ility  
existed that the a c t iv ity  of the drug was due to i t  being absorbed 
into the blood from the duodenum _and transported to the stomach where 
i t  could then exert i ts  inhibitory a c t iv ity  d ire c tly .  Although the 
time course of the response appeared to be too rapid (less than 
5 seconds) for this to occur, the present study was designed to test  
the hypothesis that the presence of high concentrations of 
proxicromil in the blood would not cause a greater inh ib ition  of 
gastric emptying than occurred a fte r  intra-duodenal administration.
The preparation of the animals was as described in detail in 
Chapter 3. B rie fly , anaesthetised rats had cannulae inserted into the 
duodenum and the stomach and an in-dwelling catheter in the t a i l  
vein. Another cannula in the stomach was also included for measuring 
the pressure changes occurring there.
Contractions of the stomach were in it ia te d  with 20 ml/kg of 0.5% 
methyl cellulose (M450) administered into the stomach, and recorded 
on a Devices MX2 recorder. Proxicromil was administered intravenously 
via the in-dwelling ta i l  catheter over periods of one to three 
minutes at a concentration of 12.5 mg/kg and at a dose volume of 
1 ml/kg.
4 .2 .2  The e f fe c t  o f  p ro x ic ro m il  on the stomach pressure changes
in pairs of rats with a common blood circulation
Evidence has been presented e a r l ie r  that the a b i l i ty  of proxicromil 
to in h ib it  stomach contractions a fte r  administration to the duodenum 
is probably due to an action on a nervous re flex . The poss ib ility  
that the drug exerts i ts  a c t iv ity  by the release of hormones or other 
chemicals into the blood vasculature, although unlikely , has not been 
completely eliminated. This study was therefore designed to show that 
i f  locally  released chemical transmitters were responsible for this  
a c t iv ity  of proxicromil, a second rat with a common blood supply 
would be s im ilarly  affected.
Pairs of male rats ( l i t t e r  mates) (designated Rat A and Rat B) were 
anaesthetised with sodium pentobarbitone (Sagatal, May & Baker Ltd.) 
intravenously through an in-dwelling catheter in a la tera l t a i l  vein. 
This catheter was also used throughout the experiment for the 
administration of further quantities of sodium pentobarbitone in 
order to maintain adequate anaesthesia.
Both rats were opened along the abdominal mid-line and the oesophagus 
ligated immediately proximal to the stomach. A dual cannula (Cannulae 
X and Y, Figure 4.1) was implanted through the f i r s t  centimetre of 
the duodenum and passed 1 to 2 cm into the stomach. In Rat A, an 
additional cannula (Cannula Z) was passed into the duodenum through 
the same opening as used to cannulate the stomach. In Rat B the 
duodenum was ligated immediately d ista l to the stomach cannula. The 
abdomens of both rats were then closed.
One end of an 18 cm long plastic cannula (PP50) f i l l e d  with 
heparinized saline (500 units of heparin per ml of saline) was then 
inserted into the right jugular vein of Rat A and tied in place. The 
other end of the cannula was inserted into the right carotid artery  
of Rat B. A second cannula was inserted into the right carotid artery  
of Rat A and the right jugular vein of Rat B. Thus the cardiac output 
entering the right carotid artery of Rat A passed into Rat B and vice 
versa (See Figure 4 .1 ) .  0.1 ml/kg of heparinized saline was then 
administered via the in-dwelling venous catheters in the ta i ls  of the 
rats.
Methyl cellulose (0.5% aqueous) was then administered into the 
stomachs of both rats through Cannulae Y until regular pressure 
changes in the stomachs of both animals were recorded via Cannulae X 
through P23BB pressure transducers recording on an MX2 Devices 
recorder. Proxicromil at 20 ml/kg in 0.5% methyl cellulose*
(0.1 mg/kg) was then administered into the duodenum of Rat A through 
the duodenal cannula (Cannula Z). Pressure recordings from the 
stomachs of both rats were continually recorded.
At the end of each experiment, 0.5 ml of a 10% Nigrosin-Eosin (50:50) 
aqueous solution was administered intravenously through the in­
dwelling t a i l  catheter of Rat A and the rapid darkening of the blood 
in the cannulae carrying blood between the two rats was taken as 
confirmation that blood was flowing freely  between the two animals. 
Any experiments in which the dye did not appear in the connecting 
cannulae were discarded as in these cases clotting of the blood, in 
or around the cannulae, had occurred. The experiments were repeated 
until three pairs of rats were obtained that had not developed 
cannula-blocking blood clots during the course of the experiment.
Cannula X
Cannula Y
RAT A
Venous/Arterial Cannulae
Jugular Vein 
Carotid Artery
-  Cannula Z
Figure 4.1 Schematic representation of stomach, duodenum 
venous and carotid cannulae in pairs of rats 
with a common blood circulation
Cannula X Connected to a P23BB pressure transducer and 
MX2 Devices multi channel recorder.
Cannula Y Stomach cannula for the administration of
0.5% methyl cellulose to induce contractions, 
Cannula Z Duodenal cannula for the administration of 
proxicromi1.
4 .2 .3  The e f fe c t  o f  a t ro p in e ,  vagotomy and d e s t ru c t io n  o f
the central nervous system on stomach contractions in 
rats and on the inhibitory effects of proxicromil
Proxicromil has been shown to in h ib it  stomach pressure changes 
in situ by a mechanism that probably involves nervous pathways. In 
order to determine more closely how this effect is achieved, a series 
of studies was undertaken in which the inhibitory a c t iv ity  of 
proxicromil was studied a fte r  e ither atropine sulphate, vagotomy or 
CNS destruction.
A. The effect of atropine sulphate on 
stomach pressure changes in situ
Male, Sprague Dawley rats were anaesthetised with intravenously 
administered sodium pentobarbitone and the ir  stomachs prepared for 
in situ recording of pressure changes as described e a r l ie r .  Atropine 
sulphate was administered either d irec tly  into the duodenum, into the 
stomach or intravenously. The a c t iv ity  of proxicromil was studied 
both before and a fter  administration of the atropine sulphate. 
Atropine sulphate was administered at 0.5 mg/kg (0.5 mg/ml) to the 
duodenum, at 10 mg/kg to the stomach to give an equivalent 
concentration in that organ ( ie .  0.5 mg/ml allowing for d ilu tion  by 
the 20 ml/kg of methyl cellulose present in the stomach to in i t ia te  
contractions), or at 2 mg/kg intravenously. Proxicromil was 
administered at 8,16 or 20 mg/kg d irec tly  into the duodenum both 
before and a fte r  atropine sulphate administration. Treatment of 
individual animals is shown in Table 4 .2 .
B. The e f fe c t  o f  vagotomy on stomach pressure changes
and the e ffec t on the responses to proxicromil
Anaesthetised rats were prepared for the recording of stomach 
contractions as described e a r l ie r .  Anaesthesia was taken to a deeper 
level and the trachea cannulated. The animals were a r t i f i c ia l l y  
respired with 1.8 ml of a ir  per breath at a rate of 100 breaths per 
minute. Stomach pressure changes were recorded. The e ffect of 
b ila tera l vagotomy on the changes in pressure in the stomach were 
monitored. Proxicromil at 20 mg/kg was administered into the duodenum 
after the vagotomised rats had recovered from the immediate effects  
of vagotomy. Responses of the stomach before and a fte r  the compound 
were recorded.
C. The effect of partia l or complete destruction of the 
central nervous system on stomach pressure changes 
and the effect on the responses to proxicromil
Anaesthetised rats were a r t i f i c i a l l y  respired with 1.8 ml of a ir  per 
inspiration at a rate of 100 inspirations per minute. The rats were 
prepared for the measurement of pressure changes in the stomach and 
for the administration of drug d irec tly  into the duodenum. Two levels  
of CNS destruction were examined. One was complete destruction of the 
brain and spinal cord by pithing the animal. The second was complete 
destruction of the brain but not of the spinal cord. After 
destruction of the various parts of the CNS, the pressure in the 
stomach was monitored throughout each.experiment. In the animals in 
which pressure changes in the stomach occurred a fte r  CNS destruction, 
proxicromil at 8 mg/kg was administered d irec tly  to the duodenum and 
the effect on stomach pressure changes recorded.
4 .2 .4  The e f f e c t  o f  a lo c a l anaes the t ic  adm in is tered
intraduodenally on the response of the stomach to 
proxicromil administered into the duodenum
Anaesthetised rats were prepared for the recording of stomach 
contractions with a cannula inserted into the proximal duodenum for 
the administration of drugs. The anaethetised animals were le f t  
breathing spontaneously until regular stomach contractions were 
established. A large dose of xylocaine (10 mg/kg) was then 
administered into the duodenum. This procedure resulted in minor and 
inconsistent changes in the stomach contractions which however 
rapidly returned to a regular pattern.
Once a regular pattern of stomach contractions was established, 
proxicromil at 16 mg/kg was administered into the duodenum as a 
suspension in 0.5% methyl cellu lose. Control animals were dosed 
intraduodenally with saline instead of the xylocaine and then 
received proxicromil at 16 mg/kg intraduodenally. Stomach pressure 
changes were recorded throughout the experiments.
4.3 RESULTS
4.3.1 In situ inhibition of gastric emptying a fter  
intravenous administration of proxicromil
Although the acute intravenous LD^q for proxicromil in conscious rats 
is approximately 125 mg/kg, i t  was apparent from this study that 
one-tenth of this dose ( i . e .  12.5 mg/kg) had adverse effects in 
anaesthetised rats , resulting in irregular respiration and a tendency 
to cause skeletal muscular spasms. These probably affected the 
stomach to some degree but, as described below, did not a ffect the 
outcome of the study.
The changes seen in frequency and amplitude a fter  intravenous 
administration were considered to be related to the generalised acute 
to x ic ity  of the compound following this route of administration. I t  
was clear that intravenous administration of proxicromil was less 
effective  in inhibiting gastric contractions than intraduodenal 
administration of the same dose. See Table 4 .1 .
Table 4.1 Results o f  p ro x ic ro m il  a d m in is t ra t io n  on
pressure recordings in the stomach
A dose of proxicromil of 12.5 mg/kg was administered 
intraduodenally to Rat No. 3 as a positive control.
i . v .  = Intravenous administration 
i .d .  = Intraduodenal administration
Rat
No.
Proxicromi1 
(mg/kg)
Response of stomach pressure to proxicromil
1 12.5 i . v . 60% reduction in amplitude with increase in 
frequency. Partia l recovery over one hour.
2 12.5 i . v .
In i t ia l  inhib ition for 3 to 4 minutes with 
recovery and gradual reduction of 
contractions over a period of one hour.
Q
12.5 i . v . Some reduction in amplitude but increase 
in frequency.
J
12.5 i .d . Immediate cessation of a l l  stomach 
pressure changes.
4 .3 .2  The e f fe c t  o f  p ro x ic ro m il  on the stomach pressure
changes in pairs of rats with a common blood circulation
An example of the pressure recordings from one of the pairs of rats 
is shown in Figure 4 .2 . As can be seen, the stomach of Rat A 
immediately ceased contracting when proxicromil was administered to 
the duodenum. The stomach of Rat B continued to contract 
uninterruptedly throughout the quiescent period of Rat A and during 
the recovery period of Rat A. These results demonstrated the absence 
of any circulating mediators released by proxicromil and thus 
confirmed the results from previous studies that the a c t iv ity  of the 
drug was due to a stimulation of a nervous re flex .
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Figure 4.2 Typical stomach pressure changes in a pair 
of rats with a common blood circulation
Proxicromil was administered intraduodenally at 20 mg/kg 
to Rat A.
Stomach contractions of Rat A ceased immediately whilst 
those of Rat B continued.
4 .3 .3  The e f fe c t  o f  a t ro p in e ,  vagotomy and d e s t ru c t io n  o f
the central nervous system on stomach contractions in 
rats and on the inhibitory effects of proxicromil
A. The e ffect of atropine sulphate and proxicromil 
on stomach pressure changes
The normal spontaneous rapid contractions of the stomach were 
inhibited by atropine sulphate administered intraduodenally or 
intravenously, See Table 4 .2 . Slow contractions were then in i t ia te d ,  
(See Figure 4.3 a ) .  Proxicromil administered intraduodenally 
inhibited these slow contractions.
B. The effect of vagotomy on stomach pressure changes 
and the e ffect of proxicromil on the responses
Vagotomy inhibited the normal spontaneous rapid contractions of the 
stomach and in it ia te d  slow contractions, See Table 4 .3 . However, 
proxicromil did not inh ib it  these slow contractions, See 
Figure 4.3 b ) .
C• The effect of partia l or complete destruction of the 
central nervous system on stomach pressure changes 
and the effect of proxicromil on the responses
Destruction of the brain markedly reduced the a c t iv ity  of the stomach 
but did not in h ib it  rapid contractions completely nor did i t  result 
in the in it ia t io n  of slow contractions, See Table 4 .4 . Proxicromil 
had l i t t l e  or no effect on the remaining contractions. Destruction of 
the brain and spinal cord inhibited a l l  contractions of the stomach.
Table 4.2 E f fe c t  o f  p ro x ic ro m il  o r  a t ro p in e  su lphate  on
spontaneous stomach contractions in situ
Proxicromil was administered intraduodenally to rats that
had been treated with atropine sulphate intravenously,
intraduodenally or d irec tly  into the stomach.
*  i . s .  = Administration into the stomach, 
i .d .  = Intraduodenal administration,
i . v .  = Intravenous administration.
Rat Compound Route* Dose Changes in normal
'io. or drug (mg/kg) Spontaneous Contractions
Atropine i . s . 10 Slow contractions induced
Atropine i .d. 0.5 No additional e ffect
1 Atropine i .s . 10 Normal contractions returning
Proxicromi1 i .d. 8 No effect
Proxicromi1 i .d . 16 No effect
Proxicromil i .d. 8 Inhibition with recovery
Atropine i .s. 10 No effect
Proxicromil i .d. 8 Inhibition with recovery
2 Atropine i .d. 0.5 Inhibition with recovery
Proxicromi1 i .d. 8 Inhibition with recovery
Atropine i .d. 0.5 No e ffec t
Proxicromi1 i .d. 8 Inhib ition with recovery
Atropine i .d. 0.5 Slow contractions induced
3 Proxicromi1 i .d. 16 Inhibition
(See Figure 4.3 a)
Atropine i .d . 0.5 No effect
4 Atropine i .d . 0.5 Slow contractions induced
Proxicromi1 i .d . 16 Partia l inhib ition
Atropine i .d . 0.5 No effect
5 Atropine i .d . 0.5 Slow contractions induced
Proxicromi1 i .d . 16 Inhibition
Atropine i .d . 0.5 L i t t le  e ffect
6 Atropine i .d . 0.5 Slower contractions induced
Proxicromi1 i .d . 16 Inhibition
Atropine i .v. 2 Inhibition with slow return
7 Atropine i .v. 2 No additional e ffect
Proxicromi1 i .d . 20 Inhibition
Atropine i .v. 2 Inhibition then
8 slow contractions
Proxicromi1 i .d . 20 Slowly developing inhib ition
9 Atropine i .v. 2 Inhibition returning slowly
Proxicromi1 i .d. 20 Brief inhib ition
Table 4.3 Changes in  spontaneous c o n t ra c t io n s
a fte r  vagotomy and proxicromil
Proxicromil was administered at '20 mg/kg intraduodenally to rats 
that had been vagotomised.
Rat
No.
Effect of vagotomy on 
stomach pressure changes
Effect of intraduodenal 
Proxicromil at 20 mg/kg
10
Contractions inhib ited. Slow 
rise and fa l l  in base-line 
in i t ia te d .
No e ffect
11
Contractions inhib ited. Slow 
rise and fa l l  in base-line 
in i t ia te d .  See Figure 4.3 b)
No effect
12 All a c t iv ity  ceased. Not administered
13
Contractions inhibited. Slow 
rise and fa l l  in base-line 
in it ia te d .
No e ffect
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Figure 4.3a Slow contractions induced by atropine sulphate 
and th e ir  in h ib it io n  by proxicromil
Atropine sulphate administered intraduodenally at 0.5 mg/kg. 
Proxicromil administered intraduodenally a t  16 mg/kg
Proxicromil 20 mg/kg
intraduodenally
Figure 4.3b Slow contractions induced by vagotomy and the 
absence o f in h ib it io n  by proxicromil
Slow contractions induced a f te r  b i la te ra l  vogotomy 
Proxicromil administered intraduodenally at 20 mg/kg
Minutes
Table 4.4 Responses o f  the stomach to  CNS
destruction and to proxicromil
Proxicromil was administered intraduodenally a fte r  the various 
sections of the central nervous system had been destroyed.
Area of CNS 
destroyed
Rat
No.
Response of stomach 
to CNS destruction
Response of stomach 
to Proxicromil at 
8 mg/kg
15 Minimum a c tiv ity Not administered
16 Minimum a c t iv ity Not administered
18 Minimum a c tiv ity  
especially in base-line
Not administered
Brain only 19 Maximum-moderate a c t iv ity Minimal change
20 Maximum-moderate ac tiv ity Not administered
21 Moderate-good ac tiv ity No effect
23 Good a c t iv ity  for three 
minutes then minimum
Not administered
14 No ac tiv ity Not administered
Brain and 
spinal cord
17 No a c t iv ity  but slight  
variation in base-line
Not administered
22 No a c tiv ity Not administered
4 .3 .4  The e f fe c t  o f  a lo ca l anaes the t ic  adm in is tered
intraduodenally on the response of the stomach to 
proxicromil administered into the duodenum
The administration of xylocaine to the duodenum induced minor and 
inconsistent responses in the stomach. These were primarily an 
in i t ia l  decrease in c o n tra c til i ty  followed by irregular contractions. 
These ir re g u la r it ies  tended to fade over a period of 15 to 30 minutes 
allowing regular contractions to become re-established. The irregular  
contractions were approximately 25% smaller in amplitude than those 
recorded prior to the administration of xylocaine.
The administration of proxicromil at 16 mg/kg; a dose shown 
previously, and confirmed in the control animals in this study, to 
induce 100% inhib ition of stomach contractions; did not in h ib it  
stomach contractions in the presence of xylocaine. There appeared to 
be a small degree of inhib ition although this consisted of a re- 
introduction of ir re g u la r it ies  in stomach contractions rather than an 
overall reduction in c o n tra c t i l i ty .
4.4 DISCUSSION
The to ta l (24 hour) absorption of proxicromil a f te r  oral 
administration to rats is approximately 40% (Fisons internal 
communication). Within five  minutes of an oral dose the amount 
absorbed would be minimal (probably less than 0.1 pg/ml in the 
plasma). Even allowing for a possible faster absorption when the drug 
is administered d irec tly  to the duodenum rather than to the stomach, 
an intravenous dose of 12.5 mg/kg far exceeds the plasma 
concentrations l ik e ly  to be encountered a fte r  12.5 mg/kg 
intraduodenally. I f  proxicromil exerted its  inhibitory action 
d irec tly  on the stomach a fte r  being absorbed into the blood, such an 
intravenous dose would therefore be expected to have at least as 
great an inhibitory a c t iv ity  as an intraduodenal dose. This was not 
the case and the results of these studies confirmed previous work 
( in vivo) that proxicromil administered intraduodenally does not 
require absorption to exert i ts  inhibitory a c t iv ity  on gastric  
emptying.
The results of the paired-rats studies confirmed that proxicromil 
acts on the duodenum to in h ib it  stomach contractions by a mechanism 
consistant with a nervous rather than a hormonal action. I f  local 
hormones had been released by proxicromil and passed via the blood to
the stomach, they would also have appeared in the c irculation of the
second rat and caused a similar cessation of stomach contractions, 
since to reach the stomach of Rat A from the duodenum of that ra t the 
blood passes into the systemic c ircu la tion . There was no indication  
of any such transfer of hormones or other chemical en tit ies  between 
Rats A and B.
Further evidence of the nervous mechanism of the action of 
proxicromil in the duodenum was provided by the inhibition of the 
drug's a c t iv ity  by the prior administration of a local anaesthetic to 
the duodenum.
Thus i t  can be concluded, (considering also the evidence presented 
e a r l ie r ) ,  that proxicromil causes inhib ition  of stomach contractions 
and hence inhibition of gastric emptying in rats by a reflex  
in it ia te d  in the duodenum.
In a preceeding chapter (Chapter 3 ) ,  two spontaneous rhythms of the 
isolated stomach were described (see Figure 3.2 of Chapter 3 ) .  One of 
these rhythms was described as rapid contractions occurring 
approximately three times per minute. The second contraction, 
superimposed on the f i r s t ,  was a much slower rise and f a l l  in the 
amplitude of contractions with a period of three minutes or more.
This second, slower contraction has not been seen in situ in any of 
the numerous studies described e a r l ie r  in which spontaneous 
contractions have always been of the rapid type and of which 
proxicromil has completely inhibited a l l  a c t iv ity  (see Figure 3.5 of 
Chapter 3 ) .
In the present studies however, both atropine sulphate (see 
Figure 4.3 a) and vagotomy (see Figure 4.3 b) abolished the rapid 
contractions and in it ia te d  much slower spontaneous responses of the 
stomach. In i t i a l l y ,  vagotomy caused complete cessation of stomach 
contractions but gradually, over f ive  to twenty minutes, contractions 
with a long periodicity developed. The slow contractions were not 
always of uniform pattern in d iffe ren t animals. Figures 4.3 a) and 
4.3 b) show typical variations that occured in both atropine-treated  
and vagotomised animals. The results of these studies suggest that
the rapid contractions are due to vagal stimulation and are abolished 
by either vagotomy or atropine sulphate, allowing the slower, locally  
induced contractions to occur. However, e a r l ie r  studies have shown 
quite c learly  that the rapid contractions also occur spontaneously 
in v itro  without any vagal stimulation.
Proxicromil administered intraduodenally inhibited the slow 
contractions induced by atropine sulphate (see Figure 4.3 a ) .  However 
in marked contrast to th is ,  the drug did not in h ib it  the slow 
contractions induced by vagotomy (see Figure 4.3 b). This indicates 
that the inhibitory a c t iv ity  of proxicromil on these slow 
contractions depends upon a centrally  mediated reflex that involves 
the vagus but does not involve the release of acetyl-choline at 
muscarinic receptors.
In conclusion, the inhibitory a c t iv ity  of proxicromil on the stomach 
has been shown to be due to a nervous reflex originating in the 
duodenum. The a c t iv ity  of the drug was c learly shown not to be due to 
circulating plasma concentrations of e ither the drug i t s e l f  or of 
circulating hormones released by the drug. The reflex appeared to 
involve a non-cholinergic component of the vagus nerve.
CHAPTER 5
5TRUCTURE-ACTIVITY RELATIONSHIPS 
OF CHROMONES AND THE ACTIVITY OF 
SOAPS AND BILE SALTS AS
INHIBITORS OF GASTRIC EMPTYING
5.1 INTRODUCTION
The design of drugs depends not only on th e ir  potential efficacy but 
also on the ir  potential side-effects or to x ic ity .  Within a related  
series of chemicals tested for the ir  to x ic ity  there usually arise a 
number of side-effects that appear with one or two chemicals but not 
with the majority. Other side-effects occur that tend to appear with 
most of the drugs and can, to a greater or lesser degree, be expected 
to occur. In the la t te r  case i t  may be possible to establish some 
facets of s tructure-activ ity  relationships that can be used to 
predict such side-effects before expense and time has been wasted on 
producing and testing a potential drug. Therefore an attempt was made 
to establish a s tructure-activ ity  relationship between the a b i l i ty  to 
in h ib it  gastric emptying and the structures of a series of chromones.
Also reported in this chapter are experiments designed to determine a 
physiological role for the reflex that is triggered by proxicromil in 
the duodenum. For this purpose the effect of b ile  salts and soaps 
were studied for th e ir  a b i l i ty  to in h ib it  gastric emptying a fter  
administration to the duodenum.
5,2 METHODS
5.2 .1  S t r u c tu r e - a c t i v i t y  r e la t io n s h ip s  o f  chromone
compounds and inhibition of gastric emptying
The studies described here were designed to use the in vivo method of
measuring gastric emptying described e a r l ie r  to study a series of 
chromones and to attempt to establish a s tructure-activ ity  
relationship. The method for the estimation of gastric emptying rates 
by measuring stomach weights was as follows. All rats used in these 
experiments were male, Fisnns-bred Sprague Dawleys that were surplus 
to Breeding Unit requirements. Up to three drugs were tested per 
experiment, each with five  animals and each experiment included a
group of five animals that were dosed with proxicromil as a standard
and a group of 10 animals that were used as controls. Results were 
expressed as percentage a c t iv it ie s  compared to proxicromil in each 
study to enable comparisons to be made between experiments. All drugs 
were administered at 50 mg/kg in 0.5% aqueous methyl cellulose and 
dosed at 10 ml/kg in a random order between dose groups.
Six minutes a fte r  dosing the compound, 20 ml/kg of tap-water was 
administered o ra lly . All rats were k il le d  by an intraperitoneal 
injection of sodium pentobarbitone (Sagatal, 60 mg/ml) 90 minutes 
a fte r  the water was administered. The animals were opened along the 
abdominal mid-line and the oesophagus and duodenum clamped close to
i
the stomach to prevent leakage of stomach contents. The stomach was 
then removed from the animals. The stomach and contents were 
immediately weighed and the weights expressed as percentages of to ta l  
bodyweights.
5.2.2 The effect of soaps and b ile  salts administered into  
the duodenum on stomach contractions in situ
The animals were anaesthetised with sodium pentobarbitone (Sagatal, 
May & Baker Ltd.) administered intravenously a fte r  the animals had 
been warmed in a heated box. The rats were opened along the midline 
from immediately below the diaphragm for approximately 5 cm, thus 
exposing the abdominal contents. For intraduodenal administration, 
one short cannula was placed through a cut in the duodenum 
approximately 1 cm from the stomach and tied in place. A second 
cannula was used for recording the pressure in the stomach and was 
passed down the centre of a th ird  cannula which was used for 
administration of methyl cellulose to the stomach. The end of this  
double cannula was placed approximately 1 cm inside the stomach and 
tied in place. All the cannulae were f i l l e d  with 0.5% aqueous methyl 
cellulose before insertion and the exposed ends closed with three-way 
taps.
The oesophagus was then ligated immediately d ista l to the stomach to 
prevent regurgitation with a consequential loss in stomach pressure. 
The abdominal wall was then closed with Michel clips and the skin 
likewise. Intraluminal stomach pressure changes were recorded via a 
P23BB pressure transducer recording on a Devices MX2 recorder. To 
in i t ia te  stomach contractions, 0.5% aqueous methyl cellulose was 
administered to the stomach at 10 ml/kg. For administration of the 
soaps or b ile  salts to the duodenum a dose volume of 1.25 ml/kg was 
used. Lauryl sulphate and stearic acid palmityl ester were used as 
examples of esters of long chain fa t ty  acids and taurocholate and 
deoxycholate as examples of b ile  sa lts . (Chemical formulae of these 
bile  salts and soaps are shwn in Table 5 .6 ) .
5.3 RESULTS
5.3 .1  S t r u c tu r e - a c t i v i t y  r e la t io n s h ip s  o f  chromone
compounds and inhibition of gastric emptying
The results, grouped into the separate experiments in which the 
particular drugs were studied, are presented in the Appendix 
(Table 2 ) .  Proxicromil as a positive control was used in each 
experiment. The results are summarized in Table 5.1 which also 
includes some results obtained with other drugs presented e a r l ie r  in 
Chapter 2. The structures of a l l  of the chromones studied are shown 
in Tables 5.2 to 5 .5 .
The a c t iv it ie s  of the chromones as inhibitors of gastric emptying 
varied greatly , from the most active FPL 52806 which resulted in 
virtual 100% inhibition over the 90 minute measuring period, to the 
completely inactive FPL 50670 ( In ta l ) .  The implications of these 
results on the predictabi1i ty  of inhib ition of gastric emptying for 
new chemical structures is considered further in the Discussion to 
this chapter.
Some chromones are known to have potent surface a c t iv ity  (detergency) 
properties. I t  was apparent during these experiments that such drugs, 
e.g. proxicromil i t s e l f ,  FPL 52758 and FPL 57579, were also very 
active inhibitors of gastric emptying. A similar association had also 
been apparent in other work carried out in the Toxicology Department, 
Fisons, between detergent properties and sensory irr itancy  to the 
respiratory t ra c t .  A s ta t is t ic a l comparison of this sensory irr itancy  
data with the inhibition of gastric emptying for the same chromones 
showed a highly significant correlation, (p < 0 .01 ). CS gas was 
included in that evaluation.
Table 5.1 Summary o f  the a c t i v i t y  o f  chromone and o the r
drugs as inhibitors of gastric emptying
* Not compared to proxicromil. Stomach weights less than control 
values and therefore only expressed as percentage change from 
control values.
* *  Non-chromone Fisons compounds.
Compound/Drug A ctiv ity  as % 
of Proxicromil
p value v 
controls
Metoclopramide -14.2* > 0.05
FPL 59219KP -14.0* > 0.05
FPL 50670 -12.3* > 0.05
Sodium aspirin -9 .3 * > 0.05
' Aspirin -0 .5 * > 0.05
FPL 59002KP 3.1 > 0.05
Indomethacin 5.7 > 0.05
FPL 55712LL 6.0 > 0.05
Ibuprofen 7.2 > 0.05
FPL 58935KP 15.7 > 0.05
Cimetidine 17.1 > 0.05
FPL 59128AA 17.8 > 0.05
FPL 58302 21.5 > 0.05
FPL 56604KP 37.8 < 0.01
FPL 59112KA 38.3 < 0.01
FPL 57788AA 42.2 < 0.05
FPL 52694 44.5 > 0.05
FPL 52370 45.8 < 0.01
FPL 59038KA 49.1 < 0.01
(C ont...)
Table 5.1 ( . . . .Cont)
Compound/Drug A ctiv ity  as % 
of Proxicromil
p value v 
controls
FPL 58665KP 51.2 < 0.001
FPL 58249KA 52.8 < 0.01
FPL 57978AA 57.6 < 0.01
FPL 58231AA 58.4 < 0.001
FPL 52791 60.7 < 0.05
FPL 52757 60.7 < 0.001
FPL 55687KA 71.9 < 0.001
FPL 52693 74.6 < 0.05
FPL 57789KA 76.4 < 0.01
FPL 57950KA 79.0 < 0.001
FPL 57978AA 79.9 < 0.001
FPL 55625KA 80.4 < 0.001
FPL 55723KA 80.7 < 0.01
FPL 52758 85.0 < 0.001
FPL 58226 86.4 < 0.001
FPL 58668KC 86.9 < 0.05
FPL 58852 92.2 < 0.01
FPL 55727KA 96.5 < 0.001
FPL 57579 99.6 < 0.01
Proxicromi1 100.0 < 0.001
FPL 55618KA 101.7 < 0.001
FPL 55731KA 103.6 < 0.001
CS Gas 105.6 < 0.001
FPL 52806 118.3 < 0.001
The following abreviations are used in Tables 5.3 to 5.5 
to describe the chemical structures of the chromones.
Abbreviation Chemical Name Structure
Et Ethyl - ch2ch3
Pr Propyl - ch2ch2ch3
All Ally! - ch2ch=ch2
MeEt 2-Methyl ethyl - ch( ch3)2
ProPAc Propionic acid - chch3cooh
t-Bu t.Butyl -C(CH303
DiMeAm Dimethyl ami no - n ( ch3)2
MeO Methoxy - och3
PrPo Propoxy - och2ch2ch3
HydPro Hydroxypropoxy -0CH2CH(0H)CH3
EtBuO 2-Ethylbutoxy -0CH2CH(CH2CH3 )2
MeBuo 2-Methylbutoxy -0CH2CH2CH(CH3)2
Tet Tetrazole
(Na)
A-C N
I I
N —  N
TetCarb
Tetrazol-carboxamide 
(Amido-tetrazole)
N-N
-CO-NH-C -1 
'N-N
+
Na
Table 5.3 S tru c tu re  o f  chromones w ith  the
basic structure shown below
# FPL 57787 = Proxicromil 
Sat = Saturated ring structure
Abbreviations used in the table below are defined in Table 5.2
Compound 
FPL No.
2 5 6 7 8 10 Mol.Wt A ctiv ity  % 
Proxicromi1
57787# COOH OH ★ * * Pr 324 100
57579KA COONa ★ * * * Pr 308 100
58852 Di Me Am * * * ★ * 243 92
57978AA COOH Di MeAm ★ ★ * Pr 366 80
57950KA COONa ★ Sat Sat Sat Pr 304 79
57789KA COONa NH * * * Pr 323 76
59038KA COONa HydPro * * * Pr 382 49
57788AA COOEt NH * * * Pr 348 42
59112KA COONa * * * * MeBuO 352 38
Table 5.4 S t ruc tu re  o f  chromones w i th  the
basic structure shown below
Notes 1 to 5 referred to in Table 5.4 are shown overleaf.
Abbreviations used in the table below are defined in Table 5.2
Compound 
FPL No
2 5 6 7 8 Mol Wt A ctiv ity  % 
Proxicromi1
52806 COONa * t-Bu * t-Bu 324 118
55731 KA COONa ★ Pr * Pr 296 104
55618 KA COONa MeBuO * * All 338 1 0 2
55727 KA COONa MeBuO Et * Et 354 97
58226 Pr PrPo NH * MeO 291 8 6
52758 COONa OH Et ★ Et 284 85
55723 KA COONa EtBuO * ★ ★ 312 81
55625 KA COONa See(l) * * All 352 80
52693 COOH HydPro * * Pr 306 75
55687 KA Tet MeBuO * * All 362 72
52791 COOH * t-Bu * t-Bu 302 61
52757 COOH OH Et * Et 263 61
52694 COONa HydPro * * Pr 328 45
56604 KP TetCarb MeO * See(2) See(2) 510 38
58302 Me Et * ProPAc * * 262 2 2
55712 LL See(3) * * See(4) Pr 644 6
50670 COONa - See(5) * ★ * 512 0
Notes to  Table 5.4
1 . ^  w N  -CH2 0-
"I
NH
1
I ©  i Na 
N = N
©
3.
2)-C0CH(CH2 ) 4 NH3+ 
0 NH+
CH,-CH
ho'/^ /^ 'O C H 2 (OH )CHCH2o ii
CH, I 2
CH2
ch3
OH
OCH
NaOOC
Table 5.5 S t ruc tu re  o f  chromones w i th  the
basic structure shown below
CH
CH.
Notes to Table 5.5
1 . X
CH,
£h2I 2  
CH3
K J
3. UN'I
CH, 
l < 
CH,
4.
Abbreviations used in the table below are defined in Table 5.2
Compound 
FPL No.
2 5 6 7 8 9 Mo 1. Wt A ctiv ity  % 
Proxicromi1
58668KC COO Ca++ * * * COOH •* 382 87
58249KA COONa MeO See Note 1 ★ 326 53
58665KP COONa * * ★ * See(2) 387 51
52370KP COONa * •k * COONa ★ 388 46
58935KP TetCarb * ★ * TetCarb ★ 522 16
59002KP COONa * * * COONa See(3) 415 3
59219KP COONa * Cl * COONa See(4) 406 0
5.3 .2  The e f f e c t  o f  soaps and b i l e  s a l t s  admin istered i n t o
the duodenum on stomach contractions in situ
As with proxicromil, the b ile  salts taurocholate and deoxycholate and 
the soaps lauryl sulphate and stearic acid palmityl ester produced 
' a l l  or none' responses on stomach contractions. The results (shown 
in Tables 5.7 and 5.8) are therefore expressed in terms of the 
duration of the inh ib ition , as was done for the dose-response curve 
established with proxicromil in Chapter 3.
Deoxycholate was generally more active in inhibiting gastric  
emptying than was taurocholate, although both induced complete 
inh ib ition of stomach contractions a fte r  administration to the 
duodenum. Potency was similar to that of proxicromil, (See 
Table 5.7)
The soaps lauryl sulphate and stearic acid palmityl ester were also 
inhibitors of gastric contractions a fte r  administration to the 
duodenum. The inhibition of gastric emptying induced by these 
detergents was rarely complete and was generally short-lived; the 
a c t iv ity  being less than that induced by proxicromil (See Table 
5 .8 ) .
Table 5.6 S t ru c tu ra l  formulae o f  the b i l e  s a l t s ,  deoxycholate
and taurocholate, and of the soaps, lauryl 
sulphate and stearic acid palmityl ester
CH-CHo-CHo-C00H
HO '
Deoxycholic acid
OH
C23H26(°H ^  3C“n' CH2"CH2 * S0 3H
Taurocholic acid
CH3 ( CH2) i i ° . s 0 3 Na
Lauryl sulphate (sodium dodecyl sulphate)
CH3 ( CH2 ) 16_C”CH2 (CH2 ) 14’"C00H
Stearic acid palmityl ester
Table 5.7 I n h i b i t i o n  o f  stomach con t ra c t io n s  in  s i t u  f o l l o w in g
the intraduodenal administration of b i le  salts
c
Bi le 
Salt
Dose
(mg/kg)
Duration of 
Inhibition  
(min)
None
Cm •  O
1
1.5
2
Taurocholate
1 0
2
3
■ 3
6
25
2  .
4
1
2.5 2
2
Deoxycholate
15
1 0 18
2 0
25
5
+ 2 0  partia l
18
Table 5.8 Inhibition of stomach contractions in situ following 
the intraduodenal administration of soaps
Soap
Dose
(mg/kg)
Duration of 
Inhibition  
(mi n)
Lauryl sulphate
2 0
< 1
1.5
4
5
50
6
> 13 
partia l
Stearic acid 
palmityl ester
1 0
1.5
2
2 0 < 1
5.4 Discussion
The chromone compounds studied in these in vivo experiments showed a 
range of a c t iv ity  as inhibitors of gastric emptying from the most 
active drug, FPL 52806 (a c t iv ity  v proxicromil = 118%, Table 5.4) to 
completely inactive drugs such as FPL 50670, ( In ta l ,  Table 5 .4 ) .  Some 
of the chromone drugs such as FPL 59219KP may even be stimulators of 
gastric emptying (See Table 5 .1 ) .  During this discussion such 
compounds are referred to as being inactive as inhibitors of gastric  
emptying.
With a ll  the three basic chromone structures i l lu s tra te d  in Tables 
5.3 , 5 .4 , & 5 .5 , any substitution greater or less than the t-butyl or 
propyl groups caused a reduction in a c t iv i ty .  When ethyl groups were 
introduced (e .g . in FPL 52757, a c t iv ity  =61%) a c t iv ity  was reduced 
( c . f .  FPL 52806 118% - t -b u ty l ,  and FPL 55731 104% - propyl) unless a 
larger group was also included, such as methylbutoxy (FPL 55727KA 
97%) in which case a c t iv ity  was restored.
In two instances, the conversion of an acid to a sodium salt markedly 
increased a c t iv ity  (FPL 52791, 61% with its  sodium s a lt ,  FPL 52806 
118%, and FPL 52757 61% with its  sodium salt FPL 52758 85%). However 
in a th ird  ac id /sa lt comparison the conversion of the acid to a 
sodium salt caused a decrease in a c t iv ity  (FPL 52693 75% with i ts  
sodium salt FPL 52694 45%). Also the conversion of a monocalcium salt  
(FPL 58668KC 87%) to a disodium salt (FPL 52370, 46%) dramatically 
reduced a c t iv ity .
The removal of the hydroxyl group from the 5 position of proxicromil 
(100%) did not e ffect the a c tiv ity  ( c . f .  FPL 57579KA 100%) but the 
introduction of any group containing a nitrogen atom at the
5 position reduced a c t iv i ty ,  in some cases severely, (e .g .
FPL 57978AA, dimethyl amino group, 80%; FPL 57789KA & FPL 57788AA NH 
group 76%, & 42% respectively. The introduction of a hydroxypropoxy 
group at this 5 position also dramatically reduced a c t iv ity  
(FPL 59038KA 49%). The introduction of e ither a tetrazole  or a 
tetrazole  carboxamide moiety also reduced a c t iv i ty ,  ( c . f .  FPL 55618KA 
102% with FPL 55687KA 72%; and FPL 58668KC 87% with FPL 58935KP 16%).
In summary, the structure-activ ity  relationships have shown the 
following to reduce the possib ility  of chromone compounds exibiting  
gastro-intestinal side e ffects . Substitutes at the carbon atom 
adjacent to the ring oxygen should be larger than propyl. The 
introduction of nitrogen at almost any position also appears to 
reduce the possib ility  of the drug being a potent inh ib itor of  
gastric emptying. The use of tetrazoles and tetrazole carboxamide 
groupings can also be expected to reduce this s ide-e ffect. Whether 
the drug is an acid or a sa lt may influence its  potential to in h ib it  
gastric emptying but this influence can be in e ither direction and is 
thus not predictable.
Proxicromil has surface a c t iv ity  properties (Eason 1981)
*
(EC5 0  = 0.18 mg/ml) that were considered as a possible mechanism for
its  (and other chromones) a c t iv ity  as an inh ib itor of gastric  
★
emptying. (EC^q is the concentration required to lyse 50% of 
erythrocytes in a test mixture. The lower the EC^ q , the higher the 
surface a c t iv i ty . )  For this reason, two soaps with known high surface 
a c t iv ity  properties were studied in s i tu . Lauryl sulphate for example 
has an EC5q as low as 0.04 mg/ml. Although both lauryl sulphate and 
stearic acid palmityl ester had a c t iv ity  as inhibitors of gastric  
emptying in situ when administered into the duodenum, th e ir  a c t iv ity  
was not as marked as that of proxicromil and generally did not result
in a to ta l 100 % inh ib ition of stomach contractions. In addition, a 
correlation test between the in vivo a c t iv ity  of chromone compounds 
and th e ir  surface tension properties did not show a positive  
correlation, p > 0.05. Thus i t  was concluded that although a high 
surface a c t iv ity  appeared to contribute to an inhib ition of gastric  
emptying, i t  was not this property alone that explained the ac tiv ity  
of proxicromil.
The b ile  sa lts , taurocholate and deoxycholate were both active as 
inhibitors of gastric emptying in s i tu . Their a c t iv ity  was similar to 
that of proxicromil. The significance of this result and its  
relevance to the mode of action of proxicromil is discusesed further  
in Chapter 6 .
Other studies carried out in the Toxicology Department, Fisons pic, 
concerned with screening chromone drugs for th e ir  potential as 
sensory ir r i ta n ts  in the lung, had shown that proxicromil had high 
sensory i r r i t a n t  properties. CS gas had been used as a positive  
control in these studies and was therefore included in the gastric  
emptying screen described in this chapter. As shown in Table 5 .1 , CS 
gas administered as a solid in suspension was very active as an 
inh ib itor of gastric emptying. A correlation test between inhib ition  
of gastric emptying induced by chromones and the ir  sensory i r r i t a n t  
properties showed a highly s ignificant correlation (p < 0 .0 1 ) .  The 
significance of this correlation is unclear but as both sensory 
irr itancy  and inhibition of gastric emptying are undesired 
side-effects for an t i-a l le rg ic  drugs, the avoidance of structures 
that are potential inhibitors of gastric emptying is also l ik e ly  to 
lead to structures with lower potential as sensory i r r i ta n ts .
CHAPTER 6
DISCUSSION
Discussion
Zbinden, (1982) advocates the study of discrete organ systems or 
functions as a more sc ie n tif ic  approach to toxicology than a general, 
non-specific screen as currently recommended by regulatory 
authorities. The work described in the preceding chapters fu l ly  
supports such an approach and il lu s tra te s  an example of the fa ilu re  
of conventional to x ic ity  studies to demonstrate the potential of a 
drug to induce significant and certa in ly  unacceptably frequent 
side-effects .
The compound studied in this thesis had been tested in almost one 
hundred to x ic ity  studies (See Appendix, Table 1 ). These studies 
ranged from acute to l i fe -t im e  studies and covered every bodily 
function including the gas'tro-intestinal t ra c t .  The studies were 
almost a l l  based on those required by regulatory authorit ies. However 
when the drug was administered to humans i t  induced side-effects that  
had not been predicted from this spectrum of conventional studies but 
which were of suffic ient severity and incidence to consider 
withdrawal of the drug. This thesis demonstrates that with a very 
simple study these particular side-effects could have been predicted 
and il lu s tra te s  how pharmaceutical toxicology could develop were i t  
allowed to do so free ly . The test developed during this work for 
example would have taken one person half a day, used ten animals and 
cost approximately one hundred pounds and would have been of more 
predictive value than the data generated from the six-month study 
that required two people for eight months, used over two hundred 
animals and cost approximately fifty-thousand pounds. This work does 
not indicate that long term chronic studies have no value (the
six-month to x ic ity  study did generate other data relating to the 
safety of the drug) but i t  does i l lu s tra te  that shorter term tests 
can have at least an equal value in predicting potential side-effects  
in humans.
A simple, quick (two to three hours) and reproducible method of 
demonstrating an inhibition of gastric emptying in vivo in rats has 
been developed. The method was shown to be suitable as a primary 
screen for detecting those drugs l ik e ly  to induce gastro-intestinal 
side effects in humans. A second screen in marmosets, probably more 
predictive than the rat model, was also shown to be suitable to study 
those drugs high-lighted by the rat screen as being potential 
inhibitors of gastric emptying.
Proxicromil was shown to be a potent inhib itor of gastric emptying in 
both rats and marmosets - an e ffect that can be extrapolated to man 
as the l ik e ly  cause of the gastro-intestinal side-effects reported in 
c lin ica l t r ia ls .  This effect was so marked in both animals and man 
that some explanation is required in order to understand how i t  could 
have fa iled  to have been detected in the numerous to x ic ity  studies 
carried out prior to c lin ic a l t r ia ls  (See Appendix, Table 1 ) .  Some 
of the longer term chronic studies had included the measurement of 
food consumption and i t  could be expected that a severe inh ib ition  of 
gastric emptying should in theory adversely influence both food 
consumption and consequently bodyweights. No such e ffect was seen.
The explanation for this lack of e ffec t on food consumption is 
probably what has been described as the "catching up phenomenon" such 
as occurs a fte r  exercise, during which gastro-intestinal m o ti l i ty  is 
reduced but over 24 hours no overall e ffect is apparent. (Hellebrant 
& Miles, 1934).
Having fa iled  to demonstrate any activ iy  in v i t r o , and in order to 
study the inhib itory action of proxicromil on gastric emptying in 
more d e ta i l ,  an in situ preparation was developed that demonstrated 
the inhibitory e ffec t of the drug on gastric emptying. This e ffect  
was shown quite c learly  in both rats and marmosets to be induced only 
when the drug was present in the duodenum acting on a negative 
feed-back mechanism to control the rate at which the stomach 
contents, and hence further quantities of the drug, entered the 
duodenum.
I t  has been further demonstrated that proxicromil inhib its  gastric  
emptying by stimulating a nervous re flex . This reflex almost 
certain ly has a physiological role and has probably evolved for a 
particular purpose. Two possible physiological roles are considered 
most l ik e ly .  One is as a defence against noxious substances that have 
been ingested. As discussed in Chapter 1, the stomach can be 
•considered, along with its  role as a reservoir, to be a major 
homeostatic organ. In evolutionary terms i t  could be envisaged that 
these two actions developed f i r s t ,  enzymic and acid a c t iv it ie s  
developing la te r .  Digestion would not have commenced until the food 
reached the in testine, into which there could be some control over 
the rate of entry.
The duodenum w ill  generally only pass the food along the small 
intestine when i t  is in a suitable form, i . e .  when the pH, 
osmolarity, glucose concentration, concentration of noxious 
substances etc. have a ll  been reduced or changed to a level that is 
acceptable to the duodenum. To do this e f f ic ie n t ly  the duodenum must 
be able to control the rate at which the food leaves the stomach. As 
described in Chapter 1, mechanisms exist for controlling the ra te*a t
which acids, fa ts , hypertonic solutions etc. enter the duodenum.
There must almost certain ly also be mechanisms for controlling the 
rate of entry of noxious substances, perhaps via i r r i t a n t  receptors, 
in order to reduce gastric emptying until duodenal secretions have 
su ff ic ien tly  d ilu ted , or otherwise neutralised, the contents to 
render them harmless.
I t  is possible that proxicromil stimulates a re flex , the 
physiological role of which is to control the rate of entry of 
noxious and i r r i t a n t  substances into the duodenum. This hypothesis is 
supported to a considerable extent by the positive correlation shown 
to exist between sensory irr itancy  in the lung and the a b i l i ty  to 
in h ib it  gastric emptying.
The second possible physiological role that proxicromil may be 
triggering is one that is normally stimulated by naturally  occurring 
substances. One of the most important secretions of the duodenum 
that is required to achieve an acceptable milieu within the small 
intestine is the b i le .  I f  stomach contents enter the duodenum faster  
than the b ile  can neutralise or otherwise render the contents 
acceptable, then either the intestine could be damaged or food 
u ti l is a t io n  greatly reduced. Thus there must be a controlling  
mechanism to reduce the rate of gastric emptying. Is this control via 
the food or via the bile? Throughout the l i te ra tu re  concerning the 
control of gastric emptying by the duodenum, the food contents are 
held d irec tly  responsible for this control. Cooke (1975) for example, 
states quite c a t e g o r i c a l l y “The rate of transfer of gastric  
contents to the small bowel is retarded by the a c t iv ity  of receptors 
sensitive to acid, fa t  e t c . . . " .  Hunt & Knox (1968) have even 
demonstrated that fa tty  acids with d iffer ing  chain lengths have
diffe ren t a f f in i t ie s  for fa t receptors in the duodenum. In fact the 
presence of receptors in the small bowel responsive to acid, fa t  or 
any other food constituent has never been shown. I t  is probably more 
correct to say th a t, for example, fa t  in the duodenum results in a 
reduced rate of gastric emptying.
Contraction of the gall bladder in man begins approximately half an 
hour a fte r  eating (Davenport, 1977). This half-hour delay suggests 
that the stimulus occurs when the food, probably f a t ,  enters the 
duodenum. I t  would be appropriate i f  a negative feed-back mechanism 
operated to prevent further gastric emptying occurring until the b ile  
had completed its  emulsifying and neutralising role on the chyme that 
had already entered the duodenum. Although such a mechanism is l ik e ly  
to exist in species with gall bladders, the absence of th is organ in 
rats does not support this explanation.
Bile is produced and secreted continuously in rats but not 
necessarily with the same constituents in the presence and absence of 
fa t .  The secretion in rats of the two major components of b i le ,  the 
b ile  acid-independent fraction and the b ile  acid-dependent fraction  
may be under separate control as they are in species with gall 
bladders. I t  is therefore possible that in rats the b ile  
acid-dependent fraction is secreted pre ferentia lly  in the presence of 
fa t .  This theory is supported by the work of Botham & Boyd (1983), 
who showed that the synthesis of b i le  acids was raised in rats fed on 
a fat-supplemented d ie t .  Therefore the presence of fa t  in the 
duodenum probably stimulates the secretion of certain components of 
bile  in a ll  species. I t  is quite possible that the d if fe ren t chain 
lengths shown by Hunt & Knox (1968) to have d iffe ren t e fficacies as 
inhibitors of gastric emptying actually have d iffe ren t e fficacies as 
stimulators of b ile  flow. The stimulation of b ile  flow probably
occurs via the release of cytocystokinin as Makhlouf (1979) has shown 
that this hormone causes gall bladder contraction in man and Geenen 
and collegues (1980) have shown that CCK relaxes the sphincter of 
Oddi.
Thus a constituent of the b i le  could be responsible for the 
inhib ition of gastric emptying and not the fa t  per se. Once again 
considering the evolutionary development of this re fle x , there is a 
wide range of fats and fa tty  acids that any receptor would have to 
recognise. How much simpler i t  would have been to evolve receptors 
that only had to recognise a specific number of chemicals (or perhaps 
to recognise the surfactant properties of chemicals) that were 
present in the normal secretions of the duodenum when stimulated by 
the presence of fats?
In order to re late  the action of b i le  to that of proxicromil the 
question was asked, " Are there any b ile  constituents l ik e ly  to be 
inhibitors of gastric emptying that could be responsible for 
triggering such a reflex? ". The most obvious candidates were 
considered to be the b ile  sa lts . In the studies reported in Chapter 5 
two b ile  salts (taurocholate and deoxycholate) were therefore 
included. Both were shown to be very active inhibitors of gastric  
emptying in rats.
Thus i t  may be the b ile  salts and not fats per se that tr igger the 
reflex which inhib its gastric emptying when fats enter the duodenum. 
Proxicromil and other active chromones could therefore exert the ir  
a c tiv ity  as inhibitors of gastric emptying by stimulating the same 
receptors that respond to the b ile  sa lts . Structurally  there are many 
d iss im ila rit ies  between the chromones and the b ile  salts and there is 
l i t t l e  ju s t i f ic a t io n  for supporting the above hypothesis on the 
grounds of structural s im ila r ity .
However, although a positive correlation between the surface ac tiv ity  
of the chromones and the ir  a c t iv ity  as inhibitors of gastric emptying 
was not demonstrated, some of them, proxicromil in particu la r , have 
very strong surface a c t iv ity  properties - a property shared by the 
b ile  sa lts . The lack of a positive correlation with surface-activ ity  
may be due to d iffe rent s o lu b il it ies  of the various compounds. In 
support of the hypothesis that proxicromil exerts its  a c t iv ity  by 
stimulating the same receptors as the b ile  salts is that fa t  only 
results in an inhibition of gastric emptying whilst present in the 
upper intestine (Best, 1911), ( c . f .  acid - active in the upper and 
the middle in tes tin e ). Like fa ts , proxicromil was shown to to be 
active only when i t  was present in the upper in testine.
Proxicromil may therefore stimulate a reflex that has a physiological 
role. However, i t  is not known whether this reflex is present as a 
defence against noxious substances or is a normal control of gastric  
emptying responsive to b ile  salts following stimulation of th e ir  
release by fa ts . (See Figure 6.1)
Why does food not normally result in nausea and vomiting whereas 
proxicromil does i f ,  d irec tly  or in d irec tly , they are acting on the 
same receptors? Food does result in nausea and vomiting when gastric  
emptying is delayed for several hours such as occurs during a 
gastro-intestinal infection. In vivo studies with proxicromil have 
shown that the drug also has a long duration of a c t iv ity  in in i biting  
gastric emptying. This naturally results in the nausea and vomiting 
observed c l in ic a l ly .  The cause of the long duration of a c t iv ity  of
proxicromil is unknown but may be due to occupation of receptors for
a long time or to an excessive stimulation of receptors resulting in
a period of refraction.
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Figure 6.1 Schematic representation of the possible mechanism of 
action of proxicromi1 -induced inhib ition of gastric  
emptying.
receptors. (+) stimulation. ( - )  in h ib it ion .
A particu larly  interesting finding was the "all or none" effect of 
proxicromil on stomach contractions. These contractions equate with 
gastric emptying since McSwiney (1932) has demonstrated that f lu id  is 
expelled from the stomach in spurts which synchronise with the antral 
contractions. Assuming that proxicromil was excessively stimulating a 
physiological re flex , this indicates that normally the stomach is 
either contracting rhythmically to expel i ts  contents into the 
duodenum or that these particular contractions are switched o ff  by 
the re flex , rather than slowed down. There appears to be no reduced 
expulsion, i . e .  the control of emptying is like  a solenoid that is 
either opened or closed rather than the in f in i te ly  variable control 
obtained by a tap. Although the stomach is normally considered to 
have an in f in i te ly  variable a b i l i ty  to regulate the rate of emptying, 
the v a r ia b il i ty  may be in the frequency of contractions rather than 
in the ir  strength.
Because of the frequency of side-effects encountered with proxicromil 
in c lin ica l t r ia ls ,  and human volunteeer studies, an attempt was made 
(before the work reported in this thesis was carried out) to reduce 
the incidence by treating human volunteers with enteric coated 
tablets of the drug (Fisons, internal document). These tablets were 
designed so that the drug would not be released until i t  had le f t  the 
stomach and entered the in testine. I t  was surprising, at that time, 
to find that the administration of enteric coated tablets did not 
reduce the frequency nor the severity of gastro-intestinal side- 
effects . As shown in the work reported in the preceding chapters, 
such a finding could have been predicted as the gastro-intestinal 
side-effects induced by proxicromil are induced only a fte r  the drug 
has le f t  the stomach. These results in humans with enteric coated 
tablets are consistent with a duodenal action of proxicromil as has
been shown to occur in rats and marmosets and thus increases the 
confidence in the use of these animal screens to predict effects in 
man.
As discussed in Chapter 2, the rate of absorption of a drug can be 
markedly affected by its  a c t iv ity  as an inhib itor of gastric  
emptying. This is not a new concept as for example Prescott (1974) 
described the reduced absorption of paracetamol following inhib ition  
of gastric emptying, and Arnaud & Getaz, (1984) suggest that dose- 
dependant kinetics of ora lly  administered caffeine may be due to a 
delayed gastric emptying and not to the previously believed limited  
capacity for caffeine metabolism. However the relevance of this fact 
to to x ic ity  studies and the prediction of the results to man has 
received l i t t l e  attention.
FPL 52806 was shown in Chapters 2'& 5 to be an active inh ib ito r of 
gastric emptying in rats. During the toxicological evaluation of th is  
drug rodents were used extensively in chronic studies of up to six 
months duration. As shown in Figure 2.12, plasma concentrations in 
rats as a result of the inhibition of gastric emptying showed a very 
slow rise to a low peak at four hours. As demonstrated in the work 
described in Chapter 2 in marmosets, and as determined by the lack of 
gastro-intestinal effects in humans, inhibition of gastric emptying 
does not occur in man and marmosets with this compound. Therefore the 
drug could enter the duodenum continuously from the stomach and thus 
be available for absorption which was shown in the marmoset to be 
rapid and to lead to high peak plasma concentrations.
Can the rodent tox ic ity  studies carried out with FPL 52806 therefore  
be expected to be predictive for man? There are two ways in which 
plasma concentrations of a drug can influence the drug's potential to
cause to x ic ity .  One is by a low, but continuous insult to an organ or 
c e ll;  the second is by delivering a short-lived but severe in su lt .  
These are the two extremes. With FPL 52806 these two extremes 
probably occur in d iffe rent species. In the rat a re la t iv e ly  low but 
sustained plasma concentration w ill  give a low but continual insult  
whereas in marmosets and probably in humans, a higher peak 
concentration with a more rapid decline occurs.
Dose for dose, the rat could therefore be considered inappropriate as 
a species for predicting to x ic ity  in man in chronic studies with this  
drug. However, because of the re la t iv e ly  non-toxic nature of the 
drug, a dose in rats up to 1 0 0  times the c lin c ia l dose could be 
administered without inducing overt to x ic ity .  Thus compared to 
c l in ic a l ly  achieved plasma concentrations, concentrations in 
rats many times greater occurred that were sustained for several 
hours. Thus adequate safety margins could be achieved. With drugs 
that cannot be administered to animals at doses greatly in excess of 
c lin ica l doses because of a narrow therapeutic margin, an inhib ition  
of gastric emptying in rats without such an inhibition occurring in 
humans would greatly reduce the predictive value of chronic to x ic ity  
studies carried out in this rodent species. With drugs such as 
proxicromil that in h ib it  gastric emptying in both rats and humans, 
the value and pred ic tab ility  of chronic rat studies w i l l  be much 
greater.
In addition, this work demonstrates that inhibition of gastric  
emptying, or the lack of i t ,  can be a major cause of d iffe r in g  plasma 
profiles between species and may explain some cases of species 
variation in response to orally  administered drugs. D ifferent rates 
of rise of plasma concentrations a fte r  oral administration that are
often assumed to be due to d iffe ren t rates of absorption per se may 
in fact be due to d iffe ren t degrees of inhibition of gastric  
emptying. This may also explain some instances of variation of both 
to x ic ity  and efficacy within a species, particu larly  in a 
heterogenous species such as man in which some individuals may be 
more susceptible to gastric inhib ition than others. Hellebrandt & 
Miles (1934) for example have shown that in normal individuals the 
rate of trans it  through the gastro-intestinal trac t can vary from 38 
to 146 hours. Such a difference must influence the plasma p ro fi le  of 
an ora lly  administered drug and hence both its  efficacy and potential 
to x ic ity .
The e ffec t that inh ib ition of gastric emptying may have on efficacy  
has received minimal attention; i ts  e ffect on to x ic ity  has received 
even less. The effect on efficacy is l ik e ly  to be sim ilar to its
e ffect on to x ic ity .  Accepting homeopathy as an exception, both
to x ic ity  and efficacy depend on a drug being delivered to its  s ite  of
action at a minimal concentration. The concentration of a drug at i ts
site  of action depends on the plasma concentration and thus for an 
orally  administered drug on i ts  rate of absorption. Studies reported 
in the preceding chapters have shown that the rate of gastric  
emptying is an important determinant of the rate of absorption.
Have the original objectives of this research programme been met?
In Chapter 1. the purpose of this work was stated as being to 
elucidate the mechanism by which proxicromil caused gastro-intestinal 
disorders in man, to determine whether the effect in humans could 
have been predicted from animal studies and, i f  so, to develop a 
simple but e ffective to x ic ity  study that could be used with future 
drugs to predict the ir  potential to induce this type of s ide-effect  
in humans.
To summarize, i t  is clear that these questions have been answered to 
varying degrees. Proxicromil causes gastro-intestinal disorders by a 
potent inhibitory a c t iv ity  on gastric-emptying. The drug exhibited 
this a c t iv ity  by stimulating a nervous reflex that probably has a 
physiological role either to protect the small intestine from noxious 
substances or to respond to naturally occurring substances such as 
the b ile  sa lts . I t  is firmly concluded from this work that this  
effect in humans could have been predicted. Simple, e ffective  animal 
screens, a primary screen in rats and a more predictive secondary 
screen in marmosets, were developed that are now used within the 
Toxicology Department, Fisons, with new drugs to predict the ir  
potential to induce gastro-intestinal disorders in man.
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APPENDIX
PROXICROMIL TOXICITY STUDIES
THE IN VIVO ACTIVITY OF A SERIES OF CHROMONES 
AS INHIBITORS OF GASTRIC EMPTYING
ANIMALS AND MATERIALS
Table 1 P rox ic rom i l  t o x i c i t y  s tud ies
All of the following studies were done as part of the safety 
evaluation assessment of proxicromil by the Toxicology Department, 
Fisons pic.
Those studies that were the responsibil ity of the author of this  
thesis are marked with an asterisk ( * ) .
Except where indicated with a hatch (#) a l l  the studies were carried 
out in the Toxicology Department, Fisons p ic . ,  Pharmaceutical 
Division during the period 1975 to 1981. Studies marked # were 
carried out externally under contract, *  indicating that the author 
acted as Responsible Scientist on behalf of Fisons pic.
1. Acute oral observation study in rats and mice.
*  2. A comparison of the acute oral tox ic i ty  of the acid and the
salt  of proxicromil in male mice.
*  3. Acute oral tox ic i ty  study in rats and mice.
4. The effect  of aminophylline, ephedrine, isoprenaline,  
mepyramine, salbutamol, tolbutamide and sodium cromoglycate on 
the acute oral tox ic i ty  of proxicromil in mice.
5. Acute intravenous observation study in mice.
6 . Acute intravenous tox ic i ty  in mice and rats.
7. Acute oral observation study in male rats.
8 . Acute oral siting study in rats.
9. Acute observation study a f ter  intraperitoneal administration.
10. Perivascular ir r itancy study in rats.
( c o n t . . ; . )
Table 1 ( . . . . c o n t )  P rox ic rom i l  t o x i c i t y  s tud ies
11. Acute oral tox ic i ty  in Dutch rabbits.
12. Acute gastric i rr itancy in guinea-pigs.
*  13. Interaction study with aspir in , using gastric i r r i tancy ,  in 
guinea-pigs.
14. Acute oral observation study in conscious cats.
15. The effect  of intravenous administration in conscious cats.
16. Effect on the gastro-intest inal m ot i l i ty  of rats a f ter  oral 
administration.
17. Effect of an acute, or f ive consecutive daily oral doses, on 
sleep induced by pentobarbitone in mice.
18. Rotarod performance in mice a fter  acute or multi-dose (4 days) 
oral administration.
19. The acute effect  on locomotor ac t iv i ty  in mice.
20. The effect on locomotor ac t iv i ty  a f ter  ten days oral treatment 
in mice.
21. The effect  on gastro-intestinal m ot i l i ty  in mice a f ter  acute 
and multidose (4 days) oral administration.
22. The effect  of an acute oral dose on the duration of ethanol 
induced sleep in mice.
23. The effect  on body temperature of mice following oral 
administration.
24. The effect on gastro-intestinal m ot i l i ty  in rats a f ter  acute 
oral administration.
25. Operant behaviour of rats a f ter  oral administration.
26. The effect on the cardiovascular and respiratory systems of 
anaesthetised cats.
( c o n t . . . . )
Table 1 ( . . . .con t ) P rox ic rom i l  t o x i c i t y  s tud ies
27. Further studies of the effects on the cardiovascular and 
respiratory systems of anaesthetised cats.
28. The effect on the somatic reflexes of anaesthetised cats.
29. Effects on the cardiovascular and respiratory systems of 
anaesthetised squirrel monkeys after  intravenous 
administration.
30. Further studies on the cardiovascular and respiratory systems 
of anaesthetised squirrel monkeys after  intravenous 
administration.
31. Seven-day interaction study with ethanol in mice.
32. Twenty-one-day interaction study with hydrocortisone in rats.
33. Twenty-one-day interaction study with salbutamol in rats.
34. Twenty-eight-day interaction study with aspirin in rats.
35. Twenty-one-day interaction study with aminophylline and 
mepyramine in rats
36. Twenty-one-day interaction study with ephedrine and salbutamol 
in rats.
37. Sixty-one-day oral study of general endocrine development in 
rats
38. Four-day oral sit ing study in rats.
39. Twenty-eight-day oral study in rats.
* 40. Three-month oral study in rats.
*# 41. Six-month oral study in rats.
42. Preliminary oral study in dogs.
*  43. Twenty-eight-day oral tox ic i ty  study in dogs.
* 44. Twenty-eight-day supplementary oral study in dogs.
*  45. Three-month oral study in dogs.
( c o n t . . . . )
Table 1 ( . . . . c o n t )  P rox ic rom i l  t o x i c i t y  s tud ies
*  46. Five-day oral study in squirrel monkeys.
*  47. Twenty-eight-day oral study in squirrel monkeys.
* 48. Three-month oral study in squirrel monkeys.
49. Perivascular ir r i tancy study in squirrel monkeys.
*  50. Twenty-eight-day oral study in Cynomolgus monkeys.
*# 51. Six-month oral study in Cynomolgus monkeys.
*# 52. Preliminary sit ing study in baboons.
*# 53. Six-month oral study in baboons.
54. Genetic ac t iv i ty  using the yeast Saccharomyces cerevisiae.
55. Ames test .
56. Assessment of mutagenic potential using in v i t ro  cytogenetic 
techniques.
57. Micronucleus study in mice.
58. Dominant lethal assay in mice.
59. Assessment of mutagenic potential a f ter  multiple human dosing 
by analysis of metaphase preparations from lymphocyte 
cultures.
60. Oral teratogenicity study in rats.
61. Oral teratogenicity study in rabbits.
62. F e r t i l i t y  and reproductive study in rats.
63. Peri/post-natal study in rats.
64. Sensory i r r i t a t io n  study of the upper airways in mice a f ter  
inhalation.
65. Pulmonary i r r i t a t io n  study in anaesthetised rabbits and 
cynomolgus monkeys after  administration by aerosol.
66. Pulmonary i r r i ta t io n  study in anaesthetised rabbits a f ter  
administration by aerosol.
( c o n t . . . . )
Table 1 ( . . . . c o n t )  P rox ic rom i l  t o x i c i t y  s tud ies
*  67. A comparison of the tox ic i ty  of proxicromil with that of
warfarin following multiple oral dosing to Wistar rats.
* 68. A comparison of the tox ic i ty  of proxicromil with that of
warfarin following multiple oral dosing to Sprague Dawley 
rats .
*  69. Acute oral dosing compared to warfarin and sodium warfarin in
rats.
*  70. Investigations of blood clott ing times in rats dosed orally
for twenty-eight days using two dietary levels of vitamin K.
*  71. Investigation of the haematuria caused by proxicromil a f ter
intravenous administration to rats.
*  72. Investigation: of the effect of high doses on clotting times in
rats.
*  73. Intravenous interaction study with vitamin K in rats.
74. Evaluation of the effect on immunological function with 
part icular reference to host defence mechanisms.
75. Further studies of the influence of proxicromil on 
immunological function and host defence mechanisms.
76. Determination of maximum tolerated dose in hamsters.
* 77. Carcinogenicity study in hamsters.
*# 78. Preliminary assessment of tox ic i ty  in rats a f ter  dietary  
administration for twenty-seven weeks.
*# 79. Carcinogenicity study in rats.
* 80. Preliminary multidose tox ic i ty  study in infant rats.
* 81. Thirty-five-day oral tox ic i ty  study in neo-natal rats.
( c o n t . . . . )
Table 1 ( . . . . c o n t )  P rox ic rom i l  t o x i c i t y  s tud ies
The following studies were also done to assess the safety of the 
drug for i t ' s  potential use in the eye and on the skin.
*  82. Eye i r r i t a t io n  of a 2% gel in rabbits.
*  83. Eye i r r i t a t io n  studies in rabbits with a gel in rabbits.
*  84. Comparison of eye i r r i t a t io n  of a gel and an aqueous
formulation in rabbits.
* 85. One-day dermal study in rabbits.
*  86. Three-day dermal ir r i tancy study in rabbits.
* 87. Twenty-eight-day dermal tox ic i ty  study in rabbits.
* 88. Twenty-eight-day dermal study in pigs.
*  89. Perivascular ir r itancy study in squirrel monkeys.
Table 2 The a c t i v i t y  o f  a se r ies  o f  chromones
as inhibitors of gastric emptying
The mean stomach weights as percentages of bodyweights are expressed 
as a percentage increase or decrease compared to control values. This 
result is then related to the ac t iv i ty  of proxicromil to allow 
comparison between experiments.
Mean results with standard errors (SE) indicated,  
p = probabil ity of the result being s ta t is t ic a l ly  d i f ferent  from 
the control value as assessed by the Student's 1t ‘ tes t .
Table 2 a) FPL 57579, FPL 58852 and FPL 58668KC
Treatment 
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 2.91 -  0.13 - -
Proxicromi1 4.57 -  0.30
+157 (100)
50 p <0.001
FPL 57579 4.55 -  0.43
+156 100
50 p <0.01
FPL 58852 4.21 -  0.43
+145 93
50 p <0.01
FPL 58668KC 3.97 i  0.39
+136 87
50 p <0.05
Table 2 b) FPL 50670
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activity  as 
% of that of 
Proxicromi1
Control 2.77 -  0.32 - -
Proxicromi! 5.04  ^ 0.75
+82 (100)
50 p <0.05
FPL 50670 2.43 -  0.35
- 1 2 No ac t iv i ty
50 p >0.05
Table 2 c) FPL 52806 and FPL 52791
Treatment 
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activity  as 
% of that of 
Proxicromi1
Control 2.06 -  0.26 - -
Proxicromi1 4.35 -  0.41
+111 (100)
50 p <0.01
FPL 52806 4.77 -  0.39
+132 118
50 p <0.001
FPL 52791 3.45 -  0.47
+68 61
50 p <0.05
Table 2 d) FPL 58231AA, FPL 58665KP and FPL 59128AA
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activity  as 
% of that of  
Proxicromi1
Control 1.74 i  0.14 - -
Proxicromi1 4.67 -  0.65
+168 (100)
50 p <0.001
FPL 58231AA 3.45 -  0.31
+98 58
50 p <0.001
FPL 58665KP 3.24 -  0.20
+86 .51
50 p <0.001
FPL 59128AA 2.96 -  0.28
+30 18
50 p >0.05
Table 2 e) FPL 57950KA, FPL S7978AA and FPL 59002KP
Treatment
(mg/kg)
Stomach weights 
as % of B/wts 
(mean -  SE)
% change 
from 
controls
Activ ity  as 
% of that of  
Proxicromi1
Control 1.51 -  0.28 - -
Proxicromi1 3.75 i  0.16
+148 (100)
50 p <0.001
FPL 57950KA 3.28 -  0.11
+117 79
50 p <0.001
FPL 57978AA 2.80 i  0.14
+85 58
50 p <0.01
FPL 59002KP 1.58 - 0.36
+5 No ac t iv i ty
50 p >0.05
Table 2 f )  FPL 52693, FPL 52694 and FPL 59219KP
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 1.73 -  0.29 - -
Proxicromi1 3.66 -  0.48
+112 (100)
50 p <0.01
FPL 52693 3.17 -  0.41
+83 75
50 p <0.05
FPL 52694 2.59 i  0.19
+50 45
50 p >0.05
FPL 59219KP 1.46 i  0.19
-15.6 No a c t iv i ty
50 p >0.05
Table 2 g) FPL 55712LL, FPL 52757 and FPL 58935KP
Treatment
(mg/kg)
Stomach weights 
as % of B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 1.56 -  0.14 - -
Proxicromi1 4.05 i  0.24
+160 (100)
50 p <0.001
FPL 55712LL 1.71 i  0.21
+10
50 p >0.05
FPL 52757 3.07 ± 0.28
+97 61
50 p <0.001
FPL 58935KP 1.95 i  0.16
+25 16
50 p >0.05
Table 2 h) FPL 57788AA, FPL 58226 and FPL 59038KP
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activity  as 
% of that of 
Proxicromi1
Control 1.21 i  0.14 - -
Proxicromi1 4.08 -  0.50
+237 (100)
50 p <0.001
FPL 57788AA 2.42 -  0.53
+100 42
50 p <0.05
FPL 58226 3.69 ± 0.55
+205 86
50 p <0.001
FPL 59038KP 2.62 -  0.51
+117 49
50 p <0.01
Table 2 i)  FPL 58249KA and FPL 55625KA
Treatment 
(mg/kg)
Stomach weights 
as % of B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 1.92 i  0.10 - -
Proxicromi1 4.57 ± 0.30
+138 (100)
50 p <0.001
FPL 58249KA 3.32 1 0.53
+73 53
50 p <0.01
FPL 55625KA 4.05 -  0.11
+111 80
50 p <0.001
Table 2 j )  FPL 527S8LL
Treatment 
(mg/kg)
Stomach weights 
as % of B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 1.71 -  0.18 - -
Proxicromi 1 4.26- -  0.25
+148 (100)
50 p <0.001
FPL 52758LL 3.88 -  0.38
+126 85
50 p <0.001
Table 2 k) FPL 58302
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activity  as 
% of that of 
Proxicromi1
Control 2.42 -  0.27 - -
Proxicromi1 5.39 i  0.55
+123 (100)
50 p <0.001
FPL 58302 3.06 -  0.95
+26 22
50 p >0.05
Table 2 1) FPL S2370, FPL 56604KP and FPL 59112KA
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi 1
Control 1.63 ± 0.15 - -
Proxicromi1 4.27 -  0.32
+162 (100)
50 p <0.001
FPL 52370 2.84 ± 0.45
+74 * 46
50 p <0.01
FPL 56604KP 2.63 -  0.33
+61 38
50 p <0.01
FPL 59112KA 2.64 i  0.23
+62 38.
50 p <0.01
Table 2 ffl) FPL 55618KA, FPL 55723KA and FPL 55727KA
Treatment 
(mg/kg)
Stomach weights 
as % of B/wts 
(mean - SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 2.26 -  0.12 - -
Proxicromi1 4.62 - 0.38
+104 (100)
50 p <0.001
FPL 55618KA 4.70 -  0.25
+108 ' 102
50 p <0.001
FPL 55723KA 3.73 -  0.40
+65 81
50 p <0.01
FPL 55727KA 4.46 -  0.27
+97 97
50 p <0.001
Table 2 n) FPL 57789KA, FPL 57978AA and CS Gas
Treatment 
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 1.53 i  0.23 - -
Proxicromi1 3.72 ± 0.49
+143 (100)
50 p <0.001
FPL 57789KA 3.21 i  0.26
+110 76
50 p <0.01
FPL 57978AA 3.29 -  0.34
+115 80
50 p <0.001
CS Gas 3.84 -  0.30
+151 106
50 p <0.001
Table 2 o) FPL 55731KA, FPL S5687KA and CS Gas
Treatment
(mg/kg)
Stomach weights 
as % of+B/wts 
(mean -  SE)
% change 
from 
controls
Activ ity  as 
% of that of 
Proxicromi1
Control 0.97 i  0.04 - -
Proxicromi1 2.74 i  0.18
+183 (100)
50 p <0.001
FPL 55731KA 2.84 i  0.35
+193 104
50 p <0.001
FPL 55687KA 1.97 - 0.22
+103 72
50 p <0.001
CS Gas 1.45 ± 0.13
+50 53
5 p <0.001
Table 3 Animals and m a te r ia ls
a) Animals
Rats Sprague Dawley (S/D) male rats used throughout the experiments 
described in Chapters 2 to 5 were from the Toxicology Department, 
(Fisons p i c . ) ,  Teratology Breeding Unit.  All of the rats used were 
surplus to breeding requirements that would normally have been 
culled. All the animals were in good c l in ica l  condition.
Ferrets The ferrets used were surplus to requirements for a twenty- 
eight-day tox ic i ty  study with a Fisons compound. These animals were 
supplied by a commercial supplier. The ferrets were c l in ic a l ly  
healthy before and during the study.
Marmosets The marmosets used were also surplus to requirements for  
a tox ic i ty  study. The animals were supplied form the Fisons Marmoset 
Breeding Unit. The marmosets were c l in ic a l ly  and behaviourally 
normal.
Table 3 ( . . . . c o n t )  Animals and m a te r ia ls
b) Materials
Aspirin BP, Calmic Ltd.
Atropine Sulphate BP, Evans Medical Supplies Ltd.
i
Barium sulphate BP, Royal infirmary, Liverpool.
Cimetidine, (Tagamet), 100 mg/ml solution, Smith, Kline & French 
Laboratories Ltd.
Codeine Phosphate BP, Evans Medical Supplies Ltd.
Deoxycholic acid, Sigma Chemical Company.
Heparin sodium, 150 units/mg, Evans Medical Supplies Ltd.
Histamine acid phosphate, BDH Chemicals Ltd.
Ibuprofen, (Brufen), Boots Company.
Indomethacin, ( Indocid), 5 mg/ml suspension, Thomas Morson 
Pharmaceuticals.
Lauryl sulphate, sodium sa l t ,  (Sodium dodecyl sulphate), Sigma 
Chemical Company.
Mepyramine maleate BP, May & Baker Ltd.
Methyl Cellulose, (Celacol), Grade M450, Batch No. 2960CT, Clinical  
Tria ls  Dept., Fisons pic.
( c o n t . . . . )
Table 3 ( . . . . c o n t )  Animals and m a te r ia ls
Metoclopramide monohydrochloride, (Maxolon), Beecham Research 
Laboratories.
o-Chlorobenzylidene-malonitrile, (CS Gas), Eastman Kodak Company.
Sodium pentobarbitone BP (Vet),  (Sagatal),  60 mg/ml solution,
May Baker Ltd.
Stearic acid palmityl ester, Sigma Chemical Company.
Taurocholic acid, Sodium sa l t ,  Sigma Chemical Company.
Xylocaine, (lignocaine hydrochloride), Astra Pharmaceuticals.
All Fisons (FPL) compounds were supplied by the Medical Chemistry 
Clinical Tr ials Supplies Departments, Fisons pic.
Proxicromi! was supplied as a micronised powder.
